Celgene (CELG) 10-K 11 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 05, 2016	Jun. 30, 2015
Document and Entity Information
Entity Registrant Name	CELGENE CORP /DE/
Entity Central Index Key	816,284
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 91,555,862,650
Entity Common Stock, Shares Outstanding		781,664,535
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,880.3	$ 4,121.6
Marketable securities available-for-sale	1,671.6	3,425.1
Accounts receivable, net of allowances of $30.3 and $32.1 at December 31, 2015 and 2014, respectively	1,420.9	1,166.7
Inventory	443.4	393.1
Other current assets	984.7	606.1
Total current assets	9,400.9	9,712.6
Property, plant and equipment, net	814.1	642.6
Intangible assets, net	10,858.1	4,067.6
Goodwill	4,879	2,191.2
Other assets	1,101.3	726.1
Total assets	27,053.4	17,340.1
Current liabilities:
Short-term borrowings and current portion of long-term debt	0	605.9
Accounts payable	240.8	198.2
Accrued expenses	1,376.7	991.1
Income taxes payable	19.8	12.7
Current portion of deferred revenue	60.6	28.5
Other current liabilities	271	275.8
Total current liabilities	1,968.9	2,112.2
Deferred revenue, net of current portion	30	27.8
Income taxes payable	324.2	272.9
Other non-current tax liabilities	2,519.2	0
Other non-current liabilities	2,041.7	2,136.7
Long-term debt, net of discount	14,250.4	6,265.7
Total liabilities	$ 21,134.4	$ 10,815.3
Commitments and Contingencies (Note 18)
Stockholders' Equity:
Preferred stock, $.01 par value per share, 5.0 million shares authorized; none outstanding at December 31, 2015 and 2014, respectively	$ 0	$ 0
Common stock, $.01 par value per share, 1,150.0 million shares authorized; issued 940.1 million and 924.8 million shares at December 31, 2015 and 2014, respectively	9.4	9.2
Common stock in treasury, at cost; 153.5 million and 124.6 million shares at December 31, 2015 and 2014, respectively	(14,051.8)	(10,698.8)
Additional paid-in capital	11,119.3	9,827.2
Retained earnings	8,074.4	6,472.4
Accumulated other comprehensive income	767.7	914.8
Total stockholders' equity	5,919	6,524.8
Total liabilities and stockholders' equity	$ 27,053.4	$ 17,340.1

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowances (in dollars)	$ 30.3	$ 32.1
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,150,000,000	1,150,000,000
Common stock, shares issued	940,100,000	924,800,000
Common stock, treasury	153,500,000	124,600,000

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Net product sales	$ 9,161.1	$ 7,563.8	$ 6,362.3
Other revenue	94.9	106.6	131.6
Total revenue	9,256	7,670.4	6,493.9
Expenses:
Cost of goods sold (excluding amortization of acquired intangible assets)	420.1	385.9	340.4
Research and development	3,697.3	2,430.6	2,226.2
Selling, general and administrative	2,305.4	2,027.9	1,684.5
Amortization of acquired intangible assets	279	258.3	262.8
Acquisition related charges and restructuring, net	299.6	48.7	171.1
Total costs and expenses	7,001.4	5,151.4	4,685
Operating income	2,254.6	2,519	1,808.9
Other income and (expense):
Interest and investment income, net	31.1	28.2	22
Interest (expense)	(310.6)	(176.1)	(91.6)
Other income (expense), net	48.4	(43.7)	(73.9)
Income before income taxes	2,023.5	2,327.4	1,665.4
Income tax provision	421.5	327.5	215.5
Net income	$ 1,602	$ 1,999.9	$ 1,449.9
Net income per share (Note 1):
Basic (in dollars per share)	$ 2.02	$ 2.49	$ 1.75
Diluted (in dollars per share)	$ 1.94	$ 2.39	$ 1.68
Weighted average shares (Note 1):
Basic (in shares)	792.2	802.7	827.7
Diluted (in shares)	824.9	836	860.6

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income	$ 1,602	$ 1,999.9	$ 1,449.9
Other comprehensive income (loss):
Foreign currency translation adjustments	(26.1)	(49.8)	27.4
Pension liability adjustment	1.6	(8.6)	3.2
Net unrealized gains (losses) related to cash flow hedges:
Unrealized holding gains (losses)	410.5	568.1	(3.2)
Tax (expense) benefit	7.2	12.3	(2.6)
Unrealized holding gains (losses), net of tax	417.7	580.4	(5.8)
Reclassification adjustment for (gains) included in net income	(348.7)	(23.1)	(7.3)
Tax (benefit)	(2.2)	(1.7)	(6.9)
Reclassification adjustment for (gains) included in net income, net of tax	(350.9)	(24.8)	(14.2)
Net unrealized gains (losses) on marketable securities available for sale:
Unrealized holding gains (losses)	(314.4)	494	205.1
Tax (expense) benefit	109.8	(173.9)	(77.1)
Unrealized holding gains (losses), net of tax	(204.6)	320.1	128
Reclassification adjustment for losses included in net income	23.4	5.4	7.3
Tax (benefit)	(8.2)	(1.9)	(2.2)
Reclassification adjustment for losses included in net income, net of tax	15.2	3.5	5.1
Total other comprehensive income (loss)	(147.1)	820.8	143.7
Comprehensive income	$ 1,454.9	$ 2,820.7	$ 1,593.6

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 1,602	$ 1,999.9	$ 1,449.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	114.9	104.3	96.9
Amortization	294	269.3	277.2
Deferred income taxes	(33.4)	(272.3)	(246.6)
Impairment charges	48.9	133.2	105.4
Change in value of contingent consideration	(7.9)	48.7	171.1
Net (gain) loss on sale of investments	(83.5)	5.4	7
Share-based compensation expense	576.6	447.6	325.8
Share-based employee benefit plan expense	35.1	40.7	32.6
Derivative instruments	(31.4)	(71.9)	(8.7)
Other, net	18.8	(13.5)	11
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(304.7)	(166.3)	(101.4)
Inventory	(50.6)	(56.5)	(89.7)
Other operating assets	(326.2)	52.6	(90.9)
Accounts payable and other operating liabilities	533	252.3	287.2
Payment of contingent consideration	0	(14.3)	(75)
Income tax payable	61.2	39.1	57.4
Deferred revenue	37.1	8	16.7
Net cash provided by operating activities	2,483.9	2,806.3	2,225.9
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	3,799.6	2,175.9	3,642.3
Purchases of marketable securities available for sale	(1,889.3)	(2,661.4)	(3,983.6)
Payments for acquisition of businesses, net of cash acquired	(7,695.1)	(710)	0
Capital expenditures	(286.3)	(150.3)	(119.7)
Proceeds from sales of investment securities	92	0	0
Purchases of investment securities	(272.5)	(67.4)	(47.1)
Other investing activities	(7.4)	(24.8)	(20.5)
Net cash used in investing activities	(6,259)	(1,438)	(528.6)
Cash flows from financing activities:
Payment for treasury shares	(3,256.8)	(2,975.1)	(2,764.6)
Proceeds from short-term borrowing	6,111.5	2,566.9	4,462
Principal repayments on short-term borrowing	(6,213.2)	(3,012.2)	(4,227.9)
Proceeds from the issuance of long-term debt, net of issuance costs	7,913.3	2,470.6	1,479.6
Repayments of long-term debt	(513.9)	0	0
Net (payments) proceeds from common equity put options	(8.6)	10.3	1.2
Payment of contingent consideration	0	(25.7)	(225)
Net proceeds from share-based compensation arrangements	251.7	297.2	551.6
Excess tax benefit from share-based compensation arrangements	300.5	250.6	169.4
Net cash provided by (used in) financing activities	4,584.5	(417.4)	(553.7)
Effect of currency rate changes on cash and cash equivalents	(50.7)	(63.7)	0.4
Net increase in cash and cash equivalents	758.7	887.2	1,144
Cash and cash equivalents at beginning of period	4,121.6	3,234.4	2,090.4
Cash and cash equivalents at end of period	4,880.3	4,121.6	3,234.4
Supplemental schedule of non-cash investing and financing activity:
Fair value of contingent consideration issued in business combinations	166	1,060	0
Change in net unrealized (gain) loss on marketable securities available for sale	314.4	(494)	(205.1)
Investment in NantBioScience, Inc. preferred equity	0	90	0
Supplemental disclosure of cash flow information:
Interest paid	243.3	196.2	90.8
Income taxes paid	$ 361.1	$ 294.6	$ 291.9

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Balances at beginning of period at Dec. 31, 2012	$ 5,694.5	$ 8.8	$ (4,823.2)	$ 7,536	$ 3,022.6	$ (49.7)
Increase (decrease) in stockholders' equity
Net income	1,449.9				1,449.9
Other comprehensive income	143.7					143.7
Exercise of stock options and conversion of restricted stock units	554	0.2	(69.7)	623.5
Shares purchased under share repurchase program	(2,769.2)		(2,769.2)
Issuance of common stock for employee benefit plans	22	0.1		21.9
Expense related to share-based compensation	325			325
Income tax benefit upon exercise of stock options	170			170
Balances at end of period at Dec. 31, 2013	5,589.9	9.1	(7,662.1)	8,676.4	4,472.5	94
Increase (decrease) in stockholders' equity
Net income	1,999.9				1,999.9
Other comprehensive income	820.8					820.8
Exercise of stock options and conversion of restricted stock units	298.2	0.1	(126.1)	424.2
Shares purchased under share repurchase program	(2,929.5)		(2,929.5)
Issuance of common stock for employee benefit plans	45.4		18.9	26.5
Expense related to share-based compensation	447.5			447.5
Income tax benefit upon exercise of stock options	252.6			252.6
Balances at end of period at Dec. 31, 2014	6,524.8	9.2	(10,698.8)	9,827.2	6,472.4	914.8
Increase (decrease) in stockholders' equity
Net income	1,602				1,602
Other comprehensive income	(147.1)					(147.1)
Exercise of stock options and conversion of restricted stock units	259.7	0.2	(135.4)	394.9
Shares purchased under share repurchase program	(3,256.8)		(3,256.8)
Issuance of common stock for employee benefit plans	57.7		39.2	18.5
Expense related to share-based compensation	576.6			576.6
Income tax benefit upon exercise of stock options	302.1			302.1
Balances at end of period at Dec. 31, 2015	$ 5,919	$ 9.4	$ (14,051.8)	$ 11,119.3	$ 8,074.4	$ 767.7

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies Celgene Corporation, together with its subsidiaries (collectively “we,” “our,” “us,” “Celgene” or the “Company”), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID ® , POMALYST ® /IMNOVID ® , ABRAXANE ® , OTEZLA ® , VIDAZA ® , azacitidine for injection (generic version of VIDAZA ® ), THALOMID ® (sold as THALOMID ® or Thalidomide Celgene TM outside of the U.S.), and ISTODAX ® . In addition we earn revenue through licensing arrangements. The consolidated financial statements include the accounts of Celgene Corporation and its subsidiaries. Investments in limited partnerships and interests where we have an equity interest of 50% or less and do not otherwise have a controlling financial interest are accounted for by either the equity or cost method. In June 2014, our stockholders voted to approve an amendment to our Certificate of Incorporation that increased the number of shares of common stock that we are authorized to issue and effected a two -for-one stock split of outstanding shares (Stock Split). As a result, our total number of authorized shares of common stock increased from 575.0 million to 1.150 billion on June 18, 2014. Stockholders of record received one additional share of common stock for each share of common stock owned. All impacted share numbers and per share amounts presented in the consolidated financial statements and the accompanying notes to the financial statements have been restated to reflect the impact of the Stock Split. Common stock held in treasury was not adjusted for the Stock Split. The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. We are subject to certain risks and uncertainties related to, among other things, product development, regulatory approval, market acceptance, scope of patent and proprietary rights, competition, outcome of legal and governmental proceedings, European credit risk, technological change and product liability. Certain prior year amounts have been reclassified to conform to the current year's presentation. Financial Instruments: Certain financial instruments reflected in the Consolidated Balance Sheets, (e.g., cash, cash equivalents, accounts receivable, certain other assets, accounts payable, short-term borrowings and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than marketable securities are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of available-for-sale marketable securities is determined utilizing the valuation techniques appropriate to the type of security (See Note 4). Derivative Instruments and Hedges: All derivative instruments are recognized on the balance sheet at their fair value. Changes in the fair value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. We assess, both at inception and on an on-going basis, whether the derivative instruments that are used in cash flow hedging transactions are highly effective in offsetting the changes in cash flows of hedged items. We assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion of derivative instruments, if any, to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealized gain or loss on the derivative instrument is recognized in current earnings. We use derivative instruments, including those not designated as part of a hedging transaction, to manage our exposure to movements in foreign exchange, our stock price and interest rates. The use of these derivative instruments modifies the exposure of these risks with the intent to reduce our risk or cost. Cash, Cash Equivalents and Marketable Securities Available for Sale: We invest our excess cash primarily in money market funds, U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency mortgage-backed securities (MBS), non-U.S. government, agency and supranational securities, global corporate debt securities and asset backed securities. All liquid investments with maturities of three months or less from the date of purchase are classified as cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities available for sale. We determine the appropriate classification of our investments in marketable debt and equity securities at the time of purchase. In addition, our equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements, are designated as marketable securities available for sale. Our marketable securities available for sale are primarily equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements. In addition, we invest in debt securities that are carried at fair value, held for an unspecified period of time and are intended for use in meeting our ongoing liquidity needs. Unrealized gains and losses on available-for-sale securities, which are deemed to be temporary, are reported as a separate component of stockholders' equity, net of tax. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization, along with realized gains and losses and other-than-temporary impairment charges, is included in interest and investment income, net. A decline in the market value of any available-for-sale security below its carrying value that is determined to be other-than-temporary would result in a charge to earnings and decrease in the security's carrying value down to its newly established fair value. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market condition in which the issuer operates; our intent to hold to maturity and an evaluation as to whether it is more likely than not that we will not have to sell before recovery of its cost basis; our expected future cash flows from the security; and issues that raise concerns about the issuer's ability to continue as a going concern. Concentration of Credit Risk: Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. We invest our excess cash primarily in money market funds, U.S. Treasury securities, U.S. government-sponsored agency securities, MBS, non-U.S. government, agency and supranational securities, global corporate debt securities and asset backed securities (See Note 6). We have established guidelines relative to diversification and maturities to maintain safety and liquidity. These guidelines are reviewed periodically and may be modified to take advantage of trends in yields and interest rates. We sell our products in the United States primarily through wholesale distributors and specialty contracted pharmacies. Therefore, wholesale distributors and large pharmacy chains account for a large portion of our U.S. trade receivables and net product revenues (See Note 19). International sales are primarily made directly to hospitals, clinics and retail chains, many of which in Europe are government owned and have extended their payment terms in recent years given the economic pressure these countries are facing. We continuously monitor the creditworthiness of our customers, including these governments, and have internal policies regarding customer credit limits. We estimate an allowance for doubtful accounts primarily based on the credit worthiness of our customers, historical payment patterns, aging of receivable balances and general economic conditions, including publicly available information on the credit worthiness of countries themselves and provinces or areas within such countries where they are the ultimate customers. We continue to monitor economic conditions, including the volatility associated with international economies, the sovereign debt crisis in certain European countries and associated impacts on the financial markets and our business. Our current business model in these markets is typically to sell our products directly to principally government owned or controlled hospitals, which in turn directly deliver critical care to patients. Our products are used to treat life-threatening diseases and we believe this business model enables timely delivery and adequate supply of products. Many of the outstanding receivable balances are related to government-funded hospitals and we believe the receivable balances are ultimately collectible. Similarly, we believe that future sales to these customers will continue to be collectible. The credit and economic conditions within Spain, Italy, Portugal and Greece, as well as increasing sales levels in those countries have in the past resulted in, and may continue to result in, an increase in the average length of time it takes to collect accounts receivable. Our total net receivables in Spain, Italy and Portugal are composed almost entirely of amounts receivable from government-owned or controlled hospitals and the public sector and amounted to $187.8 million at December 31, 2015 , compared to $241.8 million at December 31, 2014 . Approximately $31.3 million of the $187.8 million receivable at December 31, 2015 was greater than one year past due. Our exposure to the sovereign debt crisis in Greece is limited, as we do not have a material amount of receivables in Greece. We maintain timely and direct communication with hospital customers in Spain, Italy and Portugal regarding both the current and past due receivable balances. We continue to receive payments from these countries and closely monitor the plans for payment at the regional government level. Payments from customers in these countries are not received on regular intervals and several months could elapse between significant payments. We also regularly request and receive positive confirmation of the validity of our receivables from most of the regional governmental authorities. In determining the appropriate allowance for doubtful accounts for Spain, Italy and Portugal, we considered the balance of past due receivables related to sales made to government-owned or supported customers. We regularly monitor developments in Europe to assess whether the level of risk of default for any customers has increased and note the ongoing efforts by the European Union, European Monetary Union and International Monetary Fund to support countries with large public deficits and outstanding debt balances. We also monitor the efforts of individual countries to support their regions with large public deficits and outstanding debt balances. We have not experienced significant losses or write-offs with respect to the collection of our accounts receivable in these countries as a result of their economic difficulties and we do not expect to have write-offs or adjustments to accounts receivable that would have a material adverse impact on our financial position or results of operations. Inventory: Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized. Included in inventory are raw materials used in the production of preclinical and clinical products, which are charged to research and development expense when consumed. We capitalize inventory costs associated with certain products prior to regulatory approval of products, or for inventory produced in new production facilities, when management considers it highly probable that the pre-approval inventories will be saleable. The determination to capitalize is based on the particular facts and circumstances relating to the expected regulatory approval of the product or production facility being considered, and accordingly, the time frame within which the determination is made varies from product to product. The assessment of whether or not the product is considered highly probable to be saleable is made on a quarterly basis and includes, but is not limited to, how far a particular product or facility has progressed along the approval process, any known safety or efficacy concerns, potential labeling restrictions and other impediments. We could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Property, Plant and Equipment: Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation of plant and equipment is recorded using the straight-line method. Building improvements are depreciated over the remaining useful life of the building. Leasehold improvements are depreciated over the lesser of the economic useful life of the asset or the remaining term of the lease, including anticipated renewal options. The estimated useful lives of capitalized assets are as follows: Buildings 40 years Building and operating equipment 15 years Manufacturing machinery and equipment 10 years Other machinery and equipment 5 years Furniture and fixtures 5 years Computer equipment and software 3-7 years Maintenance and repairs are charged to operations as incurred, while expenditures for improvements which extend the life of an asset are capitalized. Capitalized Software Costs: We capitalize software costs incurred in connection with developing or obtaining software. Capitalized software costs are included in property, plant and equipment, net and are amortized over their estimated useful life of three to seven years from the date the systems are ready for their intended use. Investments in Other Entities: We hold a portfolio of investments in equity securities and certain investment funds that are accounted for under either the equity method or cost method. Investments in companies or certain investment funds over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other income (expense), net. Our equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements, are designated as marketable securities available for sale. Investments in equity securities of companies that become publicly traded are accounted for as available-for-sale marketable securities prospectively from the date of such companies' initial public offering if we are not restricted from selling our investment for greater than one year. Our cost method and equity method investments are included in other assets on the Consolidated Balance Sheets. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: market value or exit price of the investment based on either market-quoted prices or future rounds of financing by the investee; length of time that the market value was below its cost basis; financial condition and business prospects of the investee; our intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that we may be aware of related to the investment. Other Intangible Assets: Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is initiated for in-process research and development (IPR&D) intangible assets when their useful lives have been determined. IPR&D intangible assets which are determined to have had a drop in their fair value are adjusted downward and an expense recognized in the income statement. These IPR&D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Goodwill: Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but is subject to impairment testing. We test our goodwill for impairment at least annually or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. Impairment of Long-Lived Assets: Long-lived assets, such as property, plant and equipment and certain other long-term assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of the assets exceed their estimated future undiscounted net cash flows, an impairment charge is recognized for the amount by which the carrying amount of the assets exceed the fair value of the assets. Contingent Consideration from Business Combinations: Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period with changes in fair value recognized in income as acquisition related charges, net. Changes in fair values reflect new information about related IPR&D and other assets and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time as development work towards the achievement of the milestones progresses, and is accrued based on an accretion schedule. Foreign Currency Translation: Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities into the U.S. dollar are excluded from the determination of net income and are recorded as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net in the Consolidated Statements of Income. We had a net foreign exchange loss of $11.7 million in 2015, a loss of $9.5 million in 2014, and a gain of $22.2 million in 2013. These amounts include the impact of gains and losses on foreign exchange contracts not designated as hedging instruments (See Note 5). Research and Development Costs: Research and development costs are expensed as incurred. These include all internal and external costs related to services contracted by us. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Milestone payments made to third parties upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Income Taxes: We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. We recognize the benefit of an uncertain tax position that we have taken or expect to take on income tax returns we file if such tax position is more likely than not to be sustained. Revenue Recognition: Revenue from the sale of products is recognized when title and risk of loss of the product is transferred to the customer and the sales price is fixed and determinable. Provisions for discounts, early payments, rebates, sales returns and distributor chargebacks under terms customary in the industry are provided for in the same period the related sales are recorded. We record estimated reductions to revenue for volume-based discounts and rebates at the time of the initial sale. The estimated reductions to revenue for such volume-based discounts and rebates are based on the sales terms, historical experience and trend analysis. We base our sales returns allowance on estimated on-hand retail/hospital inventories, measured end-customer demand as reported by third-party sources, actual returns history and other factors, such as the trend experience for lots where product is still being returned or inventory centralization and rationalization initiatives conducted by major pharmacy chains, as applicable. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. Under this methodology, we track actual returns by individual production lots. Returns on closed lots, that is, lots no longer eligible for return credits, are analyzed to determine historical returns experience. Returns on open lots, that is, lots still eligible for return credits, are monitored and compared with historical return trend rates. Any changes from the historical trend rates are considered in determining the current sales return allowance. Sales discount accruals are based on payment terms extended to customers. Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. U.S. Medicaid rebate accruals are generally based on historical payment data and estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicaid rebate percentage was increased and extended to Medicaid Managed Care Organizations in March 2010. The accrual of the rebates associated with Medicaid Managed Care Organizations is calculated based on estimated historical patient data related to Medicaid Managed Care Organizations. We also analyze actual billings received from the states to further support the accrual rates. Subsequent to implementation of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the 2010 U.S. Health Care Reform Law), certain states have not completed their Medicaid Managed Care Organization billing for the years of 2010 through 2015. Our accruals for these Medicaid Managed Care Organization rebates had been at elevated levels given the delays in the receipt of complete invoices from certain states. Due to the receipt of more complete claims data during 2013, 2014 and 2015, the accruals for certain states were reduced from these elevated levels as a result of both payments being applied to the accrual during 2013, 2014 and 2015 and changes in estimate of the ultimate obligation during the fourth quarters of 2013, 2014 and 2015. We will continue to adjust the rebate accruals as more information becomes available and to reflect actual claims experience. Manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this coverage gap responsibility, we analyze data for eligible Medicare Part D patients against data for eligible Medicare Part D patients treated with our products as well as the historical invoices. This expense is recognized throughout the year as costs are incurred. In certain international markets government-sponsored programs require rebates to be paid based on program specific rules and, accordingly, the rebate accruals are determined primarily on estimated eligible sales. Rebates or administrative fees are offered to certain wholesale customers, group purchasing organizations and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to 15 months from the date of sale. We record a provision for rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of wholesaler inventories, contract sales volumes and average contract pricing. We regularly review the information related to these estimates and adjust the provision accordingly. Chargeback accruals are based on the differentials between product acquisition prices paid by wholesalers and lower government contract pricing paid by eligible customers covered under federally qualified programs. Distributor service fee accruals are based on contractual fees to be paid to the wholesale distributor for services provided. TRICARE is a health care program of the U.S. Department of Defense Military Health System that provides civilian health benefits for military personnel, military retirees and their dependents. TRICARE rebate accruals are included in chargeback accruals and are based on estimated Department of Defense eligible sales multiplied by the TRICARE rebate formula. We record estimated reductions to revenue for free goods and volume-based discounts at the time of the initial sale. The estimated reductions to revenue for such free goods and volume-based discounts are based on the sales terms, historical experience and trend analysis. The cost of free goods is included in cost of goods sold (excluding amortization of acquired intangible assets). We recognize revenue from royalties based on licensees' sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received. Share-Based Compensation: We utilize share based compensation in the form of stock options, restricted stock units (RSUs) and performance-based restricted stock units (PSUs). Compensation expense is recognized in the Consolidated Statements of Income based on the estimated fair value of the awards at grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized to date associated with grants that are not expected to vest will be reversed. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of RSU and PSU grants that are not based on market performance are based on the market value of our Common Stock on the date of grant. Certain of our PSU grants are measured based on the achievement of specified performance and market targets, including non-GAAP revenue, non-GAAP earnings per share, and relative total shareholder return. The grant date fair value for the portion of the PSUs related to non-GAAP revenue and non-GAAP earnings per share is estimated using the fair market value of our common stock on the grant date. The grant date fair value for the portion of the PSUs related to relative total shareholder return is estimated using the Monte Carlo valuation model. Earnings Per Share: Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares resulting from option exercises, RSUs, PSUs, warrants and other incentives had been issued and any proceeds thereof used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to us upon exercise of options, the amount of compensation cost attributed to future services and not yet recognized and, if applicable, the amount of excess income tax benefit that would be credited to paid-in capital upon exercise. New Accounting Pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2018 using one of two prescribed transition methods. We are currently evaluating the effect that the updated standard and transition method will have on our consolidated financial state

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions Receptos, Inc. (Receptos): On August 27, 2015 (Acquisition Date), we acquired all of the outstanding common stock of Receptos, resulting in Receptos becoming our wholly-owned subsidiary. Receptos' lead drug candidate, ozanimod, is a small molecule that modulates sphingosine 1-phosphate 1 and 5 receptors and it is in development for immune-inflammatory indications, including inflammatory bowel disease and relapsing multiple sclerosis (RMS). In clinical trial results, ozanimod demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and RMS, including its cardiac, hepatotoxicity and lymphocyte recovery profile. The phase III TRUE NORTH trial in UC is currently underway with data expected in 2018. The phase III RADIANCE and SUNBEAM RMS trials are ongoing and data are expected in the first half of 2017. The acquisition of Receptos also included RPC4046, an anti-interleukin-13 (IL-13) antibody in development for eosinophilic esophagitis (EoE), an allergic/immune-mediated orphan disease. RPC4046 was licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (collectively referred to as AbbVie) and is currently in phase II testing for EoE. The results of operations for Receptos are included in our consolidated financial statements from the Acquisition Date and the assets and liabilities of Receptos have been recorded at their respective fair values on the Acquisition Date and consolidated with our assets and liabilities. We paid approximately $7.626 billion , consisting of $7.311 billion for common stock outstanding and $0.315 billion for the portion of equity compensation attributable to the pre-combination period. In addition, we paid $0.197 billion for the portion of equity compensation attributable to the post-combination service period, which has been recorded as expense over the required service period ending in the fourth quarter of 2015. The acquisition has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and requires the fair value of acquired IPR&D to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. A preliminary purchase price allocation has been performed and the recorded amounts for intangible assets, goodwill and associated deferred tax assets and liabilities are subject to change pending finalization of valuation efforts. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. The total cash consideration for the acquisition of Receptos is summarized as follows: Total Consideration Cash paid for outstanding common stock $ 7,311.3 Cash for equity compensation attributable to pre-combination service 314.9 Total consideration $ 7,626.2 The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below. During the fourth quarter of 2015, adjustments have been recorded to increase the amounts initially recorded for deferred tax assets, deferred tax liabilities and goodwill as of the Acquisition Date. The amounts recognized will be finalized as the information necessary to complete the analyses is obtained, but no later than one year from the Acquisition Date. Amounts Recognized as of the Acquisition Date (Provisional) Working capital (1) $ 479.2 Property, plant and equipment 5.0 In-process research and development product rights 6,842.0 Current deferred tax assets 241.3 Other non-current assets 7.9 Non-current deferred tax liabilities (2) (2,519.2 ) Total identifiable net assets 5,056.2 Goodwill 2,570.0 Total net assets acquired $ 7,626.2 (1) Includes cash and cash equivalents, available-for-sale marketable securities, other current assets, accounts payable and other current liabilities. (2) Upon integration of the acquired intangible assets into our offshore research, manufacturing, and commercial operations, the deferred tax liability was reclassified to a non-current tax liability. (See Note 16) The fair values of current assets, current liabilities and property, plant and equipment were determined to approximate their book values. The fair value assigned to acquired IPR&D was based on the present value of expected after-tax cash flows attributable to ozanimod, which is in phase II and III testing. The present value of expected after-tax cash flows attributable to ozanimod and assigned to IPR&D was determined by estimating the after-tax costs to complete development of ozanimod into a commercially viable product, estimating future revenue and ongoing expenses to produce, support and sell ozanimod, on an after-tax basis, and discounting the resulting net cash flows to present value. The revenue and costs projections used were reduced based on the probability that compounds at similar stages of development will become commercially viable products. The rate utilized to discount the net cash flows to their present value reflects the risk associated with the intangible asset and is benchmarked to the cost of equity. Acquired IPR&D will be accounted for as an indefinite-lived intangible asset until regulatory approval in a major market or discontinuation of development. The excess of purchase price over the fair value amounts assigned to identifiable assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is primarily attributable to the broadening of our product portfolio and research capabilities in the inflammation and immunology therapeutic area, the assembled workforce and the deferred tax consequences of the IPR&D asset recorded for financial statement purposes. We do not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the acquisition has been recorded as a non-current asset in our Consolidated Balance Sheets and is not amortized, but is subject to review for impairment annually. As a result of the exclusive development license from AbbVie for RPC4046 that Receptos held prior to our acquisition of Receptos, AbbVie holds an option to enter into a global collaboration for RPC4046 with us following the availability of results from the current phase II study. If AbbVie does not exercise its option, we will have an exclusive worldwide license for the development and commercialization of RPC4046 that will be unlimited as to indications. We do not consider this potential collaboration arrangement to be significant. From the Acquisition Date through December 31, 2015, our Consolidated Statements of Income included expenses of $380.5 million associated with the acquisition and operations of Receptos as follows (1) : Statements of Income Location Acquisition Date Through December 31, 2015 Research and development $ 78.6 Selling, general and administrative 5.1 Acquisition related charges and restructuring, net (2) 296.8 Total $ 380.5 (1) In addition, Celgene incurred $19.9 million of acquisition related costs prior to the acquisition date. (2) Consists of acquisition-related compensation expense and transaction costs. Pro Forma Financial Information: The following table provides unaudited pro forma financial information for the twelve-month periods ended December 31, 2015 and 2014 as if the acquisition of Receptos had occurred on January 1, 2014. Twelve-Month Periods Ended December 31, 2015 2014 Total revenue $ 9,256.0 $ 7,676.3 Net income $ 1,630.8 $ 1,499.9 Net income per common share: basic $ 2.06 $ 1.87 Net income per common share: diluted $ 1.98 $ 1.79 The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Celgene and Receptos. The pro-forma financial information assumes that the acquisition-related transaction fees and costs incurred were removed from the twelve-month period ended December 31, 2015 and were assumed to have been incurred during the first quarter of 2014. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the combined operations of Celgene and Receptos. Accordingly, these unaudited pro forma results are presented for illustrative purposes and are not intended to represent or be indicative of the actual results of operations of the combined company that would have been achieved had the acquisition occurred at the beginning of the period presented, nor are they intended to represent or be indicative of future results of operations. Quanticel Pharmaceuticals, Inc. (Quanticel): On October 19, 2015, we completed our previously announced acquisition of Quanticel, a privately held biotechnology company focused on cancer drug discovery, for consideration consisting of $95.9 million in cash at closing plus contingent consideration consisting of future payments of up to $385.0 million for achieving specified discovery and development targets. We have had a research collaboration arrangement with Quanticel since 2011. Through this purchase, Quanticel has become our wholly-owned subsidiary, and we will benefit from full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s programs that target specific epigenetic modifiers, which we expect will advance our pipeline of innovative cancer therapies. The acquisition was accounted for using the acquisition method of accounting for business combinations which requires the assets and liabilities of Quanticel to be recorded at their respective fair values on the acquisition date and consolidated into our Consolidated Balance Sheets. The results of operations for Quanticel have been included in our consolidated financial statements from the date of acquisition. The fair value of consideration transferred in the acquisition of Quanticel is shown in the table below: Fair Value at the Acquisition Date Cash $ 95.9 Fair value of pre-existing equity ownership 11.4 Contingent consideration 166.0 Total fair value of consideration $ 273.3 Prior to the acquisition of Quanticel, we had an equity interest equal to approximately 5% of the company’s total capital stock (on an “as converted” basis). Based on the fair market value of this interest derived from the purchase price, we recognized a gain of $10.3 million , which is reflected as a component of other income (expense), net within our Consolidated Statement of Income for the year ended December 31, 2015. Our potential contingent consideration payments are classified as liabilities, which were measured at fair value as of the acquisition date, with $82.3 million classified as current liabilities and $83.7 million classified as non-current liabilities. We estimated the fair value of potential contingent consideration using a probability-weighted discounted cash flow approach, which reflects the probability and timing of future potential payments. This fair value measurement is based on significant inputs that are not observable in the market and thus represents a level three liability within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a discount rate based on a market participant assumption. See Note 4 for post-acquisition changes in fair value. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below. The amounts recognized will be finalized as the information necessary to complete the analyses is obtained, but no later than one year from the acquisition date. Fair Value at October 19, 2015 (Provisional) Working capital (1) $ 7.0 Property, plant and equipment 1.9 Other non-current assets 0.8 Technology platform intangible asset (2) 232.0 Debt obligations (13.9 ) Non-current deferred tax liabilities (72.3 ) Total identifiable net assets 155.5 Goodwill 117.8 Total net assets acquired $ 273.3 (1) Includes cash and cash equivalents, available-for-sale marketable securities, other current assets, accounts payable and other current liabilities. (2) Technology platform related to Quanticel’s proprietary technology platform for the single-cell genomic analysis of human cancer. The fair values of current and other non-current assets, property, plant and equipment, current liabilities and debt were determined to approximate their book values. The fair value of the technology platform intangible asset is equal to the present value of the after-tax cash flows attributable to the intangible asset, which was calculated based on the multi-period excess earnings method of the income approach. The multi-period excess earnings method of the income approach included estimating probability adjusted annual after-tax net cash flows through the cycle of development and commercialization of potential products generated by the technology platform then discounting the resulting probability adjusted net post-tax cash flows using a discount rate commensurate with the risk of our overall business operations to arrive at the net present value. The excess of purchase price over the fair value amounts assigned to the identifiable assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is largely attributable to the deferred tax consequences of the finite-lived technology platform intangible asset recorded for financial statement purposes, as well as intangible assets that do not qualify for separate recognition at the time of the acquisition. We do not expect any portion of this goodwill to be deductible for tax purposes. Goodwill attributable to the acquisition has been recorded as a non-current asset in our Consolidated Balance Sheets and is not amortized, but is subject to review for impairment annually. The results of operations and cash flows from Quanticel are included in our consolidated financial statements as of October 19, 2015. Pro forma supplemental financial information is not provided as the impact of the Quanticel acquisition was not material to our results of operations in 2015. Nogra Pharma Limited (Nogra): On April 23, 2014, we entered into a license agreement with Nogra, pursuant to which Nogra granted us an exclusive, royalty-bearing license for its intellectual property relating to GED-0301, an antisense oligonucleotide targeting Smad7, to develop and commercialize products containing GED-0301 for the treatment of Crohn’s disease and other indications. A phase II trial of GED-0301 in patients with active Crohn's disease has been completed and we have initiated a multi-trial clinical program that is designed to support global registrations of GED-0301 in Crohn's disease. Under the terms of the agreement, which became effective on May 14, 2014 after receipt of certain governmental clearances and approvals, we made an upfront payment of $710.0 million and may make additional contingent developmental, regulatory and sales milestone payments as well as payments based on percentages of annual sales of licensed products. The maximum aggregate amount payable for development and regulatory milestones is approximately $815.0 million , which covers such milestones relating to Crohn’s disease and other indications. Starting from global annual net sales of $500.0 million , aggregate tiered sales milestone payments could total a maximum of $1.050 billion if global annual net sales reach $4.000 billion . The development and application of the intellectual property covered under the license agreement will be managed by joint committees composed of members from each of Nogra and us. We have the tie-breaking vote on the joint steering committee and as such have ultimate decision-making authority for development, regulatory and commercialization decisions. The agreement also includes provisions for access to employees of Nogra, technical assistance, transfer of manufacturing agreements and transfer of Nogra know-how related to GED-0301. Based on the foregoing factors, for accounting purposes, we have concluded that the acquired assets meet the definition of a business and have accounted for the GED-0301 license as IPR&D acquired in a business combination. The acquisition method of accounting requires that (a) the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and (b) the fair value of IPR&D be classified as an indefinite-lived asset until the successful completion or abandonment of the associated research and development efforts. Pro-forma results of operations for this acquisition have not been presented because this acquisition is not material to our consolidated results of operations. The fair value of consideration transferred to acquire the license amounted to: Fair Value at the Acquisition Date Cash $ 710.0 Contingent consideration 1,060.0 Total fair value of consideration $ 1,770.0 Our potential contingent consideration payments are classified as liabilities, which were measured at fair value as of the acquisition date, with $5.0 million classified as current liabilities and $1.055 billion classified as non-current liabilities. We estimated the fair value of potential contingent consideration using a probability-weighted income approach, which reflects the probability and timing of future potential payments. This fair value measurement is based on significant inputs that are not observable in the market and thus represents a level three liability within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a discount rate based on a market participant assumption. See Note 4 for post-acquisition changes in fair value. The purchase price allocation resulted in the following amounts being allocated to the assets acquired at the acquisition date based on their respective fair values: Fair Value at the Acquisition Date In-process research and development product rights $ 1,620.0 Current deferred tax assets 1.3 Non-current deferred tax liabilities, net (1.3 ) Total identifiable net assets 1,620.0 Goodwill 150.0 Total net assets acquired $ 1,770.0 The fair value of the acquired IPR&D asset was based on the present value of expected net cash flows from the GED-0301 product candidate. Net cash flows were determined by estimating future sales, net of the costs to complete development of GED-0301 into a commercially viable product. Estimated net cash flows were adjusted to reflect the probability of successfully developing a new drug from a product candidate that has completed a phase II trial. Additionally, the projections considered the relevant market sizes and growth factors and the nature and expected timing of a new product introduction. The resulting net cash flows from such potential products include our estimates of cost of sales, operating expenses, and income taxes. The rates utilized to discount the net cash flows to their present value were commensurate with the stage of development of the project and uncertainties in the economic estimates used in the projections described above. The acquired IPR&D asset is accounted for as an indefinite-lived intangible asset until regulatory approval in a major market or discontinuation. The excess of purchase price over the fair value amounts assigned to the assets acquired represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is largely attributable to intangible assets that do not qualify for separate recognition. We expect this goodwill to be deductible for tax purposes. The license agreement may be terminated (i) at our discretion upon 180 days’ written notice to Nogra, provided that such termination will not become effective before May 14, 2017, and (ii) by either party upon material breach of the other party, subject to cure periods. Upon the expiration of our royalty payment obligations under the license agreement, on a country-by-country and licensed product-by-licensed product basis, the license granted under the license agreement will become fully paid-up, irrevocable, perpetual, and non-terminable with respect to such licensed product in such country.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share 2015 2014 2013 Net income $ 1,602.0 $ 1,999.9 $ 1,449.9 Weighted-average shares: Basic 792.2 802.7 827.7 Effect of dilutive securities: Options, RSUs, PSUs, warrants and other 32.7 33.3 32.9 Diluted 824.9 836.0 860.6 Net income per share: Basic $ 2.02 $ 2.49 $ 1.75 Diluted $ 1.94 $ 2.39 $ 1.68 The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 14.1 million in 2015 , 18.7 million in 2014 and 14.3 million in 2013 . During the period of April 2009 through December 2015, our Board of Directors approved repurchases of up to an aggregate of $17.500 billion of our common stock, including the authorization in June 2015 to repurchase an additional $4.000 billion of our common stock. As part of the management of our share repurchase program, we may, from time to time, sell put options on our common stock with strike prices that we believe represent an attractive price to purchase our shares. If the trading price of our shares exceeds the strike price of the put option at the time the option expires, we will have economically reduced the cost of our share repurchase program by the amount of the premium we received from the sale of the put option. If the trading price of our stock is below the strike price of the put option at the time the option expires, we would purchase the shares covered by the option at the strike price of the put option. During 2015 and 2014, we recorded net losses of $9.9 million and net gains of $11.6 million , respectively, from selling put options on our common stock. At December 31, 2015, we had no outstanding put options. We repurchased 28.1 million shares of common stock under the program from all sources during 2015 at a total cost of $3.257 billion . As of December 31, 2015, we had a remaining open-ended repurchase authorization of $3.890 billion .

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurement	Financial Instruments and Fair Value Measurement The table below presents information about assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2015 and 2014, and the valuation techniques we utilized to determine such fair value. • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Our Level 1 assets consist of marketable equity securities. Our Level 1 liability relates to our publicly traded Contingent Value Rights (CVRs). See Note 18 for a description of the CVRs. • Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Our Level 2 assets consist primarily of U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency MBS, non-U.S. government, agency and supranational securities, global corporate debt securities, asset backed securities, foreign currency forward contracts, purchased foreign currency options and interest rate swap contracts. Our Level 2 liabilities relate to written foreign currency options, foreign currency forward contracts and interest rate swap contracts. • Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. We do not have any Level 3 assets. Our Level 3 liabilities consist of contingent consideration related to undeveloped product rights resulting from the acquisitions of Gloucester Pharmaceuticals, Inc. (Gloucester) and Nogra in addition to contingent consideration related to the undeveloped product rights and technology platforms acquired as part of the acquisitions of Avila Therapeutics, Inc. (Avila) and Quanticel. The maximum remaining potential payments related to the contingent consideration from the acquisitions of Gloucester, Avila and Quanticel are estimated to be $120.0 million , $555.0 million and $385.0 million , respectively, and $1.865 billion plus amounts based on sales pursuant to the license agreement with Nogra. Balance at December 31, 2015 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 1,671.6 $ 1,235.9 $ 435.7 $ — Forward currency contracts 606.0 — 606.0 — Purchased currency options 46.7 — 46.7 — Interest rate swaps 52.5 — 52.5 — Total assets $ 2,376.8 $ 1,235.9 $ 1,140.9 $ — Liabilities: Contingent value rights $ (51.9 ) $ (51.9 ) $ — $ — Written currency options (19.1 ) — (19.1 ) — Other acquisition related contingent consideration (1,521.5 ) — — (1,521.5 ) Total liabilities $ (1,592.5 ) $ (51.9 ) $ (19.1 ) $ (1,521.5 ) Balance at December 31, 2014 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 3,425.1 $ 1,051.3 $ 2,373.8 $ — Forward currency contracts 550.7 — 550.7 — Purchased currency options 9.8 — 9.8 — Interest rate swaps 20.0 — 20.0 — Total assets $ 4,005.6 $ 1,051.3 $ 2,954.3 $ — Liabilities: Contingent value rights $ (136.3 ) $ (136.3 ) $ — $ — Written currency options (4.6 ) — (4.6 ) — Other acquisition related contingent consideration (1,279.0 ) — — (1,279.0 ) Total liabilities $ (1,419.9 ) $ (136.3 ) $ (4.6 ) $ (1,279.0 ) There were no security transfers between Levels 1 and 2 during years ended December 31, 2015 and 2014. The following table represents a roll-forward of the fair value of Level 3 instruments: 2015 2014 Liabilities: Balance at beginning of period $ (1,279.0 ) $ (228.5 ) Amounts acquired or issued (166.0 ) (1,060.0 ) Net change in fair value (76.5 ) (30.5 ) Settlements — 40.0 Transfers in and/or out of Level 3 — — Balance at end of period $ (1,521.5 ) $ (1,279.0 ) Level 3 liabilities outstanding as of December 31, 2015 primarily consisted of contingent consideration related to the acquisitions of Avila, Gloucester, Nogra and Quanticel. Level 3 liabilities outstanding increased by $242.5 million in 2015 compared to 2014. Amounts acquired or issued in 2015 represent $166.0 million from the October 2015 acquisition of Quanticel. The $76.5 million net increase in the fair value of Level 3 liabilities in 2015 was related to accretion of the fair value of our contingent consideration due to the passage of time, which was partly offset by reductions in the probability and delays in the assumed timing of certain contingent consideration milestones related to the acquisition of Avila. Changes to the fair value of contingent consideration are recorded on the Consolidated Statements of Income as acquisition related charges and restructuring, net.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities Our revenue and earnings, cash flows and fair values of assets and liabilities can be impacted by fluctuations in foreign exchange rates and interest rates. We actively manage the impact of foreign exchange rate and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency option contracts, foreign currency forward contracts, treasury rate lock agreements and interest rate swap contracts. In instances where these financial instruments are accounted for as cash flow hedges or fair value hedges, we may from time to time terminate the hedging relationship. If a hedging relationship is terminated we generally either settle the instrument or enter into an offsetting instrument. Foreign Currency Risk Management We maintain a foreign exchange exposure management program to mitigate the impact of volatility in foreign exchange rates on future foreign currency cash flows, translation of foreign earnings and changes in the fair value of assets and liabilities denominated in foreign currencies. Through our revenue hedging program, we endeavor to reduce the impact of possible unfavorable changes in foreign exchange rates on our future U.S. dollar cash flows that are derived from foreign currency denominated sales. To achieve this objective, we hedge a portion of our forecasted foreign currency denominated sales that are expected to occur in the foreseeable future, typically within the next three years . We manage our anticipated transaction exposure principally with foreign currency forward contracts and occasionally foreign currency put and call options. Foreign Currency Forward Contracts: We use foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, manage exchange rate volatility in the translation of foreign earnings, and reduce exposures to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. We manage a portfolio of foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated revenues and expenses of foreign subsidiaries. The foreign currency forward hedging contracts outstanding at December 31, 2015 and December 31, 2014 had settlement dates within 36 months . The spot rate components of these foreign currency forward contracts are designated as cash flow hedges and, to the extent effective, any unrealized gains or losses are reported in other comprehensive income (OCI) and reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. If a hedging relationship is terminated with respect to a foreign currency forward contract, accumulated gains or losses associated with the contract remain in OCI until the hedged forecasted transaction occurs and are reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. Any ineffectiveness on these foreign currency forward contracts is reported on the Consolidated Statements of Income in other income (expense), net. The forward point components of these foreign currency forward contracts are not designated as cash flow hedges and all fair value adjustments of forward point amounts are recorded to other income (expense), net. Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at December 31, 2015 and December 31, 2014 : Notional Amount Foreign Currency: 2015 2014 Australian Dollar $ 45.1 $ 18.8 British Pound 289.3 304.8 Canadian Dollar 135.9 43.7 Euro 2,934.3 3,375.7 Japanese Yen 510.4 541.1 Total $ 3,915.0 $ 4,284.1 We consider the impact of our own and the counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its obligations under the contract on an ongoing basis. As of December 31, 2015 , credit risk did not materially change the fair value of our foreign currency forward contracts. We also manage a portfolio of foreign currency contracts to reduce exposures to foreign currency fluctuations of certain recognized assets and liabilities denominated in foreign currencies and, from time to time, we enter into foreign currency contracts to manage exposure related to translation of foreign earnings. These foreign currency forward contracts have not been designated as hedges and, accordingly, any changes in their fair value are recognized on the Consolidated Statements of Income in other income (expense), net in the current period. The aggregate notional amount of the foreign currency forward non-designated hedging contracts outstanding at December 31, 2015 and December 31, 2014 were $920.0 million and $835.5 million , respectively. Foreign Currency Option Contracts: From time to time, we may hedge a portion of our future foreign currency exposure by utilizing a strategy that involves both a purchased local currency put option and a written local currency call option that are accounted for as hedges of future sales denominated in that local currency. Specifically, we sell (or write) a local currency call option and purchase a local currency put option with the same expiration dates and local currency notional amounts but with different strike prices. This combination of transactions is generally referred to as a “collar.” The expiration dates and notional amounts correspond to the amount and timing of forecasted foreign currency sales. If the U.S. dollar weakens relative to the currency of the hedged anticipated sales, the purchased put option value reduces to zero and we benefit from the increase in the U.S. dollar equivalent value of our anticipated foreign currency cash flows; however, this benefit would be capped at the strike level of the written call, which forms the upper end of the collar. The premium collected from the sale of the call option is equal to the premium paid for the purchased put option, resulting in a net zero cost for each collar. Outstanding foreign currency option contracts entered into to hedge forecasted revenue were as follows at December 31, 2015 and 2014 : Notional Amount 1 2015 2014 Foreign currency option contracts designated as hedging activity: Purchased Put $ 641.5 $ 152.6 Written Call $ 690.0 $ 160.9 1 U.S. dollar notional amounts are calculated as the hedged local currency amount multiplied by the strike value of the foreign currency option. The local currency notional amounts of our purchased put and written call that are designated as hedging activities are equal to each other. Interest Rate Risk Management In anticipation of issuing fixed-rate debt, we may use forward starting interest rate swaps (forward starting swaps) or treasury rate lock agreements (treasury rate locks) that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. To the extent these hedges of cash flows related to anticipated debt are effective, any realized or unrealized gains or losses on the treasury rate locks or forward starting swaps are reported in OCI and are recognized in income over the life of the anticipated fixed-rate notes. Forward Starting Interest Rate Swaps and Treasury Rate Locks: During 2014, we entered into forward starting swaps that were designated as cash flow hedges to hedge against changes in interest rates that could impact an anticipated issuance of debt in 2015. During 2015, we entered into additional forward starting swaps and treasury rate locks. Forward starting swaps and treasury rate locks with a combined aggregate notional value of $2.900 billion were settled upon the issuance of debt in August 2015, when the net fair value of the forward starting swaps and treasury rate locks in accumulated other comprehensive income was in a loss position of $21.6 million . The net loss will be recognized as interest expense over the life of the associated senior notes. During 2015 and in January 2016, we entered into forward starting swaps with effective dates in September 2017 and maturing in ten years. Interest Rate Swap Contracts: From time to time we hedge the fair value of certain debt obligations through the use of interest rate swap contracts. The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in interest rates. Since the specific terms and notional amount of the swap are intended to match those of the debt being hedged, it is assumed to be a highly effective hedge and all changes in fair value of the swap are recorded on the Consolidated Balance Sheets with no net impact recorded in income. Any net interest payments made or received on interest rate swap contracts are recognized as interest expense. If a hedging relationship is terminated for an interest rate swap contract, accumulated gains or losses associated with the contract are measured and recorded as a reduction or increase of current and future interest expense associated with the previously hedged debt obligations. We have entered into swap contracts that were designated as hedges of certain of our fixed rate notes and also terminated the hedging relationship by settling certain of those swap contracts during 2013, 2014 and 2015 . The settlement of swap contracts due to terminations and maturities resulted in the receipt of net proceeds of $10.8 million and $25.5 million in 2015 and 2014 , respectively, which are accounted for as a reduction of current and future interest expense associated with these notes. See Note 11 for additional details related to reductions of current and future interest expense. The following table summarizes the notional amounts of our outstanding interest rate swap contracts at December 31, 2015 and December 31, 2014 : Notional Amount 2015 2014 Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes: 2.450% senior notes due 2015 $ — $ 300.0 1.900% senior notes due 2017 300.0 300.0 2.300% senior notes due 2018 200.0 200.0 2.250% senior notes due 2019 500.0 500.0 3.950% senior notes due 2020 500.0 500.0 3.250% senior notes due 2022 1,000.0 750.0 4.000% senior notes due 2023 700.0 150.0 3.625% senior notes due 2024 100.0 — 3.875% senior notes due 2025 250.0 — Total $ 3,550.0 $ 2,700.0 The following table summarizes the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of December 31, 2015 and 2014 : December 31, 2015 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 356.2 $ 18.0 Other non-current assets 287.8 28.0 Interest rate swap agreements Other current assets 30.7 — Other non-current assets 26.1 4.7 Other non-current liabilities 0.2 0.9 Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 46.0 5.9 Other current liabilities 2.9 7.4 Interest rate swap agreements Other current assets 2.4 2.3 Other non-current assets 2.4 1.4 Total $ 754.7 $ 68.6 December 31, 2014 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 264.9 $ 44.9 Other current liabilities 0.1 1.7 Other non-current assets 322.3 17.5 Interest rate swap agreements Other current assets 17.9 — Other non-current assets 4.8 0.3 Other non-current liabilities — 3.8 Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 39.7 6.0 Other current liabilities 0.1 1.1 Interest rate swap agreements Other current assets 0.1 — Other non-current assets 1.3 — Total $ 651.2 $ 75.3 1 Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20. The following table summarizes the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Gain/(Loss) Recognized in OCI on Derivative 1 Location of Gain/(Loss) Reclassified from Accumulated OCI into Income Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income Location of Gain/(Loss) Recognized in Income on Derivative Amount of Gain/(Loss) Recognized in Income on Derivative Foreign exchange contracts $ 429.4 Net product sales $ 354.4 Other income, net $ 20.0 2 Treasury rate lock agreements $ (27.9 ) Interest expense $ (4.2 ) Other income, net $ (0.2 ) 3 Forward starting interest rate swaps $ 9.0 Interest expense $ (1.5 ) Other income, net $ 0.3 3 1 Net gains of $364.8 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. 2 The amount of net gains recognized in income represents $23.0 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $3.0 million in losses related to the ineffective portion of the hedging relationships. 3 The amount of net (loss) gain recognized in income relates to the ineffective portion of the hedging relationships. 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Gain/(Loss) Recognized in OCI on Derivative 1 Location of Gain/(Loss) Reclassified from Accumulated OCI into Income Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income Location of Gain/(Loss) Recognized in Income on Derivative Amount of Gain/(Loss) Recognized in Income on Derivative Foreign exchange contracts $ 600.4 Net product sales $ 27.5 Other income, net $ (12.2 ) 1 Treasury rate lock agreements $ — Interest expense $ (3.5 ) Forward starting interest rate swaps $ (32.3 ) Interest expense $ (0.9 ) Other income, net (3.6 ) 2 1 The amount of net gain recognized in income represents $18.0 million in losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $5.8 million of gains related to the ineffective portion of the hedging relationships. 2 The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships. The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : Location of Gain (Loss) Recognized in Income on Derivative Amount of Gain (Loss) Recognized in Income on Derivative Instrument 2015 2014 Interest rate swaps Interest expense $ 60.3 $ 43.0 The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : Location of Gain (Loss) Recognized in Income on Derivative Amount of Gain (Loss) Recognized in Income on Derivative Instrument 2015 2014 Foreign exchange contracts Other income, net $ 81.2 $ 79.3 Put options sold Other income, net $ (9.9 ) $ 11.6 The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Income in other income (expense), net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each Income Statement account in current and/or future periods.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities Available-for-Sale	12 Months Ended
	Dec. 31, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents and Marketable Securities Available-for-Sale	Cash, Cash Equivalents and Marketable Securities Available-for-Sale Money market funds of $1.413 billion and $2.251 billion at December 31, 2015 and 2014 , respectively, were recorded at cost, which approximates fair value and are included in cash and cash equivalents. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at December 31, 2015 and 2014 were as follows: December 31, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 153.0 $ — $ (0.4 ) $ 152.6 U.S. government-sponsored agency MBS 29.8 0.1 (0.4 ) 29.5 Corporate debt – global 219.7 — (1.6 ) 218.1 Asset backed securities 35.6 — (0.1 ) 35.5 Marketable equity securities 811.5 468.1 (43.7 ) 1,235.9 Total available-for-sale marketable securities $ 1,249.6 $ 468.2 $ (46.2 ) $ 1,671.6 December 31, 2014 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 1,044.7 $ 0.3 $ (0.8 ) $ 1,044.2 U.S. government-sponsored agency securities 145.1 0.1 (0.1 ) 145.1 U.S. government-sponsored agency MBS 531.1 1.0 (2.7 ) 529.4 Non-U.S. government, agency and supranational securities 32.4 — (0.1 ) 32.3 Corporate debt – global 446.3 0.6 (1.2 ) 445.7 Asset backed securities 177.3 — (0.2 ) 177.1 Marketable equity securities 335.2 716.3 (0.2 ) 1,051.3 Total available-for-sale marketable securities $ 2,712.1 $ 718.3 $ (5.3 ) $ 3,425.1 U.S. government-sponsored agency securities include general unsecured obligations either issued directly by or guaranteed by U.S. Government Sponsored Enterprises. U.S. government-sponsored agency MBS include mortgage-backed securities issued by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association. Non-U.S. government, agency and supranational securities consist of direct obligations of highly rated governments of nations other than the United States and obligations of sponsored agencies and other entities that are guaranteed or supported by highly rated governments of nations other than the United States. Corporate debt-global includes obligations issued by investment-grade corporations, including some issues that have been guaranteed by governments and government agencies. Asset backed securities consist of triple-A rated securities with cash flows collateralized by credit card receivables and auto loans. Marketable equity securities consist of investments in publicly traded equity securities. The decrease in net unrealized gains in marketable equity securities in 2015 compared to 2014 primarily reflects the decrease in market value for certain equity investments subsequent to their respective initial public offerings. Net unrealized losses in marketable debt securities primarily reflect the impact of increased interest rates at December 31, 2015 . The fair value of all available-for-sale securities, which have been in an unrealized loss position for less than and longer than 12 months at December 31, 2015 , was as follows: Less than 12 months 12 months or longer Total December 31, 2015 Estimated Fair Value Gross Unrealized Loss Estimated Fair Value Gross Unrealized Loss Estimated Fair Value Gross Unrealized Loss U.S. Treasury securities $ 143.6 $ (0.4 ) $ — $ — $ 143.6 $ (0.4 ) U.S. government-sponsored agency MBS 12.8 (0.3 ) 6.8 (0.1 ) 19.6 (0.4 ) Corporate debt – global 193.5 (1.6 ) — — 193.5 (1.6 ) Asset backed securities 29.6 (0.1 ) 5.9 — 35.5 (0.1 ) Marketable equity securities 494.4 (43.7 ) — — 494.4 (43.7 ) Total $ 873.9 $ (46.1 ) $ 12.7 $ (0.1 ) $ 886.6 $ (46.2 ) The Company believes that the decline in fair value of securities held at December 31, 2015 below their cost is temporary and intends to retain its investment in these securities for a sufficient period of time to allow for recovery in the market value of these investments. Duration periods of available-for-sale debt securities at December 31, 2015 were as follows: Amortized Cost Fair Value Duration of one year or less $ 58.4 $ 58.3 Duration of one through three years 363.7 361.8 Duration of three through five years 15.9 15.6 Total $ 438.0 $ 435.7

Inventory

Inventory	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory A summary of inventories by major category at December 31, 2015 and 2014 follows: 2015 2014 Raw materials $ 201.3 $ 200.0 Work in process 120.0 101.5 Finished goods 122.1 91.6 Total $ 443.4 $ 393.1

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment at December 31, 2015 and 2014 consisted of the following: 2015 2014 Land $ 75.4 $ 37.9 Buildings 274.1 260.8 Building and operating equipment 33.1 32.0 Leasehold improvements 152.3 135.5 Machinery and equipment 246.6 213.5 Furniture and fixtures 53.2 48.8 Computer equipment and software 389.6 332.8 Construction in progress 221.3 104.8 Subtotal 1,445.6 1,166.1 Less accumulated depreciation and amortization 631.5 523.5 Total $ 814.1 $ 642.6 The increase in the balance of construction in progress from December 31, 2014 to December 31, 2015 primarily relates to the expansion of our corporate headquarters in Summit, New Jersey.

Other Financial Information

Other Financial Information	12 Months Ended
	Dec. 31, 2015
Other Financial Information
Other Financial Information	Other Financial Information Accrued expenses at December 31, 2015 and 2014 consisted of the following: 2015 2014 Compensation $ 297.8 $ 285.2 Rebates, distributor chargebacks and distributor services 365.5 232.9 Clinical trial costs and grants 255.1 189.5 Interest 170.3 59.1 Royalties, license fees and collaboration agreements 75.9 26.7 Commercial related activities 38.7 56.2 Sales returns 18.8 10.2 Rent 18.1 14.0 Professional services 14.9 7.9 Other taxes 7.9 9.3 Other 113.7 100.1 Total $ 1,376.7 $ 991.1 Other current liabilities at December 31, 2015 and 2014 consisted of the following: 2015 2014 Deferred tax liability $ — $ 131.2 Contingent consideration – Quanticel acquisition 82.5 — Contingent consideration – Nogra acquisition 24.9 24.7 Contingent consideration – Avila acquisition 2.0 9.8 Compensation 55.6 32.6 Sales, use and value added tax 61.1 56.8 Derivative contracts 4.5 2.6 Collaboration agreement upfront payable 40.3 14.0 Other 0.1 4.1 Total $ 271.0 $ 275.8 Other non-current liabilities at December 31, 2015 and 2014 consisted of the following: 2015 2014 Contingent consideration – Quanticel acquisition $ 84.2 $ — Contingent consideration – Nogra acquisition 1,214.5 1,110.8 Contingent consideration – Avila acquisition 94.5 114.2 Contingent consideration – Gloucester acquisition 18.9 19.5 Contingent Value Rights - Abraxis acquisition 51.9 136.3 Deferred compensation and long-term incentives 170.5 150.5 Deferred tax liability 377.7 555.6 Other 29.5 49.8 Total $ 2,041.7 $ 2,136.7

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible Assets: Our finite lived intangible assets primarily consist of developed product rights and technology obtained from the Pharmion Corp. (Pharmion), Gloucester, Abraxis BioScience, Inc. (Abraxis), Avila and Quanticel acquisitions. Our indefinite lived intangible assets consist of acquired IPR&D product rights from the Receptos, Nogra and Gloucester acquisitions. The remaining weighted-average amortization period for finite-lived intangible assets not fully amortized is approximately 9.7 years . Intangible assets outstanding as of December 31, 2015 and December 31, 2014 are summarized as follows: December 31, 2015 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,448.3 ) $ 1,957.6 Technology 565.7 (197.1 ) 368.6 Licenses 66.7 (22.3 ) 44.4 Other 44.0 (27.1 ) 16.9 4,082.3 (1,694.8 ) 2,387.5 Non-amortized intangible assets: Acquired IPR&D product rights 8,470.6 — 8,470.6 Total intangible assets $ 12,552.9 $ (1,694.8 ) $ 10,858.1 December 31, 2014 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,234.1 ) $ 2,171.8 Technology 333.7 (135.1 ) 198.6 Licenses 67.0 (18.1 ) 48.9 Other 42.5 (22.9 ) 19.6 3,849.1 (1,410.2 ) 2,438.9 Non-amortized intangible assets: Acquired IPR&D product rights 1,628.7 — 1,628.7 Total intangible assets $ 5,477.8 $ (1,410.2 ) $ 4,067.6 The gross carrying value of intangible assets increased by $7.075 billion in 2015 compared to 2014 primarily due to the addition of $6.842 billion of IPR&D from the Receptos acquisition and $0.232 billion of a technology platform from the Quanticel acquisition. Amortization expense was $284.7 million , $263.9 million and $270.1 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Amortization expense increased by a net $20.8 million in 2015 compared to 2014, the increase primarily related to the amortization of technology related to the acquisition of Quanticel and an acceleration of amortization expense related to certain Gloucester related intangible assets. Assuming no changes in the gross carrying amount of intangible assets, the future annual amortization expense related to intangible assets is expected to be approximately $373.1 million in 2016 , $372.4 million in 2017, $299.1 million in 2018, $162.9 million in 2019, and $153.8 million in 2020. Goodwill: At December 31, 2015 , our goodwill related to the 2015 acquisitions of Receptos and Quanticel, 2014 acquisition of Nogra, the 2012 acquisition of Avila, the 2010 acquisitions of Abraxis and Gloucester, the 2008 acquisition of Pharmion and the 2004 acquisition of Penn T Limited. The change in carrying value of goodwill is summarized as follows: Balance at December 31, 2014 $ 2,191.2 Acquisition of Receptos 2,570.0 Acquisition of Quanticel 117.8 Balance at December 31, 2015 $ 4,879.0

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt Short-Term Borrowings and Current Portion of Long-Term Debt: The carrying value of short-term borrowings and current portion of long-term debt outstanding at December 31, 2015 and December 31, 2014 includes: 2015 2014 Commercial paper $ — $ 99.6 2.450% senior notes due 2015 — 506.3 Total $ — $ 605.9 Long-Term Debt: We have an aggregate $14.250 billion principal amount of senior notes outstanding at varying maturity dates and interest rates. The carrying values of the long-term portion of these senior notes at December 31, 2015 and 2014 are summarized below: 2015 2014 1.900% senior notes due 2017 $ 501.2 $ 501.0 2.125% senior notes due 2018 999.9 — 2.300% senior notes due 2018 401.7 401.2 2.250% senior notes due 2019 505.1 502.5 2.875% senior notes due 2020 1,497.5 — 3.950% senior notes due 2020 507.1 502.8 3.250% senior notes due 2022 1,016.1 1,010.2 3.550% senior notes due 2022 997.4 — 4.000% senior notes due 2023 710.3 708.5 3.625% senior notes due 2024 1,001.7 996.8 3.875% senior notes due 2025 2,475.6 — 5.700% senior notes due 2040 249.6 249.5 5.250% senior notes due 2043 396.7 396.7 4.625% senior notes due 2044 996.6 996.5 5.000% senior notes due 2045 1,993.9 — Total long-term debt $ 14,250.4 $ 6,265.7 At December 31, 2015 , the fair value of our outstanding Senior Notes was $14.299 billion and represented a Level 1 measurement within the fair value measurement hierarchy. In August 2015, we issued an additional $8.000 billion principal amount of senior notes consisting of $1.000 billion aggregate principal amount of 2.125% Senior Notes due 2018 (the 2018 notes), $1.500 billion aggregate principal amount of 2.875% Senior Notes due 2020 (the 2020 notes), $1.000 billion aggregate principal amount of 3.550% Senior Notes due 2022 (the 2022 notes), $2.500 billion aggregate principal amount of 3.875% Senior Notes due 2025 (the 2025 notes) and $2.000 billion aggregate principal amount of 5.000% Senior Notes due 2045 (the 2045 notes and together with the 2018 notes, the 2020 notes, the 2022 notes, and the 2025 notes, referred to herein as the “2015 issued notes”). The 2015 issued notes were issued at 99.994% , 99.819% , 99.729% , 99.034% , and 99.691% of par, respectively, and the discount is being amortized as additional interest expense over the period from issuance through maturity. Offering costs of approximately $50.0 million have been recorded as debt issuance costs on our Consolidated Balance Sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the 2015 issued notes is payable semi-annually in arrears on February 15 and August 15 each year beginning February 15, 2016 and the principal on each 2015 issued note is due in full at their respective maturity dates. The 2015 issued notes may be redeemed at our option, in whole or in part; the 2018 notes, the 2020 notes, and the 2022 notes may be redeemed at any time, the 2025 notes and 2045 notes may be redeemed at three months and six months prior to the maturity dates, respectively. Early redemption would be at a redemption price equaling accrued and unpaid interest plus the greater of 100% of the principal amount of the 2015 issued notes to be redeemed or the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis plus 20 basis points in the case of the 2018 notes, 20 basis points in the case of the 2020 notes, 25 basis points in the case of the 2022 notes, 30 basis points in the case of the 2025 notes, and 35 basis points in the case of the 2045 notes. If we experience a change of control accompanied by a downgrade of the debt to below investment grade, we will be required to offer to repurchase the 2015 issued notes at a purchase price equal to 101% of their principal amount plus accrued and unpaid interest. We are subject to covenants which limit our ability to pledge properties as security under borrowing arrangements and limit our ability to perform sale and leaseback transactions involving our property. In 2015, the 2.45% senior notes with a principal amount of $500.0 million matured and were repaid. We also assumed $13.9 million of debt obligations as part of the acquisition of Quanticel in 2015 that were repaid in 2015. From time to time, we have used treasury rate locks and forward starting interest rate swap contracts to hedge against changes in interest rates in anticipation of issuing fixed-rate notes. As of December 31, 2015, a balance of $68.1 million in losses remained in accumulated OCI related to settlements of these derivative instruments and will be recognized as interest expense over the life of the notes. At December 31, 2015, we were party to pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes as described in Note 5. Our swap contracts outstanding at December 31, 2015 effectively convert the hedged portion of our fixed-rate notes to floating rates. From time to time we terminate the hedging relationship on certain of our swap contracts by settling the contracts or by entering into offsetting contracts. Any net proceeds received or paid in these settlements are accounted for as a reduction or increase of current and future interest expense associated with the previously hedged notes. As of December 31, 2015, we had a balance of $33.1 million of unamortized gains recorded as a component of our debt as a result of past swap contract settlements, including $6.0 million related to the settlement of swap contracts during 2015. Commercial Paper: The carrying value of Commercial Paper as of December 31, 2015 and 2014 was $0.0 million and $99.6 million , respectively, and approximated its fair value. As of December 31, 2015, we had available capacity to issue up to $1.750 billion of Commercial Paper and there were no borrowings under the Program. Senior Unsecured Credit Facility: We maintain a senior unsecured revolving credit facility (Credit Facility) that provides revolving credit in the aggregate amount of $1.750 billion , which was increased from $1.500 billion in April 2015. Also in April 2015, the term of the Credit Facility was extended from April 18, 2018 to April 17, 2020. Subject to certain conditions, we have the right to increase the amount of the Credit Facility (but in no event more than one time per annum) up to a maximum aggregate amount of $2.000 billion . Amounts may be borrowed in U.S. dollars for general corporate purposes. The Credit Facility currently serves as backup liquidity for our Commercial Paper borrowings. At December 31, 2015 and 2014 , there was no outstanding borrowing against the Credit Facility. The Credit Facility contains affirmative and negative covenants including certain customary financial covenants. We were in compliance with all financial covenants as of December 31, 2015 .

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity Preferred Stock: Our Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 5.0 million shares of preferred stock, and to determine the price, rights, privileges, and preferences of such shares. Common Stock: At December 31, 2015 , we were authorized to issue up to 1.150 billion shares of common stock of which shares of common stock issued totaled 940.1 million . Treasury Stock: During the period of April 2009 through December 2015, our Board of Directors has approved repurchases of up to an aggregate $17.500 billion of our common stock, including the June 2015 authorization to repurchase an additional $4.000 billion of our common stock. We repurchased $3.251 billion , $2.928 billion , and $2.769 billion of treasury stock under the program in 2015 , 2014 and 2013 , respectively, excluding transaction fees. As of December 31, 2015 an aggregate 146.9 million common shares were repurchased under the program at an average price of $92.67 per common share and total cost of $13.610 billion . Other: When employee awards of RSUs vest and are settled net in order to fulfill minimum statutory tax withholding requirements, the shares withheld are reflected as treasury stock. A summary of changes in common stock issued and treasury stock is presented below (in millions of shares): Common Stock Common Stock in Treasury December 31, 2012 880.9 (78.7 ) Exercise of stock options and conversion of restricted stock units 25.0 (0.5 ) Issuance of common stock for employee benefit plans 0.6 — Shares repurchased under share repurchase program — (22.3 ) December 31, 2013 906.5 (101.5 ) Exercise of stock options and conversion of restricted stock units 18.3 (1.3 ) Issuance of common stock for employee benefit plans — 0.2 Shares repurchased under share repurchase program — (22.0 ) December 31, 2014 924.8 (124.6 ) Exercise of stock options and conversion of restricted stock units 15.3 (1.2 ) Issuance of common stock for employee benefit plans — 0.4 Shares repurchased under share repurchase program — (28.1 ) December 31, 2015 940.1 (153.5 )

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The components of other comprehensive income (loss) consist of changes in pension liability, changes in net unrealized gains (losses) on marketable securities classified as available-for-sale, net unrealized gains (losses) related to cash flow hedges and changes in foreign currency translation adjustments. The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Pension Liability Net Unrealized Gains (Losses) From Marketable Securities Net Unrealized Gains (Losses) From Hedges Foreign Currency Translation Adjustment Total Accumulated Other Comprehensive Income (Loss) Balance December 31, 2013 $ (6.9 ) $ 137.3 $ (36.0 ) $ (0.4 ) $ 94.0 Other comprehensive income (loss) before reclassifications (8.6 ) 320.1 580.4 (49.8 ) 842.1 Amount reclassified from accumulated other comprehensive income — 3.5 (24.8 ) — (21.3 ) Net current-period other comprehensive income (loss) (8.6 ) 323.6 555.6 (49.8 ) 820.8 Balance December 31, 2014 $ (15.5 ) $ 460.9 $ 519.6 $ (50.2 ) $ 914.8 Other comprehensive income (loss) before reclassifications 1.6 (204.6 ) 417.7 (26.1 ) 188.6 Amount reclassified from accumulated other comprehensive income — 15.2 (350.9 ) — (335.7 ) Net current-period other comprehensive income (loss) 1.6 (189.4 ) 66.8 (26.1 ) (147.1 ) Balance December 31, 2015 $ (13.9 ) $ 271.5 $ 586.4 $ (76.3 ) $ 767.7 Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income Components Affected Line Item in the Consolidated Statements of Income Years Ended December 31, 2015 2014 2013 Gains (losses) from cash-flow hedges: Foreign exchange contracts Net product sales $ 354.4 $ 27.5 $ 10.7 Treasury rate lock agreements Interest (expense) (4.2 ) (3.5 ) (3.4 ) Interest rate swap agreements Interest (expense) (1.5 ) (0.9 ) — Income tax benefit 2.2 1.7 6.9 Gains (losses) from available-for-sale marketable securities: Realized income (loss) on sales of marketable securities Interest and investment income, net (23.4 ) (5.4 ) (7.3 ) Income tax benefit 8.2 1.9 2.2 Total reclassification, net of tax $ 335.7 $ 21.3 $ 9.1

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We have a stockholder-approved stock incentive plan, the 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (Plan) that provides for the granting of options, RSUs, PSUs and other share-based awards to our employees and officers. The Management Compensation and Development Committee of the Board of Directors (Compensation Committee) may determine the type, amount and terms, including vesting, of any awards made under the Plan. On June 17, 2015, our stockholders approved an amendment of the Plan, which included the following key modifications: adoption of an aggregate share reserve of 247.8 million shares of Common Stock, which includes 19.8 million new shares of Common Stock; and an extension of the term of the Plan through April 15, 2025. With respect to options granted under the Plan, the exercise price may not be less than the market closing price of the common stock on the date of grant. In general, options granted under the Plan vest over periods ranging from immediate vesting to four -year vesting and expire ten years from the date of grant, subject to earlier expiration in case of termination of employment unless the participant meets the retirement provision under which the option would have a maximum of three additional years to vest. The vesting period for options granted under the Plan is subject to certain acceleration provisions if a change in control, as defined in the Plan, occurs. Plan participants may elect to exercise options at any time during the option term. However, any shares so purchased which have not vested as of the date of exercise shall be subject to forfeiture, which will lapse in accordance with the established vesting time period. During 2015, we increased our usage of PSUs and began issuing PSUs to certain executive officers that are payable in shares of our common stock at the end of a three -year performance measurement period. The number of shares to be issued at the end of the measurement period will vary, based on performance, from 0% to 200% of the target number of PSUs granted, depending on the achievement of specified performance and market targets for revenue ( 37.5% weighting), earnings per share ( 37.5% weighting), and relative total shareholder return ( 25% weighting). All shares delivered upon PSU vesting are restricted from trading for one year and one day from the vesting date. The grant date fair value for the portion of the PSUs related to revenue and earnings per share was estimated using the fair market value of our common stock on the grant date. The grant date fair value for the portion of the PSUs related to relative total shareholder return was estimated using the Monte Carlo valuation model. Shares of common stock available for future share-based grants under all plans were 38.3 million at December 31, 2015 . The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the years ended December 31, 2015 , 2014 and 2013 : 2015 2014 2013 Cost of goods sold $ 31.7 $ 26.2 $ 18.5 Research and development 250.7 196.5 144.7 Selling, general and administrative 294.2 224.9 162.6 Total share-based compensation expense 576.6 447.6 325.8 Tax benefit related to share-based compensation expense 161.2 129.3 94.5 Reduction in income $ 415.4 $ 318.3 $ 231.3 Included in share-based compensation expense for the years ended December 31, 2015 , 2014 and 2013 was compensation expense related to non-qualified stock options of $346.1 million , $276.3 million and $197.6 million , respectively. Net proceeds received from share-based compensation arrangements for the years ended December 31, 2015 , 2014 and 2013 were $251.7 million , $297.2 million and $551.6 million , respectively, and the excess tax benefit recognized was $300.5 million , $250.6 million and $169.4 million , respectively. We do not recognize a deferred tax asset for excess tax benefits that have not been realized and have adopted the tax law method as our accounting policy regarding the ordering of tax benefits to determine whether an excess tax benefit has been realized. Stock Options: As of December 31, 2015 , there was $640.9 million of total unrecognized compensation cost related to stock options granted under the plans. That cost will be recognized over an expected remaining weighted-average period of 2.0 years. The weighted-average grant date fair value of the stock options granted during the years ended December 31, 2015 , 2014 and 2013 was $38.83 per share, $27.92 per share and $20.22 per share, respectively. We estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions: 2015 2014 2013 Risk-free interest rate 1.17% - 1.72% 1.51% - 1.90% 0.68% - 1.70% Expected volatility 31% - 38% 28% - 37% 27% - 35% Weighted average expected volatility 34% 33% 31% Expected term (years) 5.02 - 5.04 5.02 - 5.06 5.03 - 5.50 Expected dividend yield 0% 0% 0% The risk-free interest rate is based on the U.S. Treasury zero-coupon curve. Expected volatility of stock option awards is estimated based on the implied volatility of our publicly traded options with settlement dates of six months. The use of implied volatility was based upon the availability of actively traded options on our common stock and the assessment that implied volatility is more representative of future stock price trends than historical volatility. The expected term of an employee share option is the period of time for which the option is expected to be outstanding. We made a determination of expected term by analyzing employees' historical exercise experience from its history of grants and exercises in our option database and management estimates. Forfeiture rates are estimated based on historical data. The following table summarizes all stock option activity for the year ended December 31, 2015 : Options Weighted Average Exercise Price Per Option Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Millions) Outstanding at December 31, 2014 77.2 $ 49.47 6.9 $ 4,823.8 Changes during the Year: Granted 11.8 118.65 Exercised (11.5 ) 34.39 Forfeited (1.7 ) 74.20 Expired (0.1 ) 39.48 Outstanding at December 31, 2015 75.7 $ 61.99 6.6 $ 4,411.8 Vested at December 31, 2015 or expected to vest in the future 75.1 $ 61.64 6.6 $ 4,400.1 Vested at December 31, 2015 41.2 $ 41.12 5.3 $ 3,238.5 The total fair value of shares vested during the years ended December 31, 2015 , 2014 and 2013 was $266.5 million , $211.3 million and $159.3 million , respectively. The total intrinsic value of stock options exercised during the years ended December 31, 2015 , 2014 and 2013 was $993.5 million , $946.6 million and $814.7 million , respectively. We primarily utilize newly issued shares to satisfy the exercise of stock options. Restricted Stock Units: We issue RSUs, under our equity program in order to provide an effective incentive award with a strong retention component. Equity awards may, at the option of employee participants, be divided between stock options and RSUs. The employee may choose between alternate Company defined mixes of stock options and RSUs, with the number of options to be granted reduced by four for every one RSU to be granted. Information regarding the Company's RSUs for the year ended December 31, 2015 is as follows: Nonvested RSUs Share Equivalent Weighted Average Grant Date Fair Value Nonvested at December 31, 2014 9.4 $ 59.02 Changes during the period: Granted 2.5 112.98 Vested (3.8 ) 37.57 Forfeited (0.4 ) 71.95 Nonvested at December 31, 2015 7.7 $ 86.28 As of December 31, 2015 , there was $325.0 million of total unrecognized compensation cost related to non-vested RSU awards. That cost is expected to be recognized over a weighted-average period of 1.4 years. The Company primarily utilizes newly issued shares to satisfy the vesting of RSUs. Performance-Based Restricted Stock Units: We grant performance-based restricted stock units that vest contingent upon the achievement of pre-determined performance-based milestones that are either related to product development or the achievement of specified performance and market targets, including revenue, earnings per share, and relative total shareholder return. The following table summarizes the Company's performance-based restricted stock unit activity for the year ended December 31, 2015 (shares in thousands): Nonvested Performance-Based RSUs Share Equivalent Weighted Average Grant Date Fair Value Nonvested at December 31, 2014 133 $ 69.57 Changes during the period: Granted 211 112.14 Vested — — Forfeited (10 ) 82.91 Non-vested at December 31, 2015 334 $ 96.07 As of December 31, 2015 , there was $17.9 million of total unrecognized compensation cost related to non-vested awards of performance-based RSUs that is expected to be recognized over a weighted-average period of 1.6 years.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans We sponsor an employee savings and retirement plan, which qualifies under Section 401(k) of the Internal Revenue Code, as amended (the Code) for our U.S. employees. Our contributions to the U.S. savings plan are discretionary and have historically been made in the form of our common stock (See Note 12). Such contributions are based on specified percentages of employee contributions up to 6% of eligible compensation or a maximum permitted by law. Total expense for contributions to the U.S. savings plans were $35.1 million , $40.7 million and $32.6 million in 2015, 2014 and 2013, respectively. We also sponsor defined contribution plans in certain foreign locations. Participation in these plans is subject to the local laws that are in effect for each country and may include statutorily imposed minimum contributions. We also maintain defined benefit plans in certain foreign locations for which the obligations and the net periodic pension costs were determined to be immaterial at December 31, 2015. In 2000, our Board of Directors approved a deferred compensation plan. The plan was frozen effective as of December 31, 2004, and no additional contributions or deferrals can be made to that plan. Accrued benefits under the frozen plan will continue to be governed by the terms under the tax laws in effect prior to the enactment of American Jobs Creation Act of 2004, Section 409A (Section 409A). In February 2005, our Board of Directors adopted the Celgene Corporation 2005 Deferred Compensation Plan, effective as of January 1, 2005, and amended the plan in February 2008. This plan operates as our ongoing deferred compensation plan and is intended to comply with Section 409A. Eligible participants, which include certain top-level executives as specified by the plan, can elect to defer up to an amended 90% of the participant's base salary, 100% of cash bonuses and equity compensation allowed under Section 409A. Company contributions to the deferred compensation plan represent a match to certain participants' deferrals up to a specified percentage, which currently ranges from 10% to 20% , depending on the employee's position as specified in the plan, of the participant's base salary. We recorded expenses of $0.3 million , $0.3 million and $0.6 million related to the deferred compensation plans in 2015, 2014 and 2013, respectively. The Company's matches are fully vested upon contribution. All other Company contributions to the plan do not vest until the specified requirements are met. At December 31, 2015 and 2014, we had a deferred compensation liability included in other non-current liabilities in the Consolidated Balance Sheets of approximately $104.5 million and $91.0 million , respectively, which included the participant's elected deferral of salaries and bonuses, the Company's matching contribution and earnings on deferred amounts as of that date. The plan provides various alternatives for the measurement of earnings on the amounts participants defer under the plan. The measurement alternatives are based on returns of a variety of funds that offer plan participants the option to spread their risk across a diverse group of investments. In 2003, we established a Long-Term Incentive Plan (LTIP) designed to provide key officers and executives with performance-based incentive opportunities contingent upon achievement of pre-established corporate performance objectives covering a three -year period. We currently have three separate three-year performance cycles running concurrently ending December 31, 2016, 2017 and 2018. Performance measures for each of the performance cycles are based on the following components: 37.5% on non-GAAP earnings per share (as defined in the LTIP); 37.5% on total non-GAAP revenue (as defined in the LTIP); and 25% on relative total shareholder return, which is a measurement of our stock price performance during the applicable three-year period compared with a group of other companies in the biopharmaceutical industry. Threshold, target and maximum cash payout levels under the three current LTIP performance cycles are calculated as a percentage between 0% to 200% of each participant’s base salary at the time the LTIP was approved by the Compensation Committee. Such awards are payable in cash or common stock or a mixture of cash and common stock, which will be determined by the Compensation Committee at the time of award delivery. Share-based payout levels are calculated using the cash-based threshold, target and maximum levels, divided by the average closing price of Celgene stock for the 30 trading days prior to the commencement of each performance cycle. Therefore, final share-based award values are reflective of the stock price at the end of the measurement period. The Compensation Committee may determine that payments made in common stock are restricted from trading for a period of time. The estimated payout value for the concluded 2015 Plan is $17.4 million , which is included in accrued expenses at December 31, 2015, and the maximum potential cash-based payout, assuming maximum objectives are achieved for the 2016, 2017 and 2018 Plans are $25.2 million , $16.4 million and $16.3 million respectively. The reduction in the maximum potential cash-based payout for the 2017 Plan reflects a shift in the mix of compensation components for certain senior executives, including performance-based equity compensation in lieu of LTIP participation. We accrue the long-term incentive liability over each three-year cycle. Prior to the end of a three-year cycle, the accrual is based on an estimate of our level of achievement during the cycle. Upon a change in control, participants will be entitled to an immediate payment equal to their target award or, if higher, an award based on actual performance through the date of the change in control. For the years ended December 31, 2015, 2014 and 2013, we recognized expense related to the LTIP of $24.9 million , $42.3 million and $40.8 million , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income before income taxes is as follows: 2015 2014 2013 U.S. $ 524.8 $ 565.0 $ 36.8 Non-U.S. 1,498.7 1,762.4 1,628.6 Income before income taxes $ 2,023.5 $ 2,327.4 $ 1,665.4 For the years ended December 31, 2015, 2014 and 2013, U.S. income before income taxes reflects charges related to share-based compensation, up-front collaboration payments, asset impairments, acquisitions and interest expense which in the aggregate, decreased in the United States from 2013 to 2014. Many of these charges are not deductible for U.S. income tax purposes. These charges were lower outside the United States in those years. The provision (benefit) for taxes on income is as follows: 2015 2014 2013 United States: Taxes currently payable: Federal $ 320.7 $ 489.4 $ 352.6 State and local 63.1 56.3 45.4 Deferred income taxes (28.7 ) (273.8 ) (245.1 ) Total U.S. tax provision 355.1 271.9 152.9 International: Taxes currently payable 71.1 54.1 64.1 Deferred income taxes (4.7 ) 1.5 (1.5 ) Total international tax provision 66.4 55.6 62.6 Total provision $ 421.5 $ 327.5 $ 215.5 Amounts are reflected in the preceding tables based on the location of the taxing authorities. We do not provide for U.S. federal or state income taxes on unremitted earnings of our international subsidiaries that are indefinitely invested outside the United States. As of December 31, 2015, we have not made a U.S. tax provision on $9.667 billion of unremitted earnings of our international subsidiaries. As these earnings are expected to be reinvested overseas indefinitely, it is not practicable to compute the estimated deferred tax liability on these earnings. Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as temporary differences. We record the tax effect on these temporary differences as deferred tax assets (generally items that can be used as a tax deduction or credit in future periods) or deferred tax liabilities (generally items for which we received a tax deduction but that have not yet been recorded in the Consolidated Statements of Income and the tax effects of acquisition related temporary differences). We periodically evaluate the likelihood of the realization of deferred tax assets, and reduce the carrying amount of these deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized. We consider many factors when assessing the likelihood of future realization of deferred tax assets, including our recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, the carryforward periods available to us for tax reporting purposes, tax planning strategies and other relevant factors. Significant judgment is required in making this assessment. At December 31, 2015 and 2014, it was more likely than not that we would realize our deferred tax assets, net of valuation allowances. The valuation allowances relate primarily to certain deferred tax assets acquired in the Receptos acquisition and certain fair value adjustments which are expected to result in non-deductible losses. Approximately $900.0 million of our foreign earnings may not be required for use in offshore operations and may be available for use in the United States. These earnings are not treated as permanently reinvested, and our deferred tax liabilities include $316.5 million for the estimated U.S. federal and state income taxes that may be incurred should these earnings be repatriated. In drawing this conclusion, we considered our future sources of funds as well as our global operating and strategic liquidity needs, including common share repurchase activities and expansion of our commercial, research, manufacturing and administrative infrastructure worldwide. At December 31, 2015 and 2014 the tax effects of temporary differences that give rise to deferred tax assets and liabilities were as follows: 2015 2014 Assets Liabilities Assets Liabilities NOL carryforwards $ 56.2 $ — $ 4.5 $ — Deferred revenue 1.8 — 1.7 — Capitalized research expenses 3.8 — 4.8 — Tax credit carryforwards 10.7 — 5.0 — Non-qualified stock options 340.9 — 250.5 — Plant and equipment, primarily differences in depreciation 2.0 — — (7.4 ) Inventory 11.3 — 14.5 — Other assets 43.0 (3.7 ) 41.5 (4.0 ) Intangible assets 661.3 (1,135.4 ) 654.7 (1,183.2 ) Accrued and other expenses 233.2 — 191.6 — Unremitted earnings — (316.5 ) — (316.5 ) Unrealized (gains) losses on securities — (129.9 ) — (236.5 ) Subtotal 1,364.2 (1,585.5 ) 1,168.8 (1,747.6 ) Valuation allowance (90.8 ) — (39.7 ) — Total deferred taxes $ 1,273.4 $ (1,585.5 ) $ 1,129.1 $ (1,747.6 ) Net deferred tax asset (liability) $ (312.1 ) $ (618.5 ) At December 31, 2015 and 2014, deferred tax assets and liabilities were classified on our Consolidated Balance Sheets as follows: 2015 2014 Current assets (1) $ — $ 11.7 Other assets (non-current) 65.6 56.6 Current liabilities (1) — (131.2 ) Other non-current liabilities (377.7 ) (555.6 ) Net deferred tax asset (liability) $ (312.1 ) $ (618.5 ) (1) Balances reflect our early adoption of ASU 2015-17 on a prospective basis, which requires companies to classify all deferred tax assets and liabilities and associated valuation allowances as non-current on the balance sheet instead of separating deferred taxes and associated valuation allowances into current and non-current amounts. Prior periods were not retrospectively adjusted. Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows: Percentages 2015 2014 2013 U.S. statutory rate 35.0 % 35.0 % 35.0 % Foreign tax rate differences (21.0 )% (22.3 )% (28.8 )% Unremitted earnings — % — % — % State taxes, net of federal benefit 1.2 % 1.0 % 0.6 % Change in valuation allowance 2.0 % 0.2 % 1.2 % Acquisition related differences 4.5 % (0.3 )% 3.7 % Changes in uncertain tax positions (0.5 )% (0.4 )% 0.8 % Other (0.4 )% 0.9 % 0.4 % Effective income tax rate 20.8 % 14.1 % 12.9 % In our reconciliation of the U.S. statutory income tax rate to our effective tax rate, we disclose changes in uncertain tax positions which include the effect of settlements, expirations of statutes of limitations, and other changes in prior year tax positions. We have operations in many foreign tax jurisdictions, which impose income taxes at different rates than the United States. The impact of these rate differences is included in the foreign tax rate differences that we disclose in our reconciliation of the U.S. statutory income tax rate to our effective tax rate. The benefit related to foreign tax rate differences primarily results from our commercial operations in Switzerland, which include significant research and development and manufacturing for worldwide markets. We operated under an income tax agreement in Switzerland through 2015 that provided an exemption from most Swiss income taxes on our operations in Switzerland. In 2013, we entered into a new agreement with the Swiss tax authorities which reflects the planned expansion of our Swiss operations and coupled with a 2014 reorganization of our Swiss operations will result in similar tax benefits through the end of 2024. The difference between the maximum statutory Swiss income tax rate (approximately 17.0% in 2015, 18.4% in 2014 and 19.7% in 2013) and our Swiss income tax rate under the tax agreement resulted in a reduction in the 2015, 2014 and 2013 effective tax rates of 25.7 , 18.0 and 25.1 percentage points, respectively. The increase in benefits reflected in the foreign tax rate differences from 2014 to 2015 resulted primarily from an increase in the proportion of consolidated income before taxes from Swiss operations. At December 31, 2015, we had federal NOL carryforwards of approximately $114.2 million and combined state NOL carryforwards of approximately $883.5 million that will expire in the years 2016 through 2035. We also have research and experimentation credit carryforwards of approximately $16.8 million that will expire in the years 2018 through 2034. Excess tax benefits related to stock option deductions incurred after December 31, 2005 are required to be recognized in the period in which the tax deduction is realized through a reduction of income taxes payable. As a result, we have not recorded deferred tax assets for certain stock option deductions included in our state NOL carryforwards and research and experimentation credit carryforwards. At December 31, 2015, deferred tax assets have not been recorded on state NOL carryforwards of approximately $476.4 million and for research and experimentation credits of approximately $4.0 million . These stock option tax benefits are expected to be recorded as an increase in additional paid-in capital when realized. We realized share-based compensation deduction benefits in 2015, 2014 and 2013 for income tax purposes and have increased additional paid-in capital in the amount of approximately $302.1 million , $252.6 million and $170.0 million , respectively. We have recorded deferred income taxes related to net unrealized gains on securities as a component of accumulated other comprehensive income resulting in a deferred income tax liability at December 31, 2015 and 2014 of $129.9 million and $236.5 million , respectively. On August 27, 2015, we acquired all of the outstanding common stock of Receptos. The acquisition was accounted for using the acquisition method of accounting, and we recorded a deferred tax liability of $2.519 billion related to the acquisition. Upon integration of the acquired assets into our offshore research, manufacturing, and commercial operations, the deferred tax liability was reclassified to a non-current tax liability. This liability represents an estimate of income tax that may be incurred in the future. This income tax liability is contingent upon successful development of the acquired IPR&D into a commercially viable product and would be incurred over the product's economic useful life. Our tax returns are under routine examination in many taxing jurisdictions. The scope of these examinations includes, but is not limited to, the review of our taxable presence in a jurisdiction, our deduction of certain items, our claims for research and development credits, our compliance with transfer pricing rules and regulations and the inclusion or exclusion of amounts from our tax returns as filed. Our U.S. federal income tax returns have now been audited by the IRS through the year ended December 31, 2008. Tax returns for the years ended December 31, 2009, 2010, and 2011 are currently under examination by the IRS. We are also subject to audits by various state and foreign taxing authorities, including, but not limited to, most U.S. states and major European and Asian countries where we have operations. We regularly reevaluate our tax positions and the associated interest and penalties, if applicable, resulting from audits of federal, state and foreign income tax filings, as well as changes in tax law (including regulations, administrative pronouncements, judicial precedents, etc.) that would reduce the technical merits of the position to below more likely than not. We believe that our accruals for tax liabilities are adequate for all open years. Many factors are considered in making these evaluations, including past history, recent interpretations of tax law and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these evaluations can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We apply a variety of methodologies in making these estimates and assumptions, which include studies performed by independent economists, advice from industry and subject experts, evaluation of public actions taken by the IRS and other taxing authorities, as well as our industry experience. These evaluations are based on estimates and assumptions that have been deemed reasonable by management. However, if management's estimates are not representative of actual outcomes, our results of operations could be materially impacted. Unrecognized tax benefits, generally represented by liabilities on the consolidated balance sheet and all subject to tax examinations, arise when the estimated benefit recorded in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2015 2014 Balance at beginning of year $ 251.8 $ 219.2 Increases related to prior year tax positions — 2.8 Decreases related to prior year tax positions — — Increases related to current year tax positions 84.8 44.4 Settlements — (10.0 ) Lapse of statute (10.8 ) (4.6 ) Balance at end of year $ 325.8 $ 251.8 These unrecognized tax benefits relate primarily to issues common among multinational corporations. If recognized, unrecognized tax benefits of approximately $300.8 million would have a net impact on the effective tax rate. We account for interest and penalties related to uncertain tax positions as part of our provision for income taxes. Accrued interest at December 31, 2015 and 2014 is approximately $32.6 million and $28.1 million , respectively. We have recorded changes in the liability for unrecognized tax benefits for current and prior year tax positions related to ongoing income tax audits in various taxing jurisdictions. The liability for unrecognized tax benefits is expected to increase in the next twelve months relating to operations occurring in that period. Any settlements of examinations with taxing authorities or statute of limitations expirations would likely result in a decrease in our liability for unrecognized tax benefits and a corresponding increase in taxes paid or payable and/or a decrease in income tax expense. It is reasonably possible that the amount of the liability for unrecognized tax benefits could change by a significant amount during the next twelve-month period as a result of settlements or statute of limitations expirations. Finalizing examinations with the relevant taxing authorities can include formal administrative and legal proceedings and, as a result, it is difficult to estimate the timing and range of possible change related to the Company’s unrecognized tax benefits. An estimate of the range of the possible change cannot be made until issues are further developed or examinations close. Our estimates of tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire.

Collaboration Agreements

Collaboration Agreements	12 Months Ended
	Dec. 31, 2015
Collaboration Agreements
Collaboration Agreements	Collaboration Agreements We enter into collaborative arrangements for the research and development, license, manufacture and/or commercialization of products and/or product candidates. In addition, we also acquire products, product candidates and research and development technology rights and establish research and development collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our research and development capabilities, product pipeline and marketed product base. These arrangements may include non-refundable, upfront payments, payments for options to acquire rights to products and product candidates and other rights, as well as potential development, regulatory and commercial performance milestone payments, cost sharing arrangements, royalty payments, profit sharing and equity investments. These arrangements could include obligations for us to make equity investments in the event of an initial public offering of equity by our partners. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success. Although we do not consider any individual alliance to be material, certain of the more notable alliances are described below. Summarized financial information related to our alliances is presented in tabular format after the description of alliances: Acceleron Pharma (Acceleron): We have worldwide strategic collaboration agreements with Acceleron for the joint development and commercialization of sotatercept (ACE-011) and luspatercept (ACE-536). Sotatercept is currently in phase II studies for treatment of renal anemia, beta-thalassemia and MDS, and luspatercept is currently in phase II studies for beta-thalassemia and MDS. On January 1, 2013 we became responsible for the payment of all development costs related to sotatercept and luspatercept and have recognized development expenses as research and development expense as they were incurred. With respect to the sotatercept program, Acceleron is eligible to receive up to $367.0 million in development, regulatory approval and sales-based milestones and up to an additional $348.0 million for each of three specific discovery stage programs. We also agreed to co-promote the developed products in North America. Acceleron will receive tiered royalties on worldwide net sales upon the commercialization of a development compound. With respect to the luspatercept program, we have an exclusive, worldwide, royalty-bearing license to luspatercept and future Acceleron products for the treatment of anemia. We also agreed to co-promote the products in the United States, Canada and Mexico. Acceleron is eligible to receive development, regulatory approval and sales-based milestones of up to $217.5 million for luspatercept and up to an additional $170.8 million for the first discovery stage program, $148.8 million for the second discovery stage program and $125.4 million for each additional discovery stage program thereafter. Acceleron will receive tiered royalties on worldwide net sales upon the commercialization of a development compound. The sotatercept agreement may be terminated by us, at our sole discretion, at any time or by either party, among other things, upon a material breach by the other party. The luspatercept agreement may be terminated by us, at our sole discretion, after completion of the initial phase II clinical trial or by either party, among other things, upon a material breach by the other party. Agios Pharmaceuticals, Inc. (Agios): During 2010, we entered into a discovery and development collaboration and license agreement with Agios that focuses on cancer metabolism targets and the discovery, development and commercialization of associated therapeutics. We have an exclusive option to license any potential products that result from the Agios cancer metabolism research platform through the end of phase I clinical trials. With respect to each product that we choose to license, Agios could receive up to approximately $120.0 million upon achievement of certain milestones and other payments plus royalties on worldwide sales, and Agios may also participate in the development and commercialization of certain products in the United States. In December 2014, we elected to extend the collaboration and license agreement for an additional year for a payment of $20.0 million . Our option to license products will terminate on April 14, 2016. In June 2014, we exercised our option to license AG-221 from Agios on an exclusive worldwide basis, with Agios retaining the right to conduct a portion of commercialization activities for AG-221 in the United States. AG-221 is currently in a phase I study in patients that present an isocitrate dehydrogenase-2 (IDH2) mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML). In January 2015, we exercised our option, subject to applicable regulatory approvals which were subsequently achieved, to an exclusive license from Agios to AG-120 outside the United States, with Agios retaining the right to conduct development and commercialization within the United States. AG-120 is an orally available, selective inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) protein for the treatment of patients with cancers that harbor an IDH1 mutation. AG-120 is currently being evaluated in two phase I dose escalation trials, one in advanced hematological malignancies and the other in advanced solid tumors. In April 2015, we and Agios entered into a new joint worldwide development and profit share collaboration for AG-881. AG-881 is a small molecule that has shown in preclinical studies to fully penetrate the blood brain barrier and inhibit IDH1 and IDH2 mutant cancer cells. Under the terms of the AG-881 collaboration, Agios received an initial payment of $10.0 million and is eligible to receive contingent payments of up to $70.0 million based on the attainment of specified regulatory goals. The upfront payment to Agios was accounted for as $9.0 million of upfront research and development collaboration expense and $1.0 million of prepaid manufacturing rights recorded on the balance sheet. We and Agios will jointly collaborate on the worldwide development program for AG-881, sharing development costs equally. The two companies will share profits equally, with Celgene recording commercial sales worldwide. Agios will lead commercialization in the U.S. with both companies sharing equally in field-based commercial activities, and we will lead commercialization ex-U.S. with Agios providing one third of field-based commercial activities in the major EU markets. Epizyme Inc. (Epizyme): In July 2015 we entered into an amendment and restatement of the collaboration and license agreement dated April 2, 2012 with Epizyme (the “Amended Agreement”). Under the original agreement, we had an exclusive license, for all countries other than the United States, to small molecule HMT inhibitors targeting DOT1L, including pinometostat (EPZ-5676), and an option, on a target-by-target basis, to exclusively license, for all countries other than the United States, rights to small molecule HMT inhibitors targeting any other HMT targets. Under the Amended Agreement: • We retain our exclusive license to small molecule HMT inhibitors targeting DOT1L outside of the United States, including pinometostat (EPZ-5676), • We have narrowed our option rights to HMT inhibitors targeting three predefined targets (the “Option Targets”), • The exclusive licenses to HMT inhibitors targeting two of the Option Targets that we may acquire have been expanded to include the United States, with the exclusive license to the third Option Target continuing to be for all countries other than the United States, • Our option period has been extended for each of the Option Targets and is exercisable at the time of Epizyme's IND filing for an HMT inhibitor targeting the applicable Option Target, • Epizyme may complete phase I clinical trials as to each Option Target following our exercise of our option at IND filing. If Epizyme chooses not to complete phase I clinical trials to an Optioned Target, future milestones and royalties on products developed for such Option Targets will be reduced. Under the terms of the Amended Agreement, we made a $10.0 million payment to Epizyme. In addition, Epizyme may earn up to $75.0 million in development milestone payments, up to $365.0 million in regulatory milestone payments and up to $170.0 million in sales milestone payments related to the Option Targets. For the DOT1L program, Epizyme remains eligible to earn $35.0 million in clinical development milestone payments and up to $100.0 million in regulatory milestone payments. Epizyme is also entitled to tiered royalties ranging from the mid-single digits to the mid-teens on annual net product sales in our territory, subject to reductions in specified circumstances. The Amended Agreement extends the research and development collaboration for at least an additional three years until July 8, 2018, subject to our exercise of our options at IND filing. The Amended Agreement will expire on a product-by-product and country-by-country basis on the date of the expiration of the applicable royalty term with respect to each licensed product in each country and in its entirety upon the expiration of all applicable royalty terms for all licensed products in all countries. We have the right to terminate the Amended Agreement in its entirety or with respect to one or more Optioned Targets upon 120 days’ notice. Upon the expiration of the royalty term of a particular license product, we will have a fully paid-up, royalty-free license to use Epizyme intellectual property to manufacture, market, use and sell such licensed products in our territory. Sutro Biopharma, Inc. (Sutro): In December 2012, we entered into a collaboration and license agreement with Sutro for the development of an antibody drug conjugate (ADC) and a bispecific antibody construct (BAC). Sutro controls and conducts initial development activities. We have the right to select one ADC among a number of different sequence-payload combinations and positional variants, and one BAC. Sutro will provide adequate quantities of any selected ADC and selected BAC to allow us to conduct all necessary preclinical studies, including toxicology and pharmacokinetics studies. Under the terms of the 2012 agreement, Sutro received payments totaling $35.0 million , which included an equity investment and other rights. In addition, the 2012 collaboration and license agreement includes certain development and regulatory milestones that could total up to $204.0 million for a selected ADC if approved in multiple indications, and up to $279.0 million for a selected BAC if approved in multiple indications, as well as tiered royalties based on annual net sales of licensed products. In September 2014, we entered into a second collaboration and license agreement with Sutro to jointly develop up to six prioritized anti-cancer BACs and/or ADCs directed primarily to immune-oncology targets. Sutro will control and conduct initial development activities. We have the right to advance any BAC and/or ADC to investigational new drug (IND)-enabling studies or to designate it as a development candidate, and in either case, we would then have the sole right and responsibility for development activities, although Sutro would still have certain limited manufacturing and supply obligations. Under the terms of the 2014 agreement, Sutro received payments totaling $95.0 million , which includes an equity investment that increases our ownership to approximately 15% , rights with respect to manufacturing and supply of BAC and ADC development candidates, and an option to acquire all of the outstanding equity of Sutro based on a pre-specified valuation procedure. The option is exercisable beginning September 2016 and expires upon the termination of the research term (as extended). For a future one-time payment, we have the right to obtain access to Sutro’s proprietary protein expression platform to use in conjunction with our intellectual property. Additionally, we have the right to have Sutro evaluate the performance of certain monospecific ADCs directed against up to five non-natural amino acid targets, and reengineer, express, and provide antibodies which incorporate a single non-natural amino acid sequence in a number of preferred locations. The research term of the collaboration and license agreement is three years, with an extension available for an additional one-and-a-half years for a payment of an additional fee. We have worldwide commercialization rights for development candidates in which at least one binding domain is directed to a certain undisclosed target, plus the first development candidate which does not include at least one binding domain directed to that certain undisclosed target but which achieves IND clearance in the U.S. For all other development candidates, Sutro has U.S. rights, while we have all ex-U.S. rights. Under the terms of the 2014 agreement, Sutro is eligible to receive research and manufacturing milestones of up to $75.0 million , clinical development and regulatory approval milestones of up to $275.0 million for each compound selected under the collaboration if approved in multiple indications, as well as tiered royalties based on annual net sales of licensed products. The collaboration and license agreement may be terminated by us at our discretion on a program-by-program basis upon 120 days prior written notice, or by either party for material breach, intellectual property challenge, or bankruptcy by the other party. With certain exceptions, the collaboration and license agreement expires in its entirety upon the expiration of all applicable royalty terms under the Agreement. bluebird bio, Inc. (bluebird): In June 2015, we amended and restated the March 2013 collaboration agreement with bluebird. The amended and restated collaboration will focus on the discovery, development and commercialization of novel disease-altering gene therapy product candidates targeting B-cell maturation antigen (BCMA). BCMA is a cell surface protein that is expressed in normal plasma cells and in most multiple myeloma cells, but is absent from other normal tissues. The collaboration applies gene therapy technology to modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells that express BCMA. We have an option to license any anti-BCMA products resulting from the collaboration after the completion of a phase I clinical study by bluebird. Under the amended and restated collaboration agreement we made an additional $25.0 million payment for bluebird to develop the lead anti-BCMA product candidate (bb2121) through a phase I clinical study and to develop next-generation anti-BCMA product candidates. The payment was recorded as prepaid research and development on the balance sheet and is being recognized as expense as development work is performed. Upon exercising our option to license a product and achievement of certain milestones, we may be obligated to pay up to $230.0 million per licensed product in aggregate potential option fees and clinical and regulatory milestone payments. bluebird also has the option to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the United States in exchange for a reduction of milestone payments. Royalties would also be paid to bluebird in regions where there is no profit share, including in the United States, if bluebird declines to exercise their co-development and profit sharing rights. We have the ability to terminate the collaboration at our discretion upon 90 days written notice to bluebird. If a product is optioned, the parties will enter into a pre-negotiated license agreement and potentially a co-development agreement should bluebird exercise its option to participate in the development and commercialization in the United States. The license agreement, if not terminated sooner, would expire upon the expiration of all applicable royalty terms under the agreement with respect to the particular product, and the co-development agreement, if not terminated sooner, would expire when the product is no longer being developed or commercialized in the United States. Upon the expiration of a particular license agreement, we will have a fully paid-up, royalty-free license to use bluebird intellectual property to manufacture, market, use and sell such licensed product. FORMA Therapeutics Holdings, LLC (FORMA): In April 2013, we entered into a collaboration agreement with FORMA to discover, develop and commercialize drug candidates to regulate protein homeostasis targets. Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. The collaboration was launched with an upfront payment that enables us to evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, we have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the United States, in exchange for research and early development payments of up to approximately $200.0 million to FORMA. Under the terms of the collaboration agreement, FORMA is incentivized to advance the full complement of drug candidates through phase I, while Celgene is responsible for all further global clinical development for each licensed candidate. FORMA is eligible to receive up to an additional $315.0 million in potential payments based upon development, regulatory and sales objectives for the first ex-U.S. license. FORMA is also eligible to receive potential payments for successive licenses, which escalate for productivity, increasing up to a maximum of an additional $430.0 million per program. In addition, FORMA will receive royalties on ex-U.S. sales and additional payments if multiple drug candidates reach defined cumulative sales objectives. The collaboration agreement includes provisions for Celgene to obtain rights with respect to development and commercialization of drug candidates inside the United States in exchange for additional payments. Under the collaboration, the parties perform initial research and development for a term of four years. If, during such research term, a drug candidate meets certain criteria, then the parties enter into a pre-negotiated license agreement and the collaboration continues until all license agreements have expired and all applicable royalty terms under the collaboration with respect to the particular products have expired. Each license agreement, if not terminated sooner, expires upon the expiration of all applicable royalty terms under such agreement. Upon the expiration of each license agreement, we will have an exclusive, fully-paid, royalty-free license to use the applicable FORMA intellectual property to manufacture, market, use and sell the product developed under such agreement outside of the United States. As of December 31, 2015, we have entered into three such license agreements with FORMA and paid the applicable upfront payments under such license agreements totaling $68.0 million . On March 21, 2014, we entered into a second collaboration arrangement with FORMA, pursuant to which FORMA granted us an option, for an additional fee, to license the rights to select current and future FORMA drug candidates during a term of three and one half years. We agreed to pay an upfront payment of $225.0 million . In addition, with respect to each subsequently licensed drug candidate, we have the obligation to pay designated amounts when certain development, regulatory and sales milestone events occur, with such amounts being variable and contingent on various factors. With respect to each licensed drug candidate, we assume responsibility for all global development activities and costs after completion of phase I clinical trials. FORMA retains U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization. Under this collaboration arrangement, we also have an option to enter into up to two additional collaborations with successive terms of two years each for additional payments totaling approximately $375.0 million . If we exercise our option to enter into both of these additional collaborations, we will receive an exclusive option to acquire FORMA, including the U.S. rights to all licensed drug candidates, and worldwide rights to other wholly owned assets within FORMA at that time. In April, 2015, we entered into the first license agreement with FORMA under the second collaboration and made a $20.0 million upfront payment for the license. Acetylon Pharmaceuticals, Inc. (Acetylon): In July 2013, we entered into a collaboration and option agreement with Acetylon. Under the agreement, the parties will support the development of Acetylon's portfolio of oral, selective HDAC inhibitors in oncology, hematology, immunology and neurologic disease indications. In addition, we have rights to receive certain research and development services from Acetylon and an exclusive right to acquire Acetylon at a later date at a purchase price based upon future independent company valuations. The collaboration focuses on the continued clinical advancement of Acetylon's lead candidate, ACY-1215, an HDAC6 inhibitor being developed for hematological malignancies, ACY-738 for neurological diseases, an HDAC1/2 inhibitor and a yet unnamed project, spanning cancer and non-cancer disease indications. Under the agreement, we made an upfront payment to Acetylon, which included a fee for entering into the collaboration, fees for the exclusive right to acquire Acetylon and the rights to receive certain research and development services from Acetylon. During the term of the agreement, Acetylon will retain control of its drug development programs. If we exercise our right to acquire Acetylon, in addition to the purchase price based upon independent company valuations to be paid at the time of the acquisition, Acetylon shareholders will be eligible to receive potential future milestone payments for approvals, or additional indications, of drugs developed by Acetylon and for accomplishing defined sales targets. If all the milestones are achieved, the aggregate amount of the milestone payments would be $1.100 billion . In August 2015, we entered into an amendment to the agreement with Acetylon to extend the expiration date of the agreement to May 2, 2016 and remove our right to further extend the expiration date. Further, we have the ability to terminate the agreement at our discretion upon written notice to Acetylon. OncoMed Pharmaceuticals, Inc. (OncoMed): On December 2, 2013, we entered into a collaboration agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed’s biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4). OncoMed will control and conduct initial clinical studies. We will have an option to license worldwide rights to up to six novel anti-CSC therapeutic candidates commencing upon the completion of enrollment of patients in a phase I trial (and with respect to demcizumab, a phase II trial) and ending 60 days after delivery by OncoMed of the applicable data package for each therapeutic candidate, subject to certain extensions. We will also have research, development and commercialization rights to small molecule compounds in another cancer stem cell pathway, with OncoMed eligible to receive milestones and royalties on any resulting products. Demcizumab is currently in multiple phase Ib, phase Ib/II, and phase II clinical studies in combination with standard-of-care therapeutics, including a trial in patients with first-line advanced pancreatic cancer. Subsequent to the exercise of our option rights, the parties will co-develop demcizumab and share global development costs on a one-third OncoMed and two-thirds Celgene split. Outside the United States, we would lead development and commercialization efforts, with OncoMed eligible to receive milestones and tiered royalties on sales outside the United States. For sales in the United States, OncoMed and Celgene would share profits equally. In addition to demcizumab, the collaboration includes up to five phase Ia, preclinical- or discovery-stage biologics programs: OncoMed’s anti-DLL4/VEGF bispecific antibody and up to four additional biologics programs targeting either the RSPO-LGR CSC pathway or another CSC pathway. We have exclusive options on these programs during or after completion of certain phase I clinical trials to be conducted by OncoMed, which if exercised, contain U.S. profit sharing and co-commercialization terms, plus one-third OncoMed and two-thirds Celgene global development cost-sharing and royalties outside the profit-sharing territory. The collaboration agreement also includes option exercise payments and payments for achievement of development, regulatory and commercial milestones, paid on a per-program basis. For the demcizumab program, these contingent payments could total up to approximately $790.0 million , and include a payment for achievement of predetermined safety criteria in phase II clinical trials, which was achieved on December 31, 2015 resulting in a $70.0 million payment in February 2016. For the anti-DLL4/VEGF bispecific antibody program, contingent payments could total up to $505.0 million . For the other four programs, each program is eligible for up to approximately $440.0 million of contingent payments. OncoMed could also receive more than $100.0 million in contingent payments for the small molecule program. The collaboration agreement may be terminated by us on a program-by-program basis upon 120 days prior written notice before exercise of that program option, and after such program option exercise, by either party for material breach by the other party. With certain exceptions, the collaboration agreement expires upon the later of (a) the last-to-expire option term and (b) if one or more options are exercised, the termination or expiration of the last to expire agreement with respect to such exercised option. NantBioScience, Inc. (NantBioScience): In January 2014, we entered into a collaboration agreement with NantBioScience, an entity controlled by Dr. Patrick Soon-Shiong in which Celgene contributed $75.0 million of cash, the rights to the future royalty stream based on net sales of certain products of Active Biomaterials, LLC, another entity controlled by Dr. Patrick Soon-Shiong, and licenses to two nab ® product candidates. In return, Celgene received a 14 percent preferred equity ownership in NantBioScience, an option to license a certain number of product candidates developed by NantBioScience, including the two nab ® product candidates that Celgene is licensing to NantBioScience, and the parent company of NantBioScience assumed, and agreed to pay and satisfy when due, our obligation to pay The Chan Soon-Shiong Institute for Advanced Health (CSS Institute) $50.0 million in contingent, matching contributions. The transaction became effective in March 2014. Unless Celgene terminates the collaboration earlier, in Celgene’s sole discretion upon 30 days written notice, the collaboration will continue until the earliest to occur of: (a) Celgene licensing four NantBioScience product candidates; (b) NantBioScience presenting data packages for ten product candidates; and (c) the date which is 10 years after the effective date. Regardless of any termination of the collaboration, the 14 percent preferred equity ownership in NantBioScience and the assumption of the $50.0 million in contingent, matching contributions by the parent company of NantBioScience remain in effect. We performed a valuation of the components of the transaction and allocated the consideration transferred as follows: $50.0 million for the collaboration agreement upfront expense; $25.0 million related to the settlement of contingent matching contributions, and; $90.0 million related to the equity ownership in NantBioScience. AstraZeneca PLC (AstraZeneca): In April 2015, we entered into a strategic collaboration agreement with MedImmune Limited (MedImmune), a subsidiary of AstraZeneca, to develop and commercialize MEDI4736, a novel anti-PD-L1 monoclonal antibody, for hematologic malignancies. The agreement provides for a negotiation period to expand the agreement for other immuno-therapeutics. Under the terms of the agreement, we made an upfront payment of $450.0 million to MedImmune. We lead clinical development across all new clinical trials within the collaboration and are responsible for all costs associated with such trials until December 31, 2016, after which we will be responsible for 75 percent of those costs. We also will be responsible for the global commercialization of approved MEDI4736 indications in hematology, and will receive royalty rates starting at 70 percent of worldwide sales from all uses in hematology. Royalty rates will decrease gradually to 50 percent over a period of 4 years after the start of commercial sales. The agreement may be terminated at our discretion upon nine months’ prior written notice to MedImmune, and by either party upon material breach of the other party, subject to cure periods. The agreement, if not terminated sooner, expires upon the expiration of all applicable royalty terms under such agreement. Lycera Corp. (Lycera): In June 2015, we entered into a collaboration and option agreement with Lycera. Under the agreement, the parties will support the development of Lycera’s portfolio of immune modulator assets, including (1) oral agonists that target ROR y , a master control switch of immune system activation, for the potential treatment of a broad range of cancers, and (2) LYC-30937, an oral gut-directed ATPase modulator currently in phase I clinical studies. In addition, we have an exclusive right to acquire Lycera at a later date at a purchase price based upon future independent company valuations. Lycera has developed orally bioavailable RORy agonists that have demonstrated single agent therapeutic activity in multiple animal models of cancer. Ex-vivo treatment with ROR y agonist compounds has been shown to enhance the therapeutic benefit of adoptive T-cell therapy by improving both immune cell persistence and activation. Development of LYC-30937 is focused on the treatment of inflammatory bowel disease, with the goal of delivering significant disease improvement without global immune suppression. Under the collaboration, Lycera also will continue to advance its other programs, including a Rho-associated protein kinase 2 (ROCK2) inhibitor. Under the terms of the agreement, we made an upfront payment of $82.5 million to Lycera. We received an exclusive option for an additional fee to license Lycera’s portfolio of ex-vivo ROR y agonist compounds, an equity interest and an exclusive right to acquire Lycera. If we exercise the acquisition right, Lycera shareholders will be also eligible to receive future success-based milestone payments of up to $190.0 million . The upfront payment to Lycera was accounted for as $69.5 million of upfront collaboration payment included in research and development expense and $13.0 million as non-current assets consisting of $10.0 million for an equity investment and $3.0 million for an option to acquire the remaining shares outstanding. The agreement has an initial term of 3 years and may be terminated earlier at our discretion upon 6 months’ prior written notice to Lycera and by either party upon material breach of the other party, subject to cure periods. In December 2015, we entered into a license agreement with Lycera, under which Lycera granted to us an exclusive license for Lycera’s portfolio of novel ex vivo RORy agonist compounds and we made a $17.5 million upfront payment which is included in research and development expense. Juno Therapeutics, Inc. (Juno): In June 2015, we announced a collaboration and investment agreement with Juno for the development and commercialization of immunotherapies for cancer and autoimmune diseases. The collaboration and investment agreement became effective on July 31, 2015 after an early termination of the Hart-Scott-Rodino Antitrust waiting period. Un

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingent Value Rights: In connection with the acquisition of Abraxis in 2010, CVRs were issued under a Contingent Value Rights Agreement, or CVR Agreement, entered into between Celgene and American Stock Transfer & Trust Company, LLC, as trustee. The CVRs are registered for trading on the NASDAQ Global Market under the symbol "CELGZ." The fair value of the liability of the Company related to payments under the CVR Agreement are subject to fluctuation based on trading prices for the publicly traded CVRs. Subsequent to the Abraxis Acquisition Date, we measured the contingent consideration represented by the CVRs at fair value with changes in fair value recognized in operating earnings. The fair value of our liability related to the CVRs was $51.9 million at the end of 2015 compared to $136.3 million at the end of 2014. Each holder of a CVR is entitled to receive a pro rata portion, based on the number of CVRs then outstanding, of each of the following contingent cash payments: • Milestone Payment #1. $250.0 million upon FDA approval of ABRAXANE ® for use in the treatment of NSCLC if such approval permits us to market ABRAXANE ® with FDA approval that includes a progression-free survival, or PFS, claim, but only if this milestone is achieved no later than the fifth anniversary of the Merger. • Milestone Payment #2. $400.0 million (if achieved no later than April 1, 2013) or $300.0 million (if achieved after April 1, 2013 and before the fifth anniversary of the Merger) upon FDA approval of ABRAXANE ® for use in the treatment of pancreatic cancer, if such approval permits us to market ABRAXANE ® with FDA approval that includes an overall survival claim. • Net Sales Payments. For each full one -year period ending December 31 during the term of the CVR Agreement, which we refer to as a net sales measuring period (with the first net sales measuring period beginning January 1, 2011 and ending December 31, 2011): ◦ 2.5% of the net sales of ABRAXANE ® and the Abraxis pipeline products that exceed $1.000 billion but are less than or equal to $2.000 billion for such period, plus ◦ an additional amount equal to 5% of the net sales of ABRAXANE ® and the Abraxis pipeline products that exceed $2.000 billion but are less than or equal to $3.000 billion for such period, plus ◦ an additional amount equal to 10% of the net sales of ABRAXANE ® and the Abraxis pipeline products that exceed $3.000 billion for such period. No payments will be due under the CVR Agreement with respect to net sales of ABRAXANE ® and the Abraxis pipeline products after December 31, 2025, which we refer to as the net sales payment termination date, unless net sales for the net sales measuring period ending on December 31, 2025 are equal to or greater than $1.000 billion , in which case the net sales payment termination date will be extended until the last day of the first net sales measuring period subsequent to December 31, 2025 during which net sales of ABRAXANE ® and the Abraxis pipeline products are less than $1.000 billion or, if earlier, December 31, 2030. Milestone Payment #1 update: In October 2012, the FDA approved ABRAXANE ® for the first-line treatment of locally advanced or metastatic NSCLC, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. The FDA approval was based on tumor response rates and did not result in the use of a marketing label that includes a progression-free survival claim, and accordingly, the CVR Milestone Payment #1, as described above, has not been achieved. This approval resulted in the related $1.172 billion intangible asset obtained from the Abraxis acquisition being reclassified in October 2012 from an acquired IPR&D intangible to an acquired developed product rights intangible asset and amortization commenced in October 2012. Milestone Payment #2 update: In September 2013, the FDA approved ABRAXANE ® for use in the treatment of pancreatic cancer, permitting us to market ABRAXANE ® with a label that includes an overall survival claim. This approval resulted in the achievement of milestone #2 and the subsequent payment of $300.0 million to CVR holders in October 2013. Leases: We lease offices and research facilities under various operating lease agreements in the United States and international markets. We also lease automobiles and certain equipment in these same markets. At December 31, 2015, the non-cancelable lease terms for the operating leases expire at various dates between 2016 and 2025 and include renewal options. In general, the Company is also required to reimburse the lessors for real estate taxes, insurance, utilities, maintenance and other operating costs associated with the leases. Future minimum lease payments under non-cancelable operating leases as of December 31, 2015 are: Operating Leases 2016 $ 56.1 2017 47.9 2018 35.1 2019 24.1 2020 19.6 Thereafter 49.5 Total minimum lease payments $ 232.3 Total rental expense under operating leases was approximately $66.2 million in 2015 , $62.2 million in 2014 and $50.9 million in 2013 . Lines of Credit: We maintain lines of credit with several banks to support our hedging programs and to facilitate the issuance of bank letters of credit and guarantees on behalf of our subsidiaries. Lines of credit supporting our hedging programs as of December 31, 2015 allowed us to enter into derivative contracts with settlement dates through 2018. As of December 31, 2015 , we have entered into derivative contracts with net notional amounts totaling $9.275 billion . Lines of credit facilitating the issuance of bank letters of credit and guarantees as of December 31, 2015 allowed us to have letters of credit and guarantees issued on behalf of our subsidiaries totaling $101.7 million . Other Commitments: Our obligations related to product supply contracts totaled $183.7 million at December 31, 2015 . In addition, we have committed to invest an aggregate $20.4 million in an investment fund, which is callable at any time. We are also committed to pay the remaining $4.0 million balance due from our acquisition of a manufacturing facility in Switzerland. Collaboration Arrangements: We have entered into certain research and development collaboration agreements, as identified in Note 17 above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial targets. Our obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly no amounts have been recorded for the potential future achievement of these targets in our accompanying Consolidated Balance Sheets at December 31, 2015 and 2014 . Contingencies: We believe we maintain insurance coverage adequate for our current needs. Our operations are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the air and water and establish standards for the treatment, storage and disposal of solid and hazardous wastes. We review the effects of such laws and regulations on our operations and modify our operations as appropriate. We believe we are in substantial compliance with all applicable environmental laws and regulations. We have ongoing customs, duties and VAT examinations in various countries that have yet to be settled. Based on our knowledge of the claims and facts and circumstances to date, none of these matters, individually or in the aggregate, are deemed to be material to our financial condition. Legal Proceedings: Like many companies in our industry, we have from time to time received inquiries and subpoenas and other types of information requests from government authorities and others and we have been subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, product recalls, costs and significant payments, which may have a material adverse effect on our results of operations, cash flows or financial condition. Pending patent proceedings include challenges to the scope, validity and/or enforceability of our patents relating to certain of our products, uses of products or processes. Further, we are subject to claims of third parties that we infringe their patents covering products or processes. Although we believe we have substantial defenses to these challenges and claims, there can be no assurance as to the outcome of these matters and an adverse decision in these proceedings could result in one or more of the following: (i) a loss of patent protection, which could lead to a significant reduction of sales that could materially affect future results of operations, (ii) our inability to continue to engage in certain activities, and (iii) significant liabilities, including payment of damages, royalties and/or license fees to any such third party. Among the principal matters pending are the following: Patent Related Proceedings: REVLIMID ® : We received Notice Letters, dated August 30, 2010, June 12, 2012 and April 3, 2014 from Natco Pharma Limited of India (Natco) notifying us of Natco’s Abbreviated New Drug Application (ANDA), which contain Paragraph IV certifications against certain of Celgene’s patents that are listed in the FDA Approved Drug Products With Therapeutic Equivalence Evaluations (the “Orange Book”) for REVLIMID ® (lenalidomide). Natco’s Notice Letters were sent in connection with its filing of an ANDA seeking permission from the FDA to market a generic version of 25mg, 15mg, 10mg and 5mg REVLIMID ® capsules. We filed separate infringement actions (which were subsequently consolidated) in the United States District Court for the District of New Jersey against Natco, Natco’s U.S. partner, Arrow International Limited (Arrow), and Arrow’s parent company, Watson Laboratories, Inc. (Watson, a wholly-owned subsidiary of Allergan plc (formerly known as Actavis, Inc.) and formerly known as Watson Pharmaceuticals, Inc.) (Natco, Arrow and Watson are collectively referred to hereinafter as “Natco”). On December 22, 2015, we announced the settlement of the litigations with Natco. As part of the settlement, the parties filed Consent Judgments with the District Court that enjoin Natco from marketing generic lenalidomide before the April 2027 expiration of Celgene’s last-to-expire patent listed in the Orange Book for REVLIMID ® . We agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States beginning on January 31, 2026. In addition, Natco will receive a volume-limited license to sell generic lenalidomide in the United States commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total lenalidomide capsules dispensed in the United States during the first year of entry. The volume limitation is expected to increase gradually each 12 months until March 2025, and is not expected to exceed one-third of the total lenalidomide capsules dispensed in the U.S. in the final year of the volume-limited license. Natco’s ability to market generic lenalidomide in the U.S. will be contingent on its obtaining approval of an Abbreviated New Drug Application. The settlement agreement has been submitted to the Federal Trade Commission for review. In 2012, our European patent EP 1667682 (the “’682 patent”) relating to certain polymorphic forms of lenalidomide expiring in 2024 was opposed in a proceeding before the European Patent Office (EPO) by Generics (UK) Ltd. and Teva Pharmaceutical Industries Ltd. On July 21, 2015, the EPO determined, based primarily on procedural grounds, that the ’682 patent was not valid. Celgene appealed the EPO ruling to the EPO Board of Appeal, which stays any revocation of the patent until the appeal is finally adjudicated. No appeal hearing date has been set. We do not anticipate a decision from the EPO Board of Appeal for several years and intend to vigorously defend all of our intellectual property rights. In 2010, Celgene’s European patent EP1505973 (the “’973 patent”) relating to certain uses of lenalidomide expiring in 2023 was opposed in a proceeding before the EPO by Synthon B.V. and an anonymous party. On February 25, 2013, the EPO determined that the ’973 patent was not valid. Celgene appealed the EPO ruling to the EPO Board of Appeal, which stays any revocation of the patent until the appeal is finally adjudicated. No appeal hearing date has been set. We do not anticipate a decision from the EPO Board of Appeal for several years and intend to vigorously defend all of our intellectual property rights. We believe that our patent portfolio for lenalidomide in Europe, including the composition of matter patent which expires in 2022, is strong and defensible. Although we believe that we will prevail in the EPO proceedings, in the event these patents are found not to be valid, we expect that we will still have patent protection in the EU for lenalidomide through at least 2022. THALOMID ® and REVLIMID ® : On October 2, 2013, Andrulis Pharmaceuticals Corporation (Andrulis) filed a lawsuit against us in the United States District Court for the District of Delaware claiming infringement of U.S. Patent No. 6,140,346 (“the ’346 patent”). Andrulis alleges that we are liable for infringement of one or more claims of the ’346 patent, which covers the use of THALOMID ® (and, as asserted by Andrulis, REVLIMID ® ) in combination with an alkylating agent (e.g., melphalan) to treat cancers. Andrulis is seeking an unspecified amount of damages, attorneys’ fees and injunctive relief. We disagree with Andrulis’ allegations and intend to vigorously defend against this infringement suit. On January 30, 2014, we filed a motion to dismiss Andrulis’ amended complaint. On April 11, 2014, the court denied our motion in part and granted our motion in part, dismissing two of Andrulis' four infringement claims without leave to amend. We filed an answer to the remaining claims on April 25, 2014. In February 2015, we filed a partial summary judgment motion. The court held hearings on claim construction and on the partial summary judgment motion on May 27, 2015 and May 28, 2015, respectively. On June 26, 2015, the court issued its claim construction ruling and held that certain claim terms were indefinite. On July 28, 2015, the court entered final judgment in favor of Celgene. On August 27, 2015, Andrulis filed a notice of appeal to the United States Court of Appeals for the Federal Circuit on the final judgment and its indefiniteness and claim construction rulings. Plaintiff's opening brief was filed on December 2, 2015 and our response is due February 16, 2016. No hearing date has been scheduled. ISTODAX® (romidepsin): We received a Notice Letter dated March 17, 2014 from Fresenius Kabi USA, LLC (Fresenius) notifying us of Fresenius’s ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against U.S. Patent Nos. 7,608,280 and 7,611,724 (the ’280 and ’724 patents) that are listed in the Orange Book for ISTODAX ® . On April 30, 2014, Celgene and Astellas Pharma Inc. (Astellas), filed an infringement action in the United States District Court for the District of Delaware against Fresenius. Celgene and Astellas have reached an agreement to settle all claims and counterclaims with Fresenius. Under the terms of the settlement agreement, which was approved by the court, the parties have stipulated to dismiss the case and Celgene will provide Fresenius a non-exclusive, royalty-free sublicense to manufacture and market the Fresenius generic product as of February 1, 2018. The settlement agreement has been submitted to the Federal Trade Commission for review. On August 4, 2014, we received a Notice Letter from InnoPharma, Inc. (InnoPharma) notifying us of Innopharma's ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against the ’280 and ’724 patents. On September 12, 2014, we and Astellas, filed an infringement action in the United States District Court for the District of Delaware against InnoPharma. Celgene and Astellas have reached an agreement to settle all claims and counterclaims with InnoPharma. Under the terms of the settlement agreement, which was approved by the court, the parties have stipulated to dismiss the case. In addition, Celgene will provide InnoPharma a non-exclusive, royalty-free sublicense to manufacture and market the InnoPharma generic product at a date after February 1, 2018 and prior to the expiration of the ’280 and ’724 patents. The settlement agreement has been submitted to the Federal Trade Commission for review. On May 28, 2015, we received a Notice Letter from Teva Pharmaceuticals USA, Inc. (Teva) notifying us of Teva’s ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against the '280 and '724 patents. On July 10, 2015, we and Astellas filed an infringement action in the United States District Court for the District of Delaware against Teva. In its answer and counterclaim, Teva asserts that the ’280 and ’724 patents are invalid and/or not infringed by its proposed generic products. As a result of the filing of our action, the FDA cannot grant final approval of Teva’s ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) November 28, 2017. Fact discovery is set to close on August 9, 2016. A claim construction hearing is scheduled for August 23, 2016. Expert discovery is set to close on April 18, 2017 and trial is scheduled to begin on June 19, 2017. On October 30, 2015, we received a Notice Letter from Teva notifying us of Teva’s New Drug Application pursuant to FDC Act § 505(b)(3)(D)(i) seeking approval to engage in the commercial manufacture, use or sale of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against the '280 and '724 patents. On December 10, 2015, we and Astellas filed an infringement action in the United States District Court for the District of Delaware against Teva. As a result of the filing of our action, the FDA cannot grant final approval of Teva’s NDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) April 30, 2018. THALOMID ® (thalidomide): We received a Notice Letter dated December 18, 2014 from Lannett Holdings, Inc. (Lannett) notifying us of Lannett’s ANDA which contains Paragraph IV certifications against U.S. Patent Nos. 5,629,327; 6,045,501; 6,315,720; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 6,908,432; 7,141,018; 7,230,012; 7,435,745; 7,874,984; 7,959,566; 8,204,763; 8,315,886; 8,589,188; and 8,626,531 that are listed in the Orange Book for THALOMID ® (thalidomide). Lannett is seeking to market a generic version of 50mg, 100mg, 150mg and 200mg of THALOMID ® capsules. On January 30, 2015, we filed an infringement action against Lannett in the United States District Court for the District of New Jersey. As a result of the filing of our action, the FDA cannot grant final approval of Lannett’s ANDA until the earlier of (i) a final decision that each of the patents is invalid, unenforceable, and/or not infringed; or (ii) June 22, 2017. On March 27, 2015, Lannett filed a motion to dismiss our complaint for lack of personal jurisdiction and we filed a response to the motion on April 20, 2015. A hearing was held on July 27, 2015 and the Court decided to administratively terminate the motion to dismiss in order to allow us to conduct jurisdictional discovery. On November 17, 2015, Lannett withdrew its motion to dismiss. On December 8, 2015, Lannett filed an answer and counterclaims asserting that the patents-in-suit are invalid, unenforceable, and/or not infringed and on January 19, 2016 we filed a reply to Lannett's counterclaims. The court has not yet entered a schedule for discovery or trial. Proceedings involving the USPTO: Under the America Invents Act (AIA), any person may seek to challenge an issued patent by petitioning the United States Patent and Trademark Office (USPTO) to institute a post grant review. On April 23, 2015, we were informed that Coalition for Affordable Drugs VI LLC filed petitions for Inter Partes Review (IPRs) challenging the validity of Celgene’s patents US 6,045,501 and US 6,315,720 covering certain aspects of our REMS program. On October 27, 2015, the USPTO Patent Trial and Appeal Board (PTAB) instituted IPR proceedings relating to these patents. An oral hearing has been scheduled for July 21, 2016 and a decision is expected by October 27, 2016. In accordance with the requirements of the AIA, we expect final decisions from the PTAB not later than one year after the institution of the IPRs. Any patent claim the PTAB determines to be unpatentable is stricken from the challenged patent. Any party may appeal final written decisions of the PTAB to the United States Court of Appeals for the Federal Circuit. We intend to continue to vigorously defend our patent claims. Other Proceedings: In 2009, we received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) seeking documents and other information relating to requests by manufacturers of generic drugs to purchase our patented REVLIMID ® and THALOMID ® brand drugs in order for the FTC to evaluate whether there may be reason to believe that we have engaged in unfair methods of competition. In 2010, the State of Connecticut issued a subpoena referring to the same issues raised by the 2009 CID. Also in 2010, we received a second CID from the FTC relating to this matter. We continue to cooperate with the FTC and State of Connecticut investigations. On April 3, 2014, Mylan Pharmaceuticals Inc. (Mylan) filed a lawsuit against us in the United States District Court for the District of New Jersey alleging that we violated various federal and state antitrust and unfair competition laws by allegedly refusing to sell samples of our THALOMID ® and REVLIMID ® brand drugs so that Mylan can conduct the bioequivalence testing necessary for ANDAs to be submitted to the FDA for approval to market generic versions of these products. Mylan is seeking injunctive relief, damages and declaratory judgment. We filed a motion to dismiss Mylan’s complaint on May 25, 2014. Mylan filed its opposition to our motion to dismiss on June 16, 2014. The Federal Trade Commission filed an amicus curiae brief in opposition to our motion to dismiss on June 17, 2014. On December 22, 2014, the court granted Celgene’s motion to dismiss (i) Mylan’s claims based on Section 1 of the Sherman Act (without prejudice), and (ii) Mylan's claims arising under the New Jersey Antitrust Act. The court denied our motion to dismiss the rest of the claims which primarily relate to Section 2 of the Sherman Act. On January 6, 2015 we filed a motion to certify for interlocutory appeal the order denying our motion to dismiss with respect to the claims relating to Section 2 of the Sherman Act, which appeal was denied by the United State Court of Appeals for the Third Circuit on March 5, 2015. On January 20, 2015, we filed an answer to Mylan’s complaint. Fact discovery is set to close April 8, 2016 and expert discovery is set to be completed by October 24, 2016. No trial date has been set. We intend to vigorously defend against Mylan’s claims. In 2011, the United States Attorney’s Office for the Central District of California informed us that they were investigating possible off-label marketing and improper payments to physicians in connection with the sales of THALOMID ® and REVLIMID ® . In 2012, we learned that two other United States Attorneys’ offices (the Northern District of Alabama and the Eastern District of Texas) and various state Attorneys General were conducting related investigations. In February 2014, three civil qui tam actions related to those investigations brought by three former Celgene employees on behalf of the federal and various state governments under the federal false claims act and similar state laws were unsealed after the United States Department of Justice (DOJ) declined to intervene in any of these actions. The DOJ retains the right to intervene in these actions at any time. Additionally, while several states have similarly declined to intervene in some of these actions, they also retain the right to intervene in the future. The plaintiffs in the Northern District of Alabama and Eastern District of Texas actions have voluntarily dismissed their cases. On April 25, 2014, we filed a motion to dismiss the complaint in the remaining (Central District of California) action, United States of America ex. rel. Beverly Brown V. Celgene Corp. , unsealed February 5, 2014 (the Brown Action), which was denied except with respect to certain state claims. We filed our answer to the complaint on August 28, 2014. Fact discovery closed on September 25, 2015. On January 21, 2016, the court vacated the expert discovery deadline. Summary judgment motions are to be filed jointly with the court by April 18, 2016. No trial date has been set. We intend to vigorously defend against the claims in the Brown Action. In February 2014, we received a letter purportedly on behalf of a stockholder demanding access to certain books and records of the Company for the purpose of investigating matters pertaining to the Brown Action. The Company complied with the demand, as modified through negotiation with counsel for the purported stockholder. In July 2014, we received a letter purportedly on behalf of two stockholders (one of which was referenced in the February 2014 letter) that demands, primarily on the basis of the allegations in the Brown Action, that our board of directors take action on the Company’s behalf to correct alleged deficiencies in the Company’s internal controls and to recover from current and past directors and officers damages those stockholders allege to have resulted from breaches of fiduciary duties related to the matters alleged in the Brown Action (the Demand). Our Board formed a Demand Investigation Committee, and with the assistance of independent counsel retained by it, the Demand Investigation Committee considered the issues raised in the stockholders’ letter. In October 2015, the Demand Investigation Committee reported to the Board of Directors, and the Board of Directors accepted the Committee’s recommendation, that the Company take no action at this time, legal or otherwise, in response to the stockholders’ demands. In November 2015, we received another letter purportedly on behalf of the same two stockholders that demands access to certain books and records of the Company for the purpose of investigating whether the Demand was wrongfully refused, the independence, good faith and due care of the Demand Investigation Committee, and whether the Demand Investigation Committee conducted a reasonable investigation of the Demand. The Company is in the process of responding to this latest letter. In November 2014, we received another letter purportedly on behalf of a stockholder demanding access to certain books and records of the Company for the purpose of investigating matters pertaining to the Brown Action. The Company complied with the demand, as modified through negotiation with counsel for the purported stockholder, and in November 2015 the stockholder filed a complaint in Delaware Chancery Court asserting derivative claims on behalf of the Company against eight current, and four former members of the Board of Directors. The complaint alleges, largely on the basis of allegations in the Brown Action, that the defendant directors breached their fiduciary duties by allowing the Company to engage in unlawful activity in its marketing of THALOMID and REVLIMID, and seeks from the defendant directors unspecified damages, including Celgene’s costs of defending against government and civil investigations and lawsuits and alleged reputational harm, and disgorgement of compensation paid to the defendant directors. On January 22, 2016, the Company filed a motion to dismiss the complaint on the basis that prior to filing the complaint asserting derivative claims the plaintiff was required under Delaware law and failed to demand that our board of directors take action on the Company’s behalf. Oral argument on the motion has not yet been scheduled. On June 7, 2013, Children's Medical Center Corporation (CMCC) filed a lawsuit against us in the Superior Court of the Commonwealth of Massachusetts alleging that our obligation to pay a 1% royalty on REVLIMID ® net sales revenue and a 2.5% royalty on POMALYST ® /IMNOVID ® net sales revenue under a license agreement entered into in December 2002 extended beyond February 28, 2013 and that our failure to make royalty payments to CMCC subsequent to February 28, 2013 breached the license agreement. CMCC is seeking unspecified damages and a declaration that the license agreement remains in full force and effect. In July 2013, we removed these proceedings to the United States District Court for the District of Massachusetts. On August 5, 2013, we filed an answer to CMCC’s complaint and a counterclaim for declaratory judgment that our obligations to pay royalties have expired. On August 26, 2013, CMCC filed an answer to our counterclaim. On July 8, 2014, CR Rev Holdings, LLC (“CR Rev”) filed a complaint against Celgene in the same action. CR Rev alleges that CMCC sold and assigned a substantial portion of the royalty payments owed by Celgene on the sale of REVLIMID ® to CR Rev. CR Rev has alleged causes of action with respect to REVLIMID ® identical to those alleged by CMCC, and seeks unspecified damages and a declaration that the license agreement is still in effect. Discovery in this matter has been completed. On August 4, 2015, Plaintiffs filed a motion for summary judgment on certain claims, including breach of contract, declaratory judgment and, with respect to Celgene’s counterclaims, patent misuse. Oral argument on the motion was held on October 21, 2015. No trial date has as yet been set by the court. We intend to vigorously defend against CMCC's and CR Rev’s claims. As of December 31, 2015, we consider the range of reasonably possible loss relating to this lawsuit to be between zero and $141.3 million , with the high end of the range being the royalty payments on REVLIMID ® we would have made to CMCC under the license agreement through December 31, 2015, if our obligation to pay royalties remained in effect. CMCC contends that our royalty obligation continues on net sales of REVLIMID ® , as well as POMALYST ® /IMNOVID ® , at least until May 2016. If CMCC prevails, we may be obligated to continue to pay royalties on sales for periods after December 31, 2015. On October 2, 2014, a complaint was filed in Delaware Chancery Court by a stockholder asserting derivative claims on behalf of the Company against the non-employee members of the Board of Directors. The complaint, as subsequently amended, alleged that equity grants made to non-employee directors in 2012, 2013 and 2014 were excessive compared to the equity grants to directors of peer companies, and that the award of such allegedly excessive compensation constituted a breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On September 14, 2015, the parties agreed to settle all claims in the case, subject to the Chancery Court’s approval of the settlement. The settlement was approved by the court in December 2015. The settlement provides prospective relief only, setting limits on equity grants to non-employee directors for at least four years and requiring certain changes in the charter of the Board’s compensation committee and certain disclosures concerning non-employee director compensation. On November 7, 2014, the International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund (IUB) filed a putative class action lawsuit against us in the Uni

Geographic and Product Informat

Geographic and Product Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Geographic and Product Information	Geographic and Product Information Operations by Geographic Area: Revenues primarily consisted of sales of REVLIMID ® , ABRAXANE ® , POMALYST ® /IMNOVID ® , OTEZLA ® , VIDAZA ® , azacitidine for injection, THALOMID ® , and ISTODAX ® . Additional sources of revenue included a licensing agreement with Novartis, which entitles us to royalties on FOCALIN XR ® and the entire RITALIN ® family of drugs, the sale of services through our Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. Revenues 2015 2014 2013 United States $ 5,604.0 $ 4,482.8 $ 3,862.1 Europe 2,624.3 2,310.8 1,865.7 All other 1,027.7 876.8 766.1 Total revenues $ 9,256.0 $ 7,670.4 $ 6,493.9 Long-Lived Assets 1 2015 2014 United States $ 585.5 $ 406.1 Europe 215.2 222.2 All other 13.4 14.3 Total long lived assets $ 814.1 $ 642.6 1 Long-lived assets consist of net property, plant and equipment. Revenues by Product: Total revenues from external customers by product for the years ended December 31, 2015 , 2014 and 2013 were as follows: 2015 2014 2013 REVLIMID ® $ 5,801.1 $ 4,980.0 $ 4,280.3 ABRAXANE ® 967.5 848.2 648.9 POMALYST ® /IMNOVID ® 983.3 679.7 305.4 OTEZLA ® 471.7 69.8 — VIDAZA ® 590.7 611.9 803.3 azacitidine for injection 83.9 78.2 23.3 THALOMID ® 185.4 221.2 244.5 ISTODAX ® 69.1 65.6 54.0 Other 8.4 9.2 2.6 Total net product sales 9,161.1 7,563.8 6,362.3 Other revenue 94.9 106.6 131.6 Total revenue $ 9,256.0 $ 7,670.4 $ 6,493.9 Major Customers: We sell our products primarily through wholesale distributors and specialty pharmacies in the United States, which account for a large portion of our total revenues. International sales are primarily made directly to hospitals, clinics and retail chains, many of which are government owned. During the three-year period of 2015 , 2014 and 2013 , customers that accounted for more than 10% of our total revenue in at least one of those years are summarized below. The percentage of amounts due from these customers compared to total net accounts receivable is also summarized below as of December 31, 2015 and 2014 . Percent of Total Revenue Percent of Net Accounts Receivable Customer 2015 2014 2013 2015 2014 Amerisource Bergen Corp. 8.1 % 9.0 % 10.7 % 8.2 % 9.7 % CVS 10.7 % 9.8 % 9.3 % 8.2 % 7.6 %

Quarterly Results of Operations

Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Quarterly Results of Operations (Unaudited)	Quarterly Results of Operations (Unaudited) 2015 1Q 2Q 3Q 3 4Q Year Total revenue $ 2,080.8 $ 2,277.8 $ 2,334.1 $ 2,563.3 $ 9,256.0 Gross profit 1 1,951.2 2,153.3 2,202.7 2,433.8 8,741.0 Income tax provision 108.2 114.6 14.2 184.5 421.5 Net income (loss) 718.9 356.2 (34.1 ) 561.0 1,602.0 Net income (loss) per share: 2 Basic $ 0.90 $ 0.45 $ (0.04 ) $ 0.71 $ 2.02 Diluted $ 0.86 $ 0.43 $ (0.04 ) $ 0.69 $ 1.94 Weighted average shares: Basic 798.9 793.0 791.1 785.8 792.2 Diluted 834.1 825.3 791.1 816.5 824.9 2014 1Q 4 2Q 3Q 4Q Year Total revenue $ 1,730.0 $ 1,872.7 $ 1,982.2 $ 2,085.5 $ 7,670.4 Gross profit 1 1,621.4 1,745.7 1,859.1 1,951.7 7,177.9 Income tax provision 52.6 109.0 69.0 96.9 327.5 Net income 279.7 597.8 508.5 613.9 1,999.9 Net income per share: 2 Basic $ 0.34 $ 0.75 $ 0.64 $ 0.77 $ 2.49 Diluted $ 0.33 $ 0.72 $ 0.61 $ 0.74 $ 2.39 Weighted average shares: Basic 811.5 799.6 799.6 800.2 802.7 Diluted 845.1 831.0 832.8 834.6 836.0 1 Gross profit is computed by subtracting cost of goods sold (excluding amortization of acquired intangible assets) from net product sales. 2 The sum of the quarters may not equal the full year due to rounding. In addition, quarterly and full year basic and diluted earnings per share are calculated separately. 3 Net income for 2015 was a loss in the third quarter primarily due to costs related to collaborations and the acquisition of Receptos. 4 Net income for 2014 was lower in the first quarter compared to each of the other three quarters primarily due to a higher level of expense related to research and development collaborations.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II – Valuation and Qualifying Accounts (In Millions) Year ended December 31, Balance at Beginning of Year Charged to Expense or Sales Deductions Balance at End of Year 2015: Allowance for doubtful accounts $ 20.6 $ (0.1 ) $ 2.4 $ 18.1 Allowance for customer discounts 11.5 111.7 1 111.0 12.2 Subtotal 32.1 111.6 113.4 30.3 Allowance for sales returns 10.2 16.3 1 9.1 17.4 Total $ 42.3 $ 127.9 $ 122.5 $ 47.7 2014: Allowance for doubtful accounts $ 27.9 $ (2.7 ) $ 4.6 $ 20.6 Allowance for customer discounts 12.1 87.9 1 88.5 11.5 Subtotal 40.0 85.2 93.1 32.1 Allowance for sales returns 15.5 2.5 1 7.8 10.2 Total $ 55.5 $ 87.7 $ 100.9 $ 42.3 2013: Allowance for doubtful accounts $ 21.8 $ 6.2 $ 0.1 $ 27.9 Allowance for customer discounts 11.2 74.3 1 73.4 12.1 Subtotal 33.0 80.5 73.5 40.0 Allowance for sales returns 13.3 9.6 1 7.4 15.5 Total $ 46.3 $ 90.1 $ 80.9 $ 55.5 1 Amounts are a reduction from gross sales.

Nature of Business, Basis of 29

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Financial Instruments	Financial Instruments: Certain financial instruments reflected in the Consolidated Balance Sheets, (e.g., cash, cash equivalents, accounts receivable, certain other assets, accounts payable, short-term borrowings and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than marketable securities are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of available-for-sale marketable securities is determined utilizing the valuation techniques appropriate to the type of security (See Note 4).
Derivative Instruments and Hedges	Derivative Instruments and Hedges: All derivative instruments are recognized on the balance sheet at their fair value. Changes in the fair value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. We assess, both at inception and on an on-going basis, whether the derivative instruments that are used in cash flow hedging transactions are highly effective in offsetting the changes in cash flows of hedged items. We assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion of derivative instruments, if any, to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealized gain or loss on the derivative instrument is recognized in current earnings. We use derivative instruments, including those not designated as part of a hedging transaction, to manage our exposure to movements in foreign exchange, our stock price and interest rates. The use of these derivative instruments modifies the exposure of these risks with the intent to reduce our risk or cost.
Cash, Cash Equivalents and Marketable Securities Available for Sale	Cash, Cash Equivalents and Marketable Securities Available for Sale: We invest our excess cash primarily in money market funds, U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency mortgage-backed securities (MBS), non-U.S. government, agency and supranational securities, global corporate debt securities and asset backed securities. All liquid investments with maturities of three months or less from the date of purchase are classified as cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities available for sale. We determine the appropriate classification of our investments in marketable debt and equity securities at the time of purchase. In addition, our equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements, are designated as marketable securities available for sale. Our marketable securities available for sale are primarily equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements. In addition, we invest in debt securities that are carried at fair value, held for an unspecified period of time and are intended for use in meeting our ongoing liquidity needs. Unrealized gains and losses on available-for-sale securities, which are deemed to be temporary, are reported as a separate component of stockholders' equity, net of tax. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization, along with realized gains and losses and other-than-temporary impairment charges, is included in interest and investment income, net. A decline in the market value of any available-for-sale security below its carrying value that is determined to be other-than-temporary would result in a charge to earnings and decrease in the security's carrying value down to its newly established fair value. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market condition in which the issuer operates; our intent to hold to maturity and an evaluation as to whether it is more likely than not that we will not have to sell before recovery of its cost basis; our expected future cash flows from the security; and issues that raise concerns about the issuer's ability to continue as a going concern.
Concentration of Credit Risk	Concentration of Credit Risk: Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. We invest our excess cash primarily in money market funds, U.S. Treasury securities, U.S. government-sponsored agency securities, MBS, non-U.S. government, agency and supranational securities, global corporate debt securities and asset backed securities (See Note 6). We have established guidelines relative to diversification and maturities to maintain safety and liquidity. These guidelines are reviewed periodically and may be modified to take advantage of trends in yields and interest rates. We sell our products in the United States primarily through wholesale distributors and specialty contracted pharmacies. Therefore, wholesale distributors and large pharmacy chains account for a large portion of our U.S. trade receivables and net product revenues (See Note 19). International sales are primarily made directly to hospitals, clinics and retail chains, many of which in Europe are government owned and have extended their payment terms in recent years given the economic pressure these countries are facing. We continuously monitor the creditworthiness of our customers, including these governments, and have internal policies regarding customer credit limits. We estimate an allowance for doubtful accounts primarily based on the credit worthiness of our customers, historical payment patterns, aging of receivable balances and general economic conditions, including publicly available information on the credit worthiness of countries themselves and provinces or areas within such countries where they are the ultimate customers. We continue to monitor economic conditions, including the volatility associated with international economies, the sovereign debt crisis in certain European countries and associated impacts on the financial markets and our business. Our current business model in these markets is typically to sell our products directly to principally government owned or controlled hospitals, which in turn directly deliver critical care to patients. Our products are used to treat life-threatening diseases and we believe this business model enables timely delivery and adequate supply of products. Many of the outstanding receivable balances are related to government-funded hospitals and we believe the receivable balances are ultimately collectible. Similarly, we believe that future sales to these customers will continue to be collectible. The credit and economic conditions within Spain, Italy, Portugal and Greece, as well as increasing sales levels in those countries have in the past resulted in, and may continue to result in, an increase in the average length of time it takes to collect accounts receivable.
Inventory	Inventory: Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized. Included in inventory are raw materials used in the production of preclinical and clinical products, which are charged to research and development expense when consumed. We capitalize inventory costs associated with certain products prior to regulatory approval of products, or for inventory produced in new production facilities, when management considers it highly probable that the pre-approval inventories will be saleable. The determination to capitalize is based on the particular facts and circumstances relating to the expected regulatory approval of the product or production facility being considered, and accordingly, the time frame within which the determination is made varies from product to product. The assessment of whether or not the product is considered highly probable to be saleable is made on a quarterly basis and includes, but is not limited to, how far a particular product or facility has progressed along the approval process, any known safety or efficacy concerns, potential labeling restrictions and other impediments. We could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors.
Property, Plant and Equipment	Property, Plant and Equipment: Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation of plant and equipment is recorded using the straight-line method. Building improvements are depreciated over the remaining useful life of the building. Leasehold improvements are depreciated over the lesser of the economic useful life of the asset or the remaining term of the lease, including anticipated renewal options. The estimated useful lives of capitalized assets are as follows: Buildings 40 years Building and operating equipment 15 years Manufacturing machinery and equipment 10 years Other machinery and equipment 5 years Furniture and fixtures 5 years Computer equipment and software 3-7 years Maintenance and repairs are charged to operations as incurred, while expenditures for improvements which extend the life of an asset are capitalized.
Capitalized Software Costs	Capitalized Software Costs: We capitalize software costs incurred in connection with developing or obtaining software. Capitalized software costs are included in property, plant and equipment, net and are amortized over their estimated useful life of three to seven years from the date the systems are ready for their intended use.
Investments in Other Entities	Investments in Other Entities: We hold a portfolio of investments in equity securities and certain investment funds that are accounted for under either the equity method or cost method. Investments in companies or certain investment funds over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other income (expense), net. Our equity investments in the publicly traded common stock of companies, including common stock of companies with whom we have entered into collaboration agreements, are designated as marketable securities available for sale. Investments in equity securities of companies that become publicly traded are accounted for as available-for-sale marketable securities prospectively from the date of such companies' initial public offering if we are not restricted from selling our investment for greater than one year. Our cost method and equity method investments are included in other assets on the Consolidated Balance Sheets. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: market value or exit price of the investment based on either market-quoted prices or future rounds of financing by the investee; length of time that the market value was below its cost basis; financial condition and business prospects of the investee; our intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that we may be aware of related to the investment.
Other Intangible Assets	Other Intangible Assets: Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is initiated for in-process research and development (IPR&D) intangible assets when their useful lives have been determined. IPR&D intangible assets which are determined to have had a drop in their fair value are adjusted downward and an expense recognized in the income statement. These IPR&D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
Goodwill	Goodwill: Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but is subject to impairment testing. We test our goodwill for impairment at least annually or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets: Long-lived assets, such as property, plant and equipment and certain other long-term assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of the assets exceed their estimated future undiscounted net cash flows, an impairment charge is recognized for the amount by which the carrying amount of the assets exceed the fair value of the assets.
Contingent Consideration from Business Combinations	Contingent Consideration from Business Combinations: Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period with changes in fair value recognized in income as acquisition related charges, net. Changes in fair values reflect new information about related IPR&D and other assets and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time as development work towards the achievement of the milestones progresses, and is accrued based on an accretion schedule.
Foreign Currency Translation	Foreign Currency Translation: Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities into the U.S. dollar are excluded from the determination of net income and are recorded as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net in the Consolidated Statements of Income.
Research and Development Costs	Research and Development Costs: Research and development costs are expensed as incurred. These include all internal and external costs related to services contracted by us. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Milestone payments made to third parties upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved
Income Taxes	Income Taxes: We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. We recognize the benefit of an uncertain tax position that we have taken or expect to take on income tax returns we file if such tax position is more likely than not to be sustained.
Revenue Recognition	Revenue Recognition: Revenue from the sale of products is recognized when title and risk of loss of the product is transferred to the customer and the sales price is fixed and determinable. Provisions for discounts, early payments, rebates, sales returns and distributor chargebacks under terms customary in the industry are provided for in the same period the related sales are recorded. We record estimated reductions to revenue for volume-based discounts and rebates at the time of the initial sale. The estimated reductions to revenue for such volume-based discounts and rebates are based on the sales terms, historical experience and trend analysis. We base our sales returns allowance on estimated on-hand retail/hospital inventories, measured end-customer demand as reported by third-party sources, actual returns history and other factors, such as the trend experience for lots where product is still being returned or inventory centralization and rationalization initiatives conducted by major pharmacy chains, as applicable. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. Under this methodology, we track actual returns by individual production lots. Returns on closed lots, that is, lots no longer eligible for return credits, are analyzed to determine historical returns experience. Returns on open lots, that is, lots still eligible for return credits, are monitored and compared with historical return trend rates. Any changes from the historical trend rates are considered in determining the current sales return allowance. Sales discount accruals are based on payment terms extended to customers. Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. U.S. Medicaid rebate accruals are generally based on historical payment data and estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicaid rebate percentage was increased and extended to Medicaid Managed Care Organizations in March 2010. The accrual of the rebates associated with Medicaid Managed Care Organizations is calculated based on estimated historical patient data related to Medicaid Managed Care Organizations. We also analyze actual billings received from the states to further support the accrual rates. Subsequent to implementation of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the 2010 U.S. Health Care Reform Law), certain states have not completed their Medicaid Managed Care Organization billing for the years of 2010 through 2015. Our accruals for these Medicaid Managed Care Organization rebates had been at elevated levels given the delays in the receipt of complete invoices from certain states. Due to the receipt of more complete claims data during 2013, 2014 and 2015, the accruals for certain states were reduced from these elevated levels as a result of both payments being applied to the accrual during 2013, 2014 and 2015 and changes in estimate of the ultimate obligation during the fourth quarters of 2013, 2014 and 2015. We will continue to adjust the rebate accruals as more information becomes available and to reflect actual claims experience. Manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this coverage gap responsibility, we analyze data for eligible Medicare Part D patients against data for eligible Medicare Part D patients treated with our products as well as the historical invoices. This expense is recognized throughout the year as costs are incurred. In certain international markets government-sponsored programs require rebates to be paid based on program specific rules and, accordingly, the rebate accruals are determined primarily on estimated eligible sales. Rebates or administrative fees are offered to certain wholesale customers, group purchasing organizations and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to 15 months from the date of sale. We record a provision for rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of wholesaler inventories, contract sales volumes and average contract pricing. We regularly review the information related to these estimates and adjust the provision accordingly. Chargeback accruals are based on the differentials between product acquisition prices paid by wholesalers and lower government contract pricing paid by eligible customers covered under federally qualified programs. Distributor service fee accruals are based on contractual fees to be paid to the wholesale distributor for services provided. TRICARE is a health care program of the U.S. Department of Defense Military Health System that provides civilian health benefits for military personnel, military retirees and their dependents. TRICARE rebate accruals are included in chargeback accruals and are based on estimated Department of Defense eligible sales multiplied by the TRICARE rebate formula. We record estimated reductions to revenue for free goods and volume-based discounts at the time of the initial sale. The estimated reductions to revenue for such free goods and volume-based discounts are based on the sales terms, historical experience and trend analysis. The cost of free goods is included in cost of goods sold (excluding amortization of acquired intangible assets). We recognize revenue from royalties based on licensees' sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.
Share-Based Compensation	Share-Based Compensation: We utilize share based compensation in the form of stock options, restricted stock units (RSUs) and performance-based restricted stock units (PSUs). Compensation expense is recognized in the Consolidated Statements of Income based on the estimated fair value of the awards at grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized to date associated with grants that are not expected to vest will be reversed. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of RSU and PSU grants that are not based on market performance are based on the market value of our Common Stock on the date of grant.
Earnings Per Share	Earnings Per Share: Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares resulting from option exercises, RSUs, PSUs, warrants and other incentives had been issued and any proceeds thereof used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to us upon exercise of options, the amount of compensation cost attributed to future services and not yet recognized and, if applicable, the amount of excess income tax benefit that would be credited to paid-in capital upon exercise.
New Accounting Pronouncements	New Accounting Pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2018 using one of two prescribed transition methods. We are currently evaluating the effect that the updated standard and transition method will have on our consolidated financial statements and related disclosures. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (ASU 2015-03). ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable IFRS standards by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, similar to the presentation of debt discounts or premiums. This accounting guidance is effective for us beginning in the first quarter of 2016. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures. In April 2015, the FASB issued Accounting Standards Update No. 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement" (ASU 2015-05). ASU 2015-05 provides guidance to help companies evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The new guidance clarifies that if a cloud computing arrangement includes a software license, the customer should account for the license consistent with its accounting for other software licenses. If the arrangement does not include a software license, the customer should account for the arrangement as a service contract. ASU 2015-05 is effective for us beginning in the first quarter of 2016. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures. In July 2015, the FASB issued Accounting Standards Update No. 2015-11, "Inventory (Topic 330): Simplifying the Measurement of Inventory" (ASU 2015-11). ASU 2015-11 applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In August 2015, the FASB issued Accounting Standards Update No. 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" (ASU 2015-15). ASU 2015-15 clarifies the presentation and subsequent measurement of debt issuance costs associated with lines of credit. These costs may be presented as an asset and amortized ratably over the term of the line of credit arrangement, regardless of whether there are outstanding borrowings on the arrangement. The effective date will be the first quarter of fiscal year 2017 and will be applied retrospectively. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures. In September 2015, the FASB issued Accounting Standards Update No. 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments" (ASU 2015-16). ASU 2015-16 replaces the requirement that an acquirer in a business combination account for measurement period adjustments retrospectively with a requirement that an acquirer recognize adjustments to the provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. ASU 2015-16 requires that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. ASU 2015-16 will be effective for us beginning in the first quarter of 2016. The guidance is to be applied prospectively to adjustments to provisional amounts that occur after the effective date of the guidance, with earlier application permitted for financial statements that have not been issued. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, "Balance Sheet Classification of Deferred Taxes" (ASU 2015-17). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities and associated valuation allowances as non-current on the balance sheet instead of separating deferred taxes and associated valuation allowances into current and non-current amounts. The update may be adopted on either a prospective or retrospective basis with early adoption permitted. In order to simplify the presentation of deferred income taxes, we have chosen to adopt ASU 2015-17 in the fourth quarter of 2015 on a prospective basis. Prior periods were not retrospectively adjusted. In January 2016, the FASB issued Accounting Standards Update 2016-01, "Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities" (ASU 2016-01). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 will be effective for us beginning in the first quarter of 2018 and early adoption is available to publicly traded companies for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. We expect the implementation of this standard to have an impact on our consolidated financial statements and related disclosures, as we held publicly traded equity investments at December 31, 2015 with a fair value of $1.236 billion , as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of ASU 2016-01 is expected to increase volatility in our net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available for sale equity investments will be reflected in net income after adoption.

Nature of Business, Basis of 30

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of estimated useful lives of capitalized assets	The estimated useful lives of capitalized assets are as follows: Buildings 40 years Building and operating equipment 15 years Manufacturing machinery and equipment 10 years Other machinery and equipment 5 years Furniture and fixtures 5 years Computer equipment and software 3-7 years

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Receptos
Business Acquisition [Line Items]
Schedule of fair value of consideration transferred	The total cash consideration for the acquisition of Receptos is summarized as follows: Total Consideration Cash paid for outstanding common stock $ 7,311.3 Cash for equity compensation attributable to pre-combination service 314.9 Total consideration $ 7,626.2
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below. During the fourth quarter of 2015, adjustments have been recorded to increase the amounts initially recorded for deferred tax assets, deferred tax liabilities and goodwill as of the Acquisition Date. The amounts recognized will be finalized as the information necessary to complete the analyses is obtained, but no later than one year from the Acquisition Date. Amounts Recognized as of the Acquisition Date (Provisional) Working capital (1) $ 479.2 Property, plant and equipment 5.0 In-process research and development product rights 6,842.0 Current deferred tax assets 241.3 Other non-current assets 7.9 Non-current deferred tax liabilities (2) (2,519.2 ) Total identifiable net assets 5,056.2 Goodwill 2,570.0 Total net assets acquired $ 7,626.2 (1) Includes cash and cash equivalents, available-for-sale marketable securities, other current assets, accounts payable and other current liabilities.
Schedule of Included Business Acquisition Expenses	From the Acquisition Date through December 31, 2015, our Consolidated Statements of Income included expenses of $380.5 million associated with the acquisition and operations of Receptos as follows (1) : Statements of Income Location Acquisition Date Through December 31, 2015 Research and development $ 78.6 Selling, general and administrative 5.1 Acquisition related charges and restructuring, net (2) 296.8 Total $ 380.5 (1) In addition, Celgene incurred $19.9 million of acquisition related costs prior to the acquisition date. (2) Consists of acquisition-related compensation expense and transaction costs.
Business Acquisition, Pro Forma Information	The following table provides unaudited pro forma financial information for the twelve-month periods ended December 31, 2015 and 2014 as if the acquisition of Receptos had occurred on January 1, 2014. Twelve-Month Periods Ended December 31, 2015 2014 Total revenue $ 9,256.0 $ 7,676.3 Net income $ 1,630.8 $ 1,499.9 Net income per common share: basic $ 2.06 $ 1.87 Net income per common share: diluted $ 1.98 $ 1.79
Quanticel
Business Acquisition [Line Items]
Schedule of fair value of consideration transferred	The fair value of consideration transferred in the acquisition of Quanticel is shown in the table below: Fair Value at the Acquisition Date Cash $ 95.9 Fair value of pre-existing equity ownership 11.4 Contingent consideration 166.0 Total fair value of consideration $ 273.3
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below. The amounts recognized will be finalized as the information necessary to complete the analyses is obtained, but no later than one year from the acquisition date. Fair Value at October 19, 2015 (Provisional) Working capital (1) $ 7.0 Property, plant and equipment 1.9 Other non-current assets 0.8 Technology platform intangible asset (2) 232.0 Debt obligations (13.9 ) Non-current deferred tax liabilities (72.3 ) Total identifiable net assets 155.5 Goodwill 117.8 Total net assets acquired $ 273.3 (1) Includes cash and cash equivalents, available-for-sale marketable securities, other current assets, accounts payable and other current liabilities. (2) Technology platform related to Quanticel’s proprietary technology platform for the single-cell genomic analysis of human cancer.
Nogra Pharma Limited
Business Acquisition [Line Items]
Schedule of fair value of consideration transferred	The fair value of consideration transferred to acquire the license amounted to: Fair Value at the Acquisition Date Cash $ 710.0 Contingent consideration 1,060.0 Total fair value of consideration $ 1,770.0
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The purchase price allocation resulted in the following amounts being allocated to the assets acquired at the acquisition date based on their respective fair values: Fair Value at the Acquisition Date In-process research and development product rights $ 1,620.0 Current deferred tax assets 1.3 Non-current deferred tax liabilities, net (1.3 ) Total identifiable net assets 1,620.0 Goodwill 150.0 Total net assets acquired $ 1,770.0

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of earnings per share	2015 2014 2013 Net income $ 1,602.0 $ 1,999.9 $ 1,449.9 Weighted-average shares: Basic 792.2 802.7 827.7 Effect of dilutive securities: Options, RSUs, PSUs, warrants and other 32.7 33.3 32.9 Diluted 824.9 836.0 860.6 Net income per share: Basic $ 2.02 $ 2.49 $ 1.75 Diluted $ 1.94 $ 2.39 $ 1.68

Financial Instruments and Fai33

Financial Instruments and Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Assets and liabilities measured at fair value on recurring basis	Balance at December 31, 2015 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 1,671.6 $ 1,235.9 $ 435.7 $ — Forward currency contracts 606.0 — 606.0 — Purchased currency options 46.7 — 46.7 — Interest rate swaps 52.5 — 52.5 — Total assets $ 2,376.8 $ 1,235.9 $ 1,140.9 $ — Liabilities: Contingent value rights $ (51.9 ) $ (51.9 ) $ — $ — Written currency options (19.1 ) — (19.1 ) — Other acquisition related contingent consideration (1,521.5 ) — — (1,521.5 ) Total liabilities $ (1,592.5 ) $ (51.9 ) $ (19.1 ) $ (1,521.5 ) Balance at December 31, 2014 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 3,425.1 $ 1,051.3 $ 2,373.8 $ — Forward currency contracts 550.7 — 550.7 — Purchased currency options 9.8 — 9.8 — Interest rate swaps 20.0 — 20.0 — Total assets $ 4,005.6 $ 1,051.3 $ 2,954.3 $ — Liabilities: Contingent value rights $ (136.3 ) $ (136.3 ) $ — $ — Written currency options (4.6 ) — (4.6 ) — Other acquisition related contingent consideration (1,279.0 ) — — (1,279.0 ) Total liabilities $ (1,419.9 ) $ (136.3 ) $ (4.6 ) $ (1,279.0 )
Roll-forward of fair value of Level 3 instruments (significant unobservable inputs), liabilities	The following table represents a roll-forward of the fair value of Level 3 instruments: 2015 2014 Liabilities: Balance at beginning of period $ (1,279.0 ) $ (228.5 ) Amounts acquired or issued (166.0 ) (1,060.0 ) Net change in fair value (76.5 ) (30.5 ) Settlements — 40.0 Transfers in and/or out of Level 3 — — Balance at end of period $ (1,521.5 ) $ (1,279.0 )

Derivative Instruments and He34

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative [Line Items]
Schedule of fair value and balance sheet location of derivative instruments	The following table summarizes the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of December 31, 2015 and 2014 : December 31, 2015 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 356.2 $ 18.0 Other non-current assets 287.8 28.0 Interest rate swap agreements Other current assets 30.7 — Other non-current assets 26.1 4.7 Other non-current liabilities 0.2 0.9 Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 46.0 5.9 Other current liabilities 2.9 7.4 Interest rate swap agreements Other current assets 2.4 2.3 Other non-current assets 2.4 1.4 Total $ 754.7 $ 68.6 December 31, 2014 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 264.9 $ 44.9 Other current liabilities 0.1 1.7 Other non-current assets 322.3 17.5 Interest rate swap agreements Other current assets 17.9 — Other non-current assets 4.8 0.3 Other non-current liabilities — 3.8 Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 39.7 6.0 Other current liabilities 0.1 1.1 Interest rate swap agreements Other current assets 0.1 — Other non-current assets 1.3 — Total $ 651.2 $ 75.3 1 Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.
Schedule of effect of derivative instruments not designated as hedging instruments on Consolidated Statements of Income	The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : Location of Gain (Loss) Recognized in Income on Derivative Amount of Gain (Loss) Recognized in Income on Derivative Instrument 2015 2014 Foreign exchange contracts Other income, net $ 81.2 $ 79.3 Put options sold Other income, net $ (9.9 ) $ 11.6
Cash flow hedges
Derivative [Line Items]
Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income	The following table summarizes the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Gain/(Loss) Recognized in OCI on Derivative 1 Location of Gain/(Loss) Reclassified from Accumulated OCI into Income Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income Location of Gain/(Loss) Recognized in Income on Derivative Amount of Gain/(Loss) Recognized in Income on Derivative Foreign exchange contracts $ 429.4 Net product sales $ 354.4 Other income, net $ 20.0 2 Treasury rate lock agreements $ (27.9 ) Interest expense $ (4.2 ) Other income, net $ (0.2 ) 3 Forward starting interest rate swaps $ 9.0 Interest expense $ (1.5 ) Other income, net $ 0.3 3 1 Net gains of $364.8 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. 2 The amount of net gains recognized in income represents $23.0 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $3.0 million in losses related to the ineffective portion of the hedging relationships. 3 The amount of net (loss) gain recognized in income relates to the ineffective portion of the hedging relationships. 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Gain/(Loss) Recognized in OCI on Derivative 1 Location of Gain/(Loss) Reclassified from Accumulated OCI into Income Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income Location of Gain/(Loss) Recognized in Income on Derivative Amount of Gain/(Loss) Recognized in Income on Derivative Foreign exchange contracts $ 600.4 Net product sales $ 27.5 Other income, net $ (12.2 ) 1 Treasury rate lock agreements $ — Interest expense $ (3.5 ) Forward starting interest rate swaps $ (32.3 ) Interest expense $ (0.9 ) Other income, net (3.6 ) 2 1 The amount of net gain recognized in income represents $18.0 million in losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $5.8 million of gains related to the ineffective portion of the hedging relationships. 2 The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships. The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Income for the years ended December 31, 2015 and 2014 : Location of Gain (Loss) Recognized in Income on Derivative Amount of Gain (Loss) Recognized in Income on Derivative Instrument 2015 2014 Interest rate swaps Interest expense $ 60.3 $ 43.0
Foreign currency forward contracts
Derivative [Line Items]
Schedule of notional amount of foreign currency forward contracts	Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at December 31, 2015 and December 31, 2014 : Notional Amount Foreign Currency: 2015 2014 Australian Dollar $ 45.1 $ 18.8 British Pound 289.3 304.8 Canadian Dollar 135.9 43.7 Euro 2,934.3 3,375.7 Japanese Yen 510.4 541.1 Total $ 3,915.0 $ 4,284.1
Foreign exchange option contracts
Derivative [Line Items]
Foreign currency option contracts entered into to hedge forecasted revenue and expenses	Outstanding foreign currency option contracts entered into to hedge forecasted revenue were as follows at December 31, 2015 and 2014 : Notional Amount 1 2015 2014 Foreign currency option contracts designated as hedging activity: Purchased Put $ 641.5 $ 152.6 Written Call $ 690.0 $ 160.9 1 U.S. dollar notional amounts are calculated as the hedged local currency amount multiplied by the strike value of the foreign currency option. The local currency notional amounts of our purchased put and written call that are designated as hedging activities are equal to each other.
Interest rate swaps
Derivative [Line Items]
Schedule of notional amount of foreign currency forward contracts	The following table summarizes the notional amounts of our outstanding interest rate swap contracts at December 31, 2015 and December 31, 2014 : Notional Amount 2015 2014 Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes: 2.450% senior notes due 2015 $ — $ 300.0 1.900% senior notes due 2017 300.0 300.0 2.300% senior notes due 2018 200.0 200.0 2.250% senior notes due 2019 500.0 500.0 3.950% senior notes due 2020 500.0 500.0 3.250% senior notes due 2022 1,000.0 750.0 4.000% senior notes due 2023 700.0 150.0 3.625% senior notes due 2024 100.0 — 3.875% senior notes due 2025 250.0 — Total $ 3,550.0 $ 2,700.0

Cash, Cash Equivalents and Ma35

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables)	12 Months Ended
	Dec. 31, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule of available-for-sale securities by major security type and class	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at December 31, 2015 and 2014 were as follows: December 31, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 153.0 $ — $ (0.4 ) $ 152.6 U.S. government-sponsored agency MBS 29.8 0.1 (0.4 ) 29.5 Corporate debt – global 219.7 — (1.6 ) 218.1 Asset backed securities 35.6 — (0.1 ) 35.5 Marketable equity securities 811.5 468.1 (43.7 ) 1,235.9 Total available-for-sale marketable securities $ 1,249.6 $ 468.2 $ (46.2 ) $ 1,671.6 December 31, 2014 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 1,044.7 $ 0.3 $ (0.8 ) $ 1,044.2 U.S. government-sponsored agency securities 145.1 0.1 (0.1 ) 145.1 U.S. government-sponsored agency MBS 531.1 1.0 (2.7 ) 529.4 Non-U.S. government, agency and supranational securities 32.4 — (0.1 ) 32.3 Corporate debt – global 446.3 0.6 (1.2 ) 445.7 Asset backed securities 177.3 — (0.2 ) 177.1 Marketable equity securities 335.2 716.3 (0.2 ) 1,051.3 Total available-for-sale marketable securities $ 2,712.1 $ 718.3 $ (5.3 ) $ 3,425.1
Schedule of available-for-sale securities in an unrealized loss position for less than and longer than 12 months	The fair value of all available-for-sale securities, which have been in an unrealized loss position for less than and longer than 12 months at December 31, 2015 , was as follows: Less than 12 months 12 months or longer Total December 31, 2015 Estimated Fair Value Gross Unrealized Loss Estimated Fair Value Gross Unrealized Loss Estimated Fair Value Gross Unrealized Loss U.S. Treasury securities $ 143.6 $ (0.4 ) $ — $ — $ 143.6 $ (0.4 ) U.S. government-sponsored agency MBS 12.8 (0.3 ) 6.8 (0.1 ) 19.6 (0.4 ) Corporate debt – global 193.5 (1.6 ) — — 193.5 (1.6 ) Asset backed securities 29.6 (0.1 ) 5.9 — 35.5 (0.1 ) Marketable equity securities 494.4 (43.7 ) — — 494.4 (43.7 ) Total $ 873.9 $ (46.1 ) $ 12.7 $ (0.1 ) $ 886.6 $ (46.2 )
Schedule of duration periods of available-for-sale debt securities	Duration periods of available-for-sale debt securities at December 31, 2015 were as follows: Amortized Cost Fair Value Duration of one year or less $ 58.4 $ 58.3 Duration of one through three years 363.7 361.8 Duration of three through five years 15.9 15.6 Total $ 438.0 $ 435.7

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Summary of inventories by major category	A summary of inventories by major category at December 31, 2015 and 2014 follows: 2015 2014 Raw materials $ 201.3 $ 200.0 Work in process 120.0 101.5 Finished goods 122.1 91.6 Total $ 443.4 $ 393.1

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Schedule of property, plant and equipment	Property, plant and equipment at December 31, 2015 and 2014 consisted of the following: 2015 2014 Land $ 75.4 $ 37.9 Buildings 274.1 260.8 Building and operating equipment 33.1 32.0 Leasehold improvements 152.3 135.5 Machinery and equipment 246.6 213.5 Furniture and fixtures 53.2 48.8 Computer equipment and software 389.6 332.8 Construction in progress 221.3 104.8 Subtotal 1,445.6 1,166.1 Less accumulated depreciation and amortization 631.5 523.5 Total $ 814.1 $ 642.6

Other Financial Information (Ta

Other Financial Information (Tables)	12 Months Ended
	Dec. 31, 2015
Other Financial Information
Schedule of accrued expenses	Accrued expenses at December 31, 2015 and 2014 consisted of the following: 2015 2014 Compensation $ 297.8 $ 285.2 Rebates, distributor chargebacks and distributor services 365.5 232.9 Clinical trial costs and grants 255.1 189.5 Interest 170.3 59.1 Royalties, license fees and collaboration agreements 75.9 26.7 Commercial related activities 38.7 56.2 Sales returns 18.8 10.2 Rent 18.1 14.0 Professional services 14.9 7.9 Other taxes 7.9 9.3 Other 113.7 100.1 Total $ 1,376.7 $ 991.1
Schedule of other current liabilities	Other current liabilities at December 31, 2015 and 2014 consisted of the following: 2015 2014 Deferred tax liability $ — $ 131.2 Contingent consideration – Quanticel acquisition 82.5 — Contingent consideration – Nogra acquisition 24.9 24.7 Contingent consideration – Avila acquisition 2.0 9.8 Compensation 55.6 32.6 Sales, use and value added tax 61.1 56.8 Derivative contracts 4.5 2.6 Collaboration agreement upfront payable 40.3 14.0 Other 0.1 4.1 Total $ 271.0 $ 275.8
Schedule of other non-current liabilities	Other non-current liabilities at December 31, 2015 and 2014 consisted of the following: 2015 2014 Contingent consideration – Quanticel acquisition $ 84.2 $ — Contingent consideration – Nogra acquisition 1,214.5 1,110.8 Contingent consideration – Avila acquisition 94.5 114.2 Contingent consideration – Gloucester acquisition 18.9 19.5 Contingent Value Rights - Abraxis acquisition 51.9 136.3 Deferred compensation and long-term incentives 170.5 150.5 Deferred tax liability 377.7 555.6 Other 29.5 49.8 Total $ 2,041.7 $ 2,136.7

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite-lived intangible assets	Intangible assets outstanding as of December 31, 2015 and December 31, 2014 are summarized as follows: December 31, 2015 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,448.3 ) $ 1,957.6 Technology 565.7 (197.1 ) 368.6 Licenses 66.7 (22.3 ) 44.4 Other 44.0 (27.1 ) 16.9 4,082.3 (1,694.8 ) 2,387.5 Non-amortized intangible assets: Acquired IPR&D product rights 8,470.6 — 8,470.6 Total intangible assets $ 12,552.9 $ (1,694.8 ) $ 10,858.1 December 31, 2014 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,234.1 ) $ 2,171.8 Technology 333.7 (135.1 ) 198.6 Licenses 67.0 (18.1 ) 48.9 Other 42.5 (22.9 ) 19.6 3,849.1 (1,410.2 ) 2,438.9 Non-amortized intangible assets: Acquired IPR&D product rights 1,628.7 — 1,628.7 Total intangible assets $ 5,477.8 $ (1,410.2 ) $ 4,067.6
Schedule of indefinite-lived intangible assets	Intangible assets outstanding as of December 31, 2015 and December 31, 2014 are summarized as follows: December 31, 2015 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,448.3 ) $ 1,957.6 Technology 565.7 (197.1 ) 368.6 Licenses 66.7 (22.3 ) 44.4 Other 44.0 (27.1 ) 16.9 4,082.3 (1,694.8 ) 2,387.5 Non-amortized intangible assets: Acquired IPR&D product rights 8,470.6 — 8,470.6 Total intangible assets $ 12,552.9 $ (1,694.8 ) $ 10,858.1 December 31, 2014 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,234.1 ) $ 2,171.8 Technology 333.7 (135.1 ) 198.6 Licenses 67.0 (18.1 ) 48.9 Other 42.5 (22.9 ) 19.6 3,849.1 (1,410.2 ) 2,438.9 Non-amortized intangible assets: Acquired IPR&D product rights 1,628.7 — 1,628.7 Total intangible assets $ 5,477.8 $ (1,410.2 ) $ 4,067.6
Schedule of changes in carrying value of goodwill	The change in carrying value of goodwill is summarized as follows: Balance at December 31, 2014 $ 2,191.2 Acquisition of Receptos 2,570.0 Acquisition of Quanticel 117.8 Balance at December 31, 2015 $ 4,879.0

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Short-term Debt	The carrying value of short-term borrowings and current portion of long-term debt outstanding at December 31, 2015 and December 31, 2014 includes: 2015 2014 Commercial paper $ — $ 99.6 2.450% senior notes due 2015 — 506.3 Total $ — $ 605.9
Carrying values of the senior notes	The carrying values of the long-term portion of these senior notes at December 31, 2015 and 2014 are summarized below: 2015 2014 1.900% senior notes due 2017 $ 501.2 $ 501.0 2.125% senior notes due 2018 999.9 — 2.300% senior notes due 2018 401.7 401.2 2.250% senior notes due 2019 505.1 502.5 2.875% senior notes due 2020 1,497.5 — 3.950% senior notes due 2020 507.1 502.8 3.250% senior notes due 2022 1,016.1 1,010.2 3.550% senior notes due 2022 997.4 — 4.000% senior notes due 2023 710.3 708.5 3.625% senior notes due 2024 1,001.7 996.8 3.875% senior notes due 2025 2,475.6 — 5.700% senior notes due 2040 249.6 249.5 5.250% senior notes due 2043 396.7 396.7 4.625% senior notes due 2044 996.6 996.5 5.000% senior notes due 2045 1,993.9 — Total long-term debt $ 14,250.4 $ 6,265.7

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Summary of changes in common stock issued and treasury stock	A summary of changes in common stock issued and treasury stock is presented below (in millions of shares): Common Stock Common Stock in Treasury December 31, 2012 880.9 (78.7 ) Exercise of stock options and conversion of restricted stock units 25.0 (0.5 ) Issuance of common stock for employee benefit plans 0.6 — Shares repurchased under share repurchase program — (22.3 ) December 31, 2013 906.5 (101.5 ) Exercise of stock options and conversion of restricted stock units 18.3 (1.3 ) Issuance of common stock for employee benefit plans — 0.2 Shares repurchased under share repurchase program — (22.0 ) December 31, 2014 924.8 (124.6 ) Exercise of stock options and conversion of restricted stock units 15.3 (1.2 ) Issuance of common stock for employee benefit plans — 0.4 Shares repurchased under share repurchase program — (28.1 ) December 31, 2015 940.1 (153.5 )

Accumulated Other Comprehensi42

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Summary of other comprehensive income (loss)	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Pension Liability Net Unrealized Gains (Losses) From Marketable Securities Net Unrealized Gains (Losses) From Hedges Foreign Currency Translation Adjustment Total Accumulated Other Comprehensive Income (Loss) Balance December 31, 2013 $ (6.9 ) $ 137.3 $ (36.0 ) $ (0.4 ) $ 94.0 Other comprehensive income (loss) before reclassifications (8.6 ) 320.1 580.4 (49.8 ) 842.1 Amount reclassified from accumulated other comprehensive income — 3.5 (24.8 ) — (21.3 ) Net current-period other comprehensive income (loss) (8.6 ) 323.6 555.6 (49.8 ) 820.8 Balance December 31, 2014 $ (15.5 ) $ 460.9 $ 519.6 $ (50.2 ) $ 914.8 Other comprehensive income (loss) before reclassifications 1.6 (204.6 ) 417.7 (26.1 ) 188.6 Amount reclassified from accumulated other comprehensive income — 15.2 (350.9 ) — (335.7 ) Net current-period other comprehensive income (loss) 1.6 (189.4 ) 66.8 (26.1 ) (147.1 ) Balance December 31, 2015 $ (13.9 ) $ 271.5 $ 586.4 $ (76.3 ) $ 767.7
Reclassification out of Accumulated Other Comprehensive Income	Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income Components Affected Line Item in the Consolidated Statements of Income Years Ended December 31, 2015 2014 2013 Gains (losses) from cash-flow hedges: Foreign exchange contracts Net product sales $ 354.4 $ 27.5 $ 10.7 Treasury rate lock agreements Interest (expense) (4.2 ) (3.5 ) (3.4 ) Interest rate swap agreements Interest (expense) (1.5 ) (0.9 ) — Income tax benefit 2.2 1.7 6.9 Gains (losses) from available-for-sale marketable securities: Realized income (loss) on sales of marketable securities Interest and investment income, net (23.4 ) (5.4 ) (7.3 ) Income tax benefit 8.2 1.9 2.2 Total reclassification, net of tax $ 335.7 $ 21.3 $ 9.1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of share-based compensation expense	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the years ended December 31, 2015 , 2014 and 2013 : 2015 2014 2013 Cost of goods sold $ 31.7 $ 26.2 $ 18.5 Research and development 250.7 196.5 144.7 Selling, general and administrative 294.2 224.9 162.6 Total share-based compensation expense 576.6 447.6 325.8 Tax benefit related to share-based compensation expense 161.2 129.3 94.5 Reduction in income $ 415.4 $ 318.3 $ 231.3
Schedule of assumptions used in the estimation of fair value of options granted	We estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions: 2015 2014 2013 Risk-free interest rate 1.17% - 1.72% 1.51% - 1.90% 0.68% - 1.70% Expected volatility 31% - 38% 28% - 37% 27% - 35% Weighted average expected volatility 34% 33% 31% Expected term (years) 5.02 - 5.04 5.02 - 5.06 5.03 - 5.50 Expected dividend yield 0% 0% 0%
Schedule of stock option activity	The following table summarizes all stock option activity for the year ended December 31, 2015 : Options Weighted Average Exercise Price Per Option Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Millions) Outstanding at December 31, 2014 77.2 $ 49.47 6.9 $ 4,823.8 Changes during the Year: Granted 11.8 118.65 Exercised (11.5 ) 34.39 Forfeited (1.7 ) 74.20 Expired (0.1 ) 39.48 Outstanding at December 31, 2015 75.7 $ 61.99 6.6 $ 4,411.8 Vested at December 31, 2015 or expected to vest in the future 75.1 $ 61.64 6.6 $ 4,400.1 Vested at December 31, 2015 41.2 $ 41.12 5.3 $ 3,238.5
Schedule of restricted stock units	Information regarding the Company's RSUs for the year ended December 31, 2015 is as follows: Nonvested RSUs Share Equivalent Weighted Average Grant Date Fair Value Nonvested at December 31, 2014 9.4 $ 59.02 Changes during the period: Granted 2.5 112.98 Vested (3.8 ) 37.57 Forfeited (0.4 ) 71.95 Nonvested at December 31, 2015 7.7 $ 86.28
Schedule of performance-based restricted stock units	The following table summarizes the Company's performance-based restricted stock unit activity for the year ended December 31, 2015 (shares in thousands): Nonvested Performance-Based RSUs Share Equivalent Weighted Average Grant Date Fair Value Nonvested at December 31, 2014 133 $ 69.57 Changes during the period: Granted 211 112.14 Vested — — Forfeited (10 ) 82.91 Non-vested at December 31, 2015 334 $ 96.07

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of income (loss) before income taxes	Income before income taxes is as follows: 2015 2014 2013 U.S. $ 524.8 $ 565.0 $ 36.8 Non-U.S. 1,498.7 1,762.4 1,628.6 Income before income taxes $ 2,023.5 $ 2,327.4 $ 1,665.4
Schedule of provision (benefit) for taxes on income	The provision (benefit) for taxes on income is as follows: 2015 2014 2013 United States: Taxes currently payable: Federal $ 320.7 $ 489.4 $ 352.6 State and local 63.1 56.3 45.4 Deferred income taxes (28.7 ) (273.8 ) (245.1 ) Total U.S. tax provision 355.1 271.9 152.9 International: Taxes currently payable 71.1 54.1 64.1 Deferred income taxes (4.7 ) 1.5 (1.5 ) Total international tax provision 66.4 55.6 62.6 Total provision $ 421.5 $ 327.5 $ 215.5
Schedule of tax effects of temporary differences that give rise to deferred tax assets and liabilities	At December 31, 2015 and 2014 the tax effects of temporary differences that give rise to deferred tax assets and liabilities were as follows: 2015 2014 Assets Liabilities Assets Liabilities NOL carryforwards $ 56.2 $ — $ 4.5 $ — Deferred revenue 1.8 — 1.7 — Capitalized research expenses 3.8 — 4.8 — Tax credit carryforwards 10.7 — 5.0 — Non-qualified stock options 340.9 — 250.5 — Plant and equipment, primarily differences in depreciation 2.0 — — (7.4 ) Inventory 11.3 — 14.5 — Other assets 43.0 (3.7 ) 41.5 (4.0 ) Intangible assets 661.3 (1,135.4 ) 654.7 (1,183.2 ) Accrued and other expenses 233.2 — 191.6 — Unremitted earnings — (316.5 ) — (316.5 ) Unrealized (gains) losses on securities — (129.9 ) — (236.5 ) Subtotal 1,364.2 (1,585.5 ) 1,168.8 (1,747.6 ) Valuation allowance (90.8 ) — (39.7 ) — Total deferred taxes $ 1,273.4 $ (1,585.5 ) $ 1,129.1 $ (1,747.6 ) Net deferred tax asset (liability) $ (312.1 ) $ (618.5 )
Schedule of deferred tax assets and liabilities classified on the company's balance sheet	At December 31, 2015 and 2014, deferred tax assets and liabilities were classified on our Consolidated Balance Sheets as follows: 2015 2014 Current assets (1) $ — $ 11.7 Other assets (non-current) 65.6 56.6 Current liabilities (1) — (131.2 ) Other non-current liabilities (377.7 ) (555.6 ) Net deferred tax asset (liability) $ (312.1 ) $ (618.5 )
Reconciliation of U.S. statutory income tax rate to company's effective tax rate for continuing operations	Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows: Percentages 2015 2014 2013 U.S. statutory rate 35.0 % 35.0 % 35.0 % Foreign tax rate differences (21.0 )% (22.3 )% (28.8 )% Unremitted earnings — % — % — % State taxes, net of federal benefit 1.2 % 1.0 % 0.6 % Change in valuation allowance 2.0 % 0.2 % 1.2 % Acquisition related differences 4.5 % (0.3 )% 3.7 % Changes in uncertain tax positions (0.5 )% (0.4 )% 0.8 % Other (0.4 )% 0.9 % 0.4 % Effective income tax rate 20.8 % 14.1 % 12.9 %
Reconciliation of beginning and ending amount of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2015 2014 Balance at beginning of year $ 251.8 $ 219.2 Increases related to prior year tax positions — 2.8 Decreases related to prior year tax positions — — Increases related to current year tax positions 84.8 44.4 Settlements — (10.0 ) Lapse of statute (10.8 ) (4.6 ) Balance at end of year $ 325.8 $ 251.8

Collaboration Agreements (Table

Collaboration Agreements (Tables)	12 Months Ended
	Dec. 31, 2015
Collaboration Agreements
Schedule of Collaboration Agreements	Summarized financial information related to our collaboration agreements is presented below: Year ended December 31, As of December 31, 1 Research and Development Expense Upfront Fees Milestones Extension/ Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Intangible Asset Balance Equity Investment Balance Percentage of Outstanding Equity Acceleron 2015 $ — $ — $ — $ — $ — $ — $ 224.9 14 % 2014 — — — — 52.4 — 179.7 14 % 2013 — 17.0 — — 10.0 2012 and prior 70.0 27.5 — — 30.5 Acetylon 2015 — — — 20.2 15.0 0.2 30.0 14 % 2014 — — — 15.3 — 20.4 25.0 10 % 2013 50.0 — — 4.3 10.0 2012 and prior — — — — 15.0 Agios 2015 9.0 — — — — 1.0 340.4 13 % 2014 — — 20.0 — 38.3 — 587.4 14 % 2013 — — 20.0 — 12.8 2012 and prior 121.2 — 20.0 — 37.5 AstraZeneca 2015 450.0 — — — — — N/A N/A bluebird 2015 — — — 4.9 — 20.2 N/A N/A 2014 — — — 0.1 — 0.1 N/A N/A 2013 74.7 — — — — Epizyme 2015 — — 10.0 — — — 58.9 9 % 2014 — — — — 9.9 — 69.3 11 % 2013 — 25.0 — — 1.0 2012 65.0 — — — 25.0 FORMA 2015 59.0 — — — — 0.1 N/A N/A 2014 225.0 — — 0.1 — 0.1 N/A N/A 2013 52.8 — — — — Juno 2015 575.1 — — — 424.9 — 401.8 9 % Lycera 2015 87.0 — — — 10.0 3.0 10.0 8 % NantBioScience 2 2015 — — — — — — 90.0 13 % 2014 50.0 — — — 90.0 — 90.0 14 % Nurix 2015 149.8 — — — 17.0 0.2 17.0 11 % OncoMed 2015 2.5 70.0 — — — — 33.1 5 % 2014 2.5 — — — — — 32.0 5 % 2013 155.0 — — — 22.2 Year ended December 31, As of December 31, 1 Research and Development Expense Upfront Fees Milestones Extension/ Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Intangible Asset Balance Equity Investment Balance Percentage of Outstanding Equity Sutro 2015 — — — 4.8 — 22.9 17.6 16 % 2014 72.6 — — 0.2 11.9 12.8 17.6 15 % 2013 — — — 2.1 1.7 2012 26.3 — — 0.2 4.0 Other Collaboration Arrangements 2015 69.8 8.0 8.1 0.9 50.0 25.0 105.4 N/A 2014 103.5 8.3 — 7.5 55.7 34.4 132.7 N/A 2013 243.3 1.0 — 0.9 71.7 1 Year-end balance and percentage of outstanding equity are presented for the current and prior year. 2 $25.0 million of expense related to the settlement of contingent matching contributions was also recognized in 2014 at the inception of the collaboration agreement with NantBioScience and included in Selling, General and Administrative expense.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments under non-cancelable operating leases	Future minimum lease payments under non-cancelable operating leases as of December 31, 2015 are: Operating Leases 2016 $ 56.1 2017 47.9 2018 35.1 2019 24.1 2020 19.6 Thereafter 49.5 Total minimum lease payments $ 232.3

Geographic and Product Inform47

Geographic and Product Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of revenues and long-lived assets by geographic area	Revenues 2015 2014 2013 United States $ 5,604.0 $ 4,482.8 $ 3,862.1 Europe 2,624.3 2,310.8 1,865.7 All other 1,027.7 876.8 766.1 Total revenues $ 9,256.0 $ 7,670.4 $ 6,493.9 Long-Lived Assets 1 2015 2014 United States $ 585.5 $ 406.1 Europe 215.2 222.2 All other 13.4 14.3 Total long lived assets $ 814.1 $ 642.6 1 Long-lived assets consist of net property, plant and equipment.
Schedule of total revenues from external customers by product	Total revenues from external customers by product for the years ended December 31, 2015 , 2014 and 2013 were as follows: 2015 2014 2013 REVLIMID ® $ 5,801.1 $ 4,980.0 $ 4,280.3 ABRAXANE ® 967.5 848.2 648.9 POMALYST ® /IMNOVID ® 983.3 679.7 305.4 OTEZLA ® 471.7 69.8 — VIDAZA ® 590.7 611.9 803.3 azacitidine for injection 83.9 78.2 23.3 THALOMID ® 185.4 221.2 244.5 ISTODAX ® 69.1 65.6 54.0 Other 8.4 9.2 2.6 Total net product sales 9,161.1 7,563.8 6,362.3 Other revenue 94.9 106.6 131.6 Total revenue $ 9,256.0 $ 7,670.4 $ 6,493.9
Schedule of customer concentration risk based on total revenues and net accounts receivable	The percentage of amounts due from these customers compared to total net accounts receivable is also summarized below as of December 31, 2015 and 2014 . Percent of Total Revenue Percent of Net Accounts Receivable Customer 2015 2014 2013 2015 2014 Amerisource Bergen Corp. 8.1 % 9.0 % 10.7 % 8.2 % 9.7 % CVS 10.7 % 9.8 % 9.3 % 8.2 % 7.6 %

Quarterly Results of Operatio48

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Schedule of quarterly results of operations	2015 1Q 2Q 3Q 3 4Q Year Total revenue $ 2,080.8 $ 2,277.8 $ 2,334.1 $ 2,563.3 $ 9,256.0 Gross profit 1 1,951.2 2,153.3 2,202.7 2,433.8 8,741.0 Income tax provision 108.2 114.6 14.2 184.5 421.5 Net income (loss) 718.9 356.2 (34.1 ) 561.0 1,602.0 Net income (loss) per share: 2 Basic $ 0.90 $ 0.45 $ (0.04 ) $ 0.71 $ 2.02 Diluted $ 0.86 $ 0.43 $ (0.04 ) $ 0.69 $ 1.94 Weighted average shares: Basic 798.9 793.0 791.1 785.8 792.2 Diluted 834.1 825.3 791.1 816.5 824.9 2014 1Q 4 2Q 3Q 4Q Year Total revenue $ 1,730.0 $ 1,872.7 $ 1,982.2 $ 2,085.5 $ 7,670.4 Gross profit 1 1,621.4 1,745.7 1,859.1 1,951.7 7,177.9 Income tax provision 52.6 109.0 69.0 96.9 327.5 Net income 279.7 597.8 508.5 613.9 1,999.9 Net income per share: 2 Basic $ 0.34 $ 0.75 $ 0.64 $ 0.77 $ 2.49 Diluted $ 0.33 $ 0.72 $ 0.61 $ 0.74 $ 2.39 Weighted average shares: Basic 811.5 799.6 799.6 800.2 802.7 Diluted 845.1 831.0 832.8 834.6 836.0 1 Gross profit is computed by subtracting cost of goods sold (excluding amortization of acquired intangible assets) from net product sales. 2 The sum of the quarters may not equal the full year due to rounding. In addition, quarterly and full year basic and diluted earnings per share are calculated separately. 3 Net income for 2015 was a loss in the third quarter primarily due to costs related to collaborations and the acquisition of Receptos. 4 Net income for 2014 was lower in the first quarter compared to each of the other three quarters primarily due to a higher level of expense related to research and development collaborations.

Nature of Business, Basis of 49

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details) $ in Millions	1 Months Ended
	Jun. 30, 2014	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Jun. 18, 2014shares
Concentration of Credit Risk:
Stock split (ratio)	2
Common stock, shares authorized | shares		1,150,000,000	1,150,000,000	1,150,000,000
Net receivables | Spain, Italy and Portugal
Concentration of Credit Risk:
Accounts receivable, net | $		$ 187.8	$ 241.8
Accounts receivable, net, noncurrent | $		$ 31.3
Previously Reported
Concentration of Credit Risk:
Common stock, shares authorized | shares				575,000,000

Nature of Business, Basis of 50

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Foreign Currency Translation:
Net foreign exchange gain (loss)	$ (11.7)	$ (9.5)	$ 22.2
Revenue Recognition
Percentage of responsibility for patient's cost of branded prescription taken by manufacturers	50.00%
Minimum
Revenue Recognition
Period for settlement of rebates and fees	1 month
Maximum
Revenue Recognition
Period for settlement of rebates and fees	15 months
Buildings
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	40 years
Building and operating equipment
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	15 years
Manufacturing machinery and equipment
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	10 years
Other machinery and equipment
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	5 years
Furniture and fixtures
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	5 years
Computer equipment and software | Minimum
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	3 years
Computer equipment and software | Maximum
Property, Plant and Equipment:
Estimated useful lives of capitalized assets (in years)	7 years

Nature of Business, Basis of 51

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details 3) $ in Millions	Dec. 31, 2015USD ($)
Accounting Policies [Abstract]
Publicly traded equity investments held by company	$ 1,236

Acquisitions - Receptos (Detail

Acquisitions - Receptos (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 27, 2015	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill		$ 4,879	$ 4,879	$ 2,191.2
Business Combination, Separately Recognized Transactions
Acquisition related charges			299.6	48.7	$ 171.1
Receptos
Business Combination, Consideration Transferred
Total consideration	$ 7,626.2
Cash paid for outstanding common stock	7,311.3
Cash for equity compensation attributable to pre-combination service	314.9
Cash for the portion of equity compensation attributable to the post-combination service period	197
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Working capital	479.2
Property, plant and equipment	5
In-process research and development product rights	6,842
Current deferred tax assets	241.3
Other non-current assets	7.9
Non-current deferred tax liabilities(2)	(2,519.2)
Total identifiable net assets	5,056.2
Goodwill	2,570
Total net assets acquired	$ 7,626.2
Business Combination, Separately Recognized Transactions
Expense associated with the acquisition and operations of Receptos included in Celgene's Consolidated Statements of Operation		380.5
Acquisition related charges		19.9
Business Acquisition, Pro Forma Information
Total revenue			9,256	7,676.3
Net income			$ 1,630.8	$ 1,499.9
Net income per common share: basic (dollars per share)			$ 2.06	$ 1.87
Net income per common share: diluted (dollars per share)			$ 1.98	$ 1.79
Receptos | Research and development
Business Combination, Separately Recognized Transactions
Expense associated with the acquisition and operations of Receptos included in Celgene's Consolidated Statements of Operation		78.6
Receptos | Selling, general and administrative
Business Combination, Separately Recognized Transactions
Expense associated with the acquisition and operations of Receptos included in Celgene's Consolidated Statements of Operation		5.1
Receptos | Acquisition related (gains) charges and restructuring, net
Business Combination, Separately Recognized Transactions
Expense associated with the acquisition and operations of Receptos included in Celgene's Consolidated Statements of Operation		$ 296.8

Acquisitions - Quanticel (Detai

Acquisitions - Quanticel (Details) - USD ($) $ in Millions	Oct. 19, 2015	Dec. 31, 2015	Oct. 18, 2015	Dec. 31, 2014
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill		$ 4,879		$ 2,191.2
Current Liabilities
Business Acquisition [Line Items]
Contingent consideration	$ 82.3
Noncurrent Liabilities
Business Acquisition [Line Items]
Contingent consideration	83.7
Other Income (Expense)
Business Acquisition [Line Items]
Gain recognized based on faiv market value of interest derived from purchase price		$ 10.3
Quanticel
Business Acquisition [Line Items]
Cash	95.9
Contingent consideration	166
Cash	95.9
Fair value of pre-existing equity ownership	11.4
Total fair value of consideration	273.3
Ownership percentage prior to acquisition			5.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Working capital	7
Property, plant and equipment	1.9
Other non-current assets	0.8
Intangible asset	232
Debt obligations	(13.9)
Non-current deferred tax liabilities	(72.3)
Total identifiable net assets	155.5
Goodwill	117.8
Total net assets acquired	273.3
Quanticel | Discovery and Development Targets
Business Acquisition [Line Items]
Contingent consideration	$ 385

Acquisitions - Nogra Pharma Lim

Acquisitions - Nogra Pharma Limited Acquisition (Details) - USD ($) $ in Millions	May. 14, 2014	Dec. 31, 2015	Oct. 19, 2015	Dec. 31, 2014
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill		$ 4,879		$ 2,191.2
Current Liabilities
Business Combination, Consideration Transferred
Contingent consideration			$ 82.3
Noncurrent Liabilities
Business Combination, Consideration Transferred
Contingent consideration			$ 83.7
Nogra Pharma Limited
Business Acquisition [Line Items]
Estimated maximum potential payments related to contingent consideration	$ 815	$ 1,865
Potential milestones payment, annual sales achievement	500
Potential milestone payments	1,050
Business Combination, Consideration Transferred
Cash	710
Contingent consideration	1,060
Total fair value of consideration	1,770
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
In-process research and development product rights	1,620
Current deferred tax assets	1.3
Non-current deferred tax liabilities(2)	(1.3)
Total identifiable net assets	1,620
Goodwill	150
Total net assets acquired	1,770
Collaboration agreement, termination of agreement, period		180 days
Nogra Pharma Limited | Maximum
Business Acquisition [Line Items]
Potential milestones payment, annual sales achievement	$ 4,000
Nogra Pharma Limited | Current Liabilities
Business Combination, Consideration Transferred
Contingent consideration		$ 5
Nogra Pharma Limited | Noncurrent Liabilities
Business Combination, Consideration Transferred
Contingent consideration		$ 1,055

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net income	$ 561,000,000	$ (34,100,000)	$ 356,200,000	$ 718,900,000	$ 613,900,000	$ 508,500,000	$ 597,800,000	$ 279,700,000	$ 1,602,000,000	$ 1,999,900,000	$ 1,449,900,000
Weighted average shares:
Basic (in shares)	785,800,000	791,100,000	793,000,000	798,900,000	800,200,000	799,600,000	799,600,000	811,500,000	792,200,000	802,700,000	827,700,000
Effect of dilutive securities:
Options, restricted stock units, warrants and other (in shares)									32,700,000	33,300,000	32,900,000
Diluted (in shares)	816,500,000	791,100,000	825,300,000	834,100,000	834,600,000	832,800,000	831,000,000	845,100,000	824,900,000	836,000,000	860,600,000
Net income per share attributable to Celgene:
Basic (in dollars per share)	$ 0.71	$ (0.04)	$ 0.45	$ 0.90	$ 0.77	$ 0.64	$ 0.75	$ 0.34	$ 2.02	$ 2.49	$ 1.75
Diluted (in dollars per share)	$ 0.69	$ (0.04)	$ 0.43	$ 0.86	$ 0.74	$ 0.61	$ 0.72	$ 0.33	$ 1.94	$ 2.39	$ 1.68
Anti-dilutive securities
Antidilutive securities excluded from computation of earnings per share (in shares)									14,100,000	18,700,000	14,300,000
Approved common share repurchase amount	$ 17,500,000,000		$ 4,000,000,000						$ 17,500,000,000
Put option premium net gains (losses)									$ (9,900,000)	$ 11,600,000
Put options outstanding	0								0
Common stock repurchased under the program during the period (in shares)									28,100,000
Common stock repurchased under the program during the period									$ 3,257,000,000
Remaining open-ended repurchase authorization	$ 3,890,000,000								$ 3,890,000,000

Financial Instruments and Fai56

Financial Instruments and Fair Value Measurement (Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	May. 14, 2014
Recurring basis | Quoted Price in Active Markets for Identical Assets (Level 1)
Assets:
Available-for-sale securities	$ 1,235.9	$ 1,051.3
Total assets	1,235.9	1,051.3
Liabilities:
Contingent value rights	(51.9)	(136.3)
Total liabilities	(51.9)	(136.3)
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale securities	435.7	2,373.8
Forward currency contracts	606	550.7
Purchased currency options	46.7	9.8
Interest rate swaps	52.5	20
Total assets	1,140.9	2,954.3
Liabilities:
Written currency options	(19.1)	(4.6)
Total liabilities	(19.1)	(4.6)
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Other acquisition related contingent consideration	(1,521.5)	(1,279)
Total liabilities	(1,521.5)	(1,279)
Recurring basis | Fair Value
Assets:
Available-for-sale securities	1,671.6	3,425.1
Forward currency contracts	606	550.7
Purchased currency options	46.7	9.8
Interest rate swaps	52.5	20
Total assets	2,376.8	4,005.6
Liabilities:
Contingent value rights	(51.9)	(136.3)
Written currency options	(19.1)	(4.6)
Other acquisition related contingent consideration	(1,521.5)	(1,279)
Total liabilities	(1,592.5)	$ (1,419.9)
Gloucester Pharmaceuticals, Inc.
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	120
Avila Therapeutics, Inc.
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	555
Quanticel
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	385
Nogra Pharma Limited
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	$ 1,865		$ 815

Financial Instruments and Fai57

Financial Instruments and Fair Value Measurement (Level 3 Liabilities) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Liabilities:
Balance at beginning of period		$ (1,279)	$ (228.5)
Amounts acquired or issued		(166)	(1,060)
Net change in fair value		(76.5)	(30.5)
Settlements		0	40
Transfers in and/or out of Level 3		0	0
Balance at end of period		(1,521.5)	$ (1,279)
Change in Level 3 liabilities		242.5
Quanticel
Liabilities:
Amounts acquired or issued	$ (166)
Avila Therapeutics, Inc.
Liabilities:
Change in Level 3 liabilities		$ 76.5

Derivative Instruments and He58

Derivative Instruments and Hedging Activities (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Derivative [Line Items]
Notional amount	$ 9,275
Foreign currency forward contracts
Derivative [Line Items]
Period to settlement dates of derivatives is within this period	3 years
Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Period to settlement dates of derivatives is within this period	36 months	36 months
Notional amount	$ 3,915	$ 4,284.1
Not designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	920	835.5
Australian Dollar | Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	45.1	18.8
British Pound | Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	289.3	304.8
Canadian Dollar | Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	135.9	43.7
Euro | Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	2,934.3	3,375.7
Japanese Yen | Designated as hedging instruments | Foreign currency forward contracts
Derivative [Line Items]
Notional amount	$ 510.4	$ 541.1

Derivative Instruments and He59

Derivative Instruments and Hedging Activities (Foreign Currency Option Contracts) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Derivative [Line Items]
Notional amount	$ 9,275
Designated as hedging instruments | Foreign exchange contracts
Derivative [Line Items]
Notional amount	3,915	$ 4,284.1
Purchased Put | Designated as hedging instruments | Foreign exchange contracts
Derivative [Line Items]
Notional amount	641.5	152.6
Written Call | Designated as hedging instruments | Foreign exchange contracts
Derivative [Line Items]
Notional amount	$ 690	$ 160.9

Derivative Instruments and He60

Derivative Instruments and Hedging Activities (Forward Starting Interest Rate Swaps) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Aug. 31, 2015
Derivative [Line Items]
Notional amount	$ 9,275
Accumulated OCI, loss position	$ 21.6
Forward Currency and Treasury Locks
Derivative [Line Items]
Notional amount		$ 2,900
Forward starting interest rate swaps
Derivative [Line Items]
Maturity period (in years)	10 years

Derivative Instruments and He61

Derivative Instruments and Hedging Activities (Interest Rate Swap Contracts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2015
Derivative [Line Items]
Notional amount	$ 9,275
Interest rate swaps
Derivative [Line Items]
Notional amount	3,550	$ 2,700
Interest rate swaps | Designated as hedging instruments
Derivative [Line Items]
Proceeds from settlement of interest rate swap contracts	$ 10.8	25.5
2.450% senior notes due 2015
Derivative [Line Items]
Interest rate (as a percent)	2.45%
3.875% senior notes due 2025
Derivative [Line Items]
Interest rate (as a percent)			3.875%
Senior Notes | 2.450% senior notes due 2015 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 0	$ 300
Interest rate (as a percent)	2.45%
Senior Notes | 1.900% senior notes due 2017
Derivative [Line Items]
Interest rate (as a percent)	1.90%	1.90%
Senior Notes | 1.900% senior notes due 2017 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 300	$ 300
Interest rate (as a percent)	1.90%
Senior Notes | 2.300% senior notes due 2018
Derivative [Line Items]
Interest rate (as a percent)	2.30%	2.30%
Senior Notes | 2.300% senior notes due 2018 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 200	$ 200
Interest rate (as a percent)	2.30%
Senior Notes | 2.250% senior notes due 2019
Derivative [Line Items]
Interest rate (as a percent)	2.25%	2.25%
Senior Notes | 2.250% senior notes due 2019 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 500	$ 500
Interest rate (as a percent)	2.25%
Senior Notes | 3.950% senior notes due 2020
Derivative [Line Items]
Interest rate (as a percent)	3.95%	3.95%
Senior Notes | 3.950% senior notes due 2020 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 500	$ 500
Interest rate (as a percent)	3.95%
Senior Notes | 3.250% senior notes due 2022
Derivative [Line Items]
Interest rate (as a percent)	3.25%
Senior Notes | 3.250% senior notes due 2022 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 1,000	$ 750
Interest rate (as a percent)	3.25%
Senior Notes | 4.000% senior notes due 2023
Derivative [Line Items]
Interest rate (as a percent)	4.00%	4.00%
Senior Notes | 4.000% senior notes due 2023 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 700	$ 150
Interest rate (as a percent)	4.00%
Senior Notes | 3.625% senior notes due 2024
Derivative [Line Items]
Interest rate (as a percent)	3.625%	3.625%
Senior Notes | 3.625% senior notes due 2024 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 100	$ 0
Interest rate (as a percent)	3.625%
Senior Notes | 3.875% senior notes due 2025
Derivative [Line Items]
Interest rate (as a percent)	3.875%
Senior Notes | 3.875% senior notes due 2025 | Interest rate swaps
Derivative [Line Items]
Notional amount	$ 250	$ 0
Interest rate (as a percent)	3.875%

Derivative Instruments and He62

Derivative Instruments and Hedging Activities (Fair Value and Presentation in the Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Fair value of derivative instruments
Asset Derivatives	$ 754.7	$ 651.2
Liability Derivatives	68.6	75.3
Designated as hedging instruments | Foreign exchange contracts | Other current assets
Fair value of derivative instruments
Asset Derivatives	356.2	264.9
Liability Derivatives	18	44.9
Designated as hedging instruments | Foreign exchange contracts | Other non-current assets
Fair value of derivative instruments
Asset Derivatives	287.8	322.3
Liability Derivatives	28	17.5
Designated as hedging instruments | Foreign exchange contracts | Other current liabilities
Fair value of derivative instruments
Asset Derivatives		0.1
Liability Derivatives		1.7
Designated as hedging instruments | Interest rate swaps | Other current assets
Fair value of derivative instruments
Asset Derivatives	30.7	17.9
Liability Derivatives	0	0
Designated as hedging instruments | Interest rate swaps | Other non-current assets
Fair value of derivative instruments
Asset Derivatives	26.1	4.8
Liability Derivatives	4.7	0.3
Designated as hedging instruments | Interest rate swaps | Other non-current liabilities
Fair value of derivative instruments
Asset Derivatives	0.2	0
Liability Derivatives	0.9	3.8
Not designated as hedging instruments | Foreign exchange contracts | Other current assets
Fair value of derivative instruments
Asset Derivatives	46	39.7
Liability Derivatives	5.9	6
Not designated as hedging instruments | Foreign exchange contracts | Other current liabilities
Fair value of derivative instruments
Asset Derivatives	2.9	0.1
Liability Derivatives	7.4	1.1
Not designated as hedging instruments | Interest rate swaps | Other current assets
Fair value of derivative instruments
Asset Derivatives	2.4	0.1
Liability Derivatives	2.3	0
Not designated as hedging instruments | Interest rate swaps | Other non-current assets
Fair value of derivative instruments
Asset Derivatives	2.4	1.3
Liability Derivatives	$ 1.4	$ 0

Derivative Instruments and He63

Derivative Instruments and Hedging Activities (Schedule of Impacts on Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Derivative instruments gain loss
Gains (losses) expected to be reclassified from accumulated OCI into operations in the next 12 months	$ 364.8
Gains (losses) related to amounts excluded from assessment of hedge effectiveness		$ 5.8
Gains (losses) related to ineffective portion of hedging relationships		(18)
Designated as hedging instruments | Cash flow hedges | Foreign exchange contracts
Derivative instruments gain loss
Amount of gain/(loss) recognized in OCI on derivative	429.4	600.4
Designated as hedging instruments | Cash flow hedges | Foreign exchange contracts | Net product sales
Derivative instruments gain loss
Amount of gain/(loss) reclassified from accumulated OCI into income	354.4	27.5
Designated as hedging instruments | Cash flow hedges | Foreign exchange contracts | Other income, net
Derivative instruments gain loss
Amount of gain/(loss) recognized in income on derivative	20	(12.2)
Gains (losses) related to amounts excluded from assessment of hedge effectiveness	23
Derivative, net hedge ineffectiveness gain (loss)	(3)
Designated as hedging instruments | Cash flow hedges | Treasury rate lock agreements
Derivative instruments gain loss
Amount of gain/(loss) recognized in OCI on derivative	(27.9)	0
Designated as hedging instruments | Cash flow hedges | Treasury rate lock agreements | Other income, net
Derivative instruments gain loss
Amount of gain/(loss) recognized in income on derivative	(0.2)
Designated as hedging instruments | Cash flow hedges | Treasury rate lock agreements | Interest expense
Derivative instruments gain loss
Amount of gain/(loss) reclassified from accumulated OCI into income	(4.2)	(3.5)
Designated as hedging instruments | Cash flow hedges | Forward starting interest rate swaps
Derivative instruments gain loss
Amount of gain/(loss) recognized in OCI on derivative	9	(32.3)
Designated as hedging instruments | Cash flow hedges | Forward starting interest rate swaps | Other income, net
Derivative instruments gain loss
Amount of gain/(loss) recognized in income on derivative	0.3	(3.6)
Designated as hedging instruments | Cash flow hedges | Forward starting interest rate swaps | Interest expense
Derivative instruments gain loss
Amount of gain/(loss) reclassified from accumulated OCI into income	(1.5)	(0.9)
Designated as hedging instruments | Fair value hedges | Interest rate swaps | Interest expense
Derivative instruments gain loss
Amount of gain/(loss) recognized in income on derivative	60.3	43
Not designated as hedging instruments | Foreign exchange contracts | Other income, net
Derivative instruments not designated as hedging instruments
Amount of gain/(loss) recognized in income on derivative	81.2	79.3
Not designated as hedging instruments | Put options sold | Other income, net
Derivative instruments not designated as hedging instruments
Amount of gain/(loss) recognized in income on derivative	$ (9.9)	$ 11.6

Cash, Cash Equivalents and Ma64

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Amortized Cost, Gross Unrealized Gain/Loss, and Estimated Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents
Money market funds	$ 1,413	$ 2,251
Available-for-sale securities by major security type and class of security
Amortized Cost	1,249.6	2,712.1
Gross Unrealized Gain	468.2	718.3
Gross Unrealized Loss	(46.2)	(5.3)
Estimated Fair Value	1,671.6	3,425.1
U.S. Treasury securities
Available-for-sale securities by major security type and class of security
Amortized Cost	153	1,044.7
Gross Unrealized Gain	0	0.3
Gross Unrealized Loss	(0.4)	(0.8)
Estimated Fair Value	152.6	1,044.2
U.S. government-sponsored agency securities
Available-for-sale securities by major security type and class of security
Amortized Cost		145.1
Gross Unrealized Gain		0.1
Gross Unrealized Loss		(0.1)
Estimated Fair Value		145.1
U.S. government-sponsored agency MBS
Available-for-sale securities by major security type and class of security
Amortized Cost	29.8	531.1
Gross Unrealized Gain	0.1	1
Gross Unrealized Loss	(0.4)	(2.7)
Estimated Fair Value	29.5	529.4
Non-U.S. government, agency and supranational securities
Available-for-sale securities by major security type and class of security
Amortized Cost		32.4
Gross Unrealized Gain		0
Gross Unrealized Loss		(0.1)
Estimated Fair Value		32.3
Corporate debt – global
Available-for-sale securities by major security type and class of security
Amortized Cost	219.7	446.3
Gross Unrealized Gain	0	0.6
Gross Unrealized Loss	(1.6)	(1.2)
Estimated Fair Value	218.1	445.7
Asset backed securities
Available-for-sale securities by major security type and class of security
Amortized Cost	35.6	177.3
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(0.1)	(0.2)
Estimated Fair Value	35.5	177.1
Marketable equity securities
Available-for-sale securities by major security type and class of security
Amortized Cost	811.5	335.2
Gross Unrealized Gain	468.1	716.3
Gross Unrealized Loss	(43.7)	(0.2)
Estimated Fair Value	$ 1,235.9	$ 1,051.3

Cash, Cash Equivalents and Ma65

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Continuous Unrealized Loss Positions) (Details) $ in Millions	Dec. 31, 2015USD ($)
Estimated Fair Value
Less than 12 months	$ 873.9
12 months or longer	12.7
Total	886.6
Gross Unrealized Loss
Less than 12 months	(46.1)
12 months or longer	(0.1)
Total	(46.2)
U.S. Treasury securities
Estimated Fair Value
Less than 12 months	143.6
12 months or longer	0
Total	143.6
Gross Unrealized Loss
Less than 12 months	(0.4)
12 months or longer	0
Total	(0.4)
U.S. government-sponsored agency MBS
Estimated Fair Value
Less than 12 months	12.8
12 months or longer	6.8
Total	19.6
Gross Unrealized Loss
Less than 12 months	(0.3)
12 months or longer	(0.1)
Total	(0.4)
Corporate debt – global
Estimated Fair Value
Less than 12 months	193.5
12 months or longer	0
Total	193.5
Gross Unrealized Loss
Less than 12 months	(1.6)
12 months or longer	0
Total	(1.6)
Asset backed securities
Estimated Fair Value
Less than 12 months	29.6
12 months or longer	5.9
Total	35.5
Gross Unrealized Loss
Less than 12 months	(0.1)
12 months or longer	0
Total	(0.1)
Marketable equity securities
Estimated Fair Value
Less than 12 months	494.4
12 months or longer	0
Total	494.4
Gross Unrealized Loss
Less than 12 months	(43.7)
12 months or longer	0
Total	$ (43.7)

Cash, Cash Equivalents and Ma66

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Debt Securities, Amortized Cost and Fair Value) (Details) $ in Millions	Dec. 31, 2015USD ($)
Amortized Cost
Duration of one year or less	$ 58.4
Duration of one through three years	363.7
Duration of three through five years	15.9
Total	438
Fair Value
Duration of one year or less	58.3
Duration of one through three years	361.8
Duration of three through five years	15.6
Total	$ 435.7

Inventory (Details)

Inventory (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 201.3	$ 200
Work in process	120	101.5
Finished goods	122.1	91.6
Total	$ 443.4	$ 393.1

Property, Plant and Equipment68

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment:
Subtotal	$ 1,445.6	$ 1,166.1
Less accumulated depreciation and amortization	631.5	523.5
Total	814.1	642.6
Land
Property, Plant and Equipment:
Subtotal	75.4	37.9
Buildings
Property, Plant and Equipment:
Subtotal	274.1	260.8
Building and operating equipment
Property, Plant and Equipment:
Subtotal	33.1	32
Leasehold improvements
Property, Plant and Equipment:
Subtotal	152.3	135.5
Machinery and equipment
Property, Plant and Equipment:
Subtotal	246.6	213.5
Furniture and fixtures
Property, Plant and Equipment:
Subtotal	53.2	48.8
Computer equipment and software
Property, Plant and Equipment:
Subtotal	389.6	332.8
Construction in progress
Property, Plant and Equipment:
Subtotal	$ 221.3	$ 104.8

Other Financial Information (De

Other Financial Information (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Accrued expenses
Compensation	$ 297.8	$ 285.2
Rebates, distributor chargebacks and distributor services	365.5	232.9
Clinical trial costs and grants	255.1	189.5
Interest	170.3	59.1
Royalties, license fees and collaboration agreements	75.9	26.7
Commercial related activities	38.7	56.2
Sales returns	18.8	10.2
Rent	18.1	14
Professional services	14.9	7.9
Other taxes	7.9	9.3
Other	113.7	100.1
Total	1,376.7	991.1
Other current liabilities
Deferred tax liability	0	131.2
Compensation	55.6	32.6
Sales, use and value added tax	61.1	56.8
Derivative contracts	4.5	2.6
Collaboration agreement upfront payable	40.3	14
Other	0.1	4.1
Total	271	275.8
Other non-current liabilities
Deferred compensation and long-term incentives	170.5	150.5
Deferred tax liability	377.7	555.6
Other	29.5	49.8
Total	2,041.7	2,136.7
Quanticel
Other current liabilities
Contingent consideration	82.5	0
Other non-current liabilities
Contingent consideration	84.2	0
Nogra Pharma Limited
Other current liabilities
Contingent consideration	24.9	24.7
Other non-current liabilities
Contingent consideration	1,214.5	1,110.8
Avila Therapeutics, Inc.
Other current liabilities
Contingent consideration	2	9.8
Other non-current liabilities
Contingent consideration	94.5	114.2
Gloucester Pharmaceuticals, Inc.
Other non-current liabilities
Contingent consideration	18.9	19.5
Abraxis Bio Science, Inc.
Other non-current liabilities
Contingent consideration	$ 51.9	$ 136.3

Intangible Assets and Goodwil70

Intangible Assets and Goodwill (Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets By Category
Amortization period related to non-IPR&D intangible assets, minimum (in years)	9 years 8 months
Gross Carrying Value	$ 4,082.3	$ 3,849.1
Accumulated Amortization	(1,694.8)	(1,410.2)
Intangible Assets, Net	2,387.5	2,438.9
Total intangible assets
Gross Carrying Value	12,552.9	5,477.8
Accumulated Amortization	(1,694.8)	(1,410.2)
Intangible Assets, Net	10,858.1	4,067.6
Increase in the gross carrying value of the intangible assets	7,075
Amortization	284.7	263.9	$ 270.1
Increase in amortization expense	20.8
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Estimated amortization expense, 2016	373.1
Estimated amortization expense, 2017	372.4
Estimated amortization expense, 2018	299.1
Estimated amortization expense, 2019	162.9
Estimated amortization expense, 2020	153.8
Acquired developed product rights
Intangible Assets By Category
Gross Carrying Value	3,405.9	3,405.9
Accumulated Amortization	(1,448.3)	(1,234.1)
Intangible Assets, Net	1,957.6	2,171.8
Total intangible assets
Accumulated Amortization	(1,448.3)	(1,234.1)
Technology
Intangible Assets By Category
Gross Carrying Value	565.7	333.7
Accumulated Amortization	(197.1)	(135.1)
Intangible Assets, Net	368.6	198.6
Total intangible assets
Accumulated Amortization	(197.1)	(135.1)
Licenses
Intangible Assets By Category
Gross Carrying Value	66.7	67
Accumulated Amortization	(22.3)	(18.1)
Intangible Assets, Net	44.4	48.9
Total intangible assets
Accumulated Amortization	(22.3)	(18.1)
Other
Intangible Assets By Category
Gross Carrying Value	44	42.5
Accumulated Amortization	(27.1)	(22.9)
Intangible Assets, Net	16.9	19.6
Total intangible assets
Accumulated Amortization	(27.1)	(22.9)
Acquired IPR&D product rights
Non-amortized intangible assets:
Gross Carrying Value	8,470.6	$ 1,628.7
Nogra Pharma Limited | Acquired IPR&D product rights
Total intangible assets
Intangible assets acquired	6,842
Quanticel | Technology
Total intangible assets
Intangible assets acquired	$ 232

Intangible Assets and Goodwil71

Intangible Assets and Goodwill (Goodwill) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Summary of changes in carrying value of goodwill
Beginning balance	$ 2,191.2
Ending balance	4,879
Receptos
Summary of changes in carrying value of goodwill
Acquisition	2,570
Quanticel
Summary of changes in carrying value of goodwill
Acquisition	$ 117.8

Debt (Short-Term Borrowings and

Debt (Short-Term Borrowings and Current Portion of Long-Term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Short-term Debt [Line Items]
Commercial paper	$ 0	$ 99.6
2.450% senior notes due 2015	0	506.3
Total	$ 0	$ 605.9
2.450% senior notes due 2015
Short-term Debt [Line Items]
Interest rate (as a percent)	2.45%	2.45%

Debt (Long-Term Debt) (Details)

Debt (Long-Term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Aug. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt, net of discount	$ 14,250.4		$ 6,265.7
2.125% senior notes due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)		2.125%
2.875% senior notes due 2020
Debt Instrument [Line Items]
Interest rate (as a percent)		2.875%
3.550% senior notes due 2022
Debt Instrument [Line Items]
Interest rate (as a percent)		3.55%
3.875% senior notes due 2025
Debt Instrument [Line Items]
Interest rate (as a percent)		3.875%
5.000% senior notes due 2045
Debt Instrument [Line Items]
Interest rate (as a percent)		5.00%
Senior Notes
Debt Instrument [Line Items]
Long-term debt, net of discount	$ 14,250.4		$ 6,265.7
Senior Notes | 1.900% senior notes due 2017
Debt Instrument [Line Items]
Interest rate (as a percent)	1.90%		1.90%
Long-term debt, net of discount	$ 501.2		$ 501
Senior Notes | 2.125% senior notes due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)	2.125%
Long-term debt, net of discount	$ 999.9		$ 0
Senior Notes | 2.300% senior notes due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)	2.30%		2.30%
Long-term debt, net of discount	$ 401.7		$ 401.2
Senior Notes | 2.250% senior notes due 2019
Debt Instrument [Line Items]
Interest rate (as a percent)	2.25%		2.25%
Long-term debt, net of discount	$ 505.1		$ 502.5
Senior Notes | 2.875% senior notes due 2020
Debt Instrument [Line Items]
Interest rate (as a percent)	2.875%
Long-term debt, net of discount	$ 1,497.5		$ 0
Senior Notes | 3.950% senior notes due 2020
Debt Instrument [Line Items]
Interest rate (as a percent)	3.95%		3.95%
Long-term debt, net of discount	$ 507.1		$ 502.8
Senior Notes | 3.250% senior notes due 2022
Debt Instrument [Line Items]
Interest rate (as a percent)	3.25%
Long-term debt, net of discount	$ 1,016.1		$ 1,010.2
Senior Notes | 3.550% senior notes due 2022
Debt Instrument [Line Items]
Interest rate (as a percent)	3.55%		3.55%
Long-term debt, net of discount	$ 997.4		$ 0
Senior Notes | 4.000% senior notes due 2023
Debt Instrument [Line Items]
Interest rate (as a percent)	4.00%		4.00%
Long-term debt, net of discount	$ 710.3		$ 708.5
Senior Notes | 3.625% senior notes due 2024
Debt Instrument [Line Items]
Interest rate (as a percent)	3.625%		3.625%
Long-term debt, net of discount	$ 1,001.7		$ 996.8
Senior Notes | 3.875% senior notes due 2025
Debt Instrument [Line Items]
Interest rate (as a percent)	3.875%
Long-term debt, net of discount	$ 2,475.6		$ 0
Senior Notes | 5.700% senior notes due 2040
Debt Instrument [Line Items]
Interest rate (as a percent)	5.70%		5.70%
Long-term debt, net of discount	$ 249.6		$ 249.5
Senior Notes | 5.250% senior notes due 2043
Debt Instrument [Line Items]
Interest rate (as a percent)	5.25%		5.25%
Long-term debt, net of discount	$ 396.7		$ 396.7
Senior Notes | 4.625% senior notes due 2044
Debt Instrument [Line Items]
Interest rate (as a percent)	4.625%		4.625%
Long-term debt, net of discount	$ 996.6		$ 996.5
Senior Notes | 5.000% senior notes due 2045
Debt Instrument [Line Items]
Interest rate (as a percent)	5.00%
Long-term debt, net of discount	$ 1,993.9		$ 0

Debt (Narrative) (Details)

Debt (Narrative) (Details)	1 Months Ended	12 Months Ended
	Aug. 31, 2015USD ($)	Dec. 31, 2015USD ($)Time_Per_Annum	Apr. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Long-term debt, fair value		$ 14,299,000,000
Debt instrument, face amount	$ 8,000,000,000
Debt issuance cost		50,000,000
Accumulated OCI, loss position		21,600,000
Commercial paper carrying value		0		$ 99,600,000
Commercial Paper, remaining borrowing capacity		1,750,000,000
Quanticel
Debt Instrument [Line Items]
Amount of debt paid off		13,900,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,750,000,000	$ 1,500,000,000
Maximum number of credit facility increases | Time_Per_Annum		1
Maximum borrowing capacity, subject to certain conditions		$ 2,000,000,000
Outstanding uncommitted facility		0		$ 0
Commercial Paper
Debt Instrument [Line Items]
Commercial paper debt outstanding		$ 0
2.125% senior notes due 2018
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Interest rate (as a percent)	2.125%
Debt instrument, issuance price as percentage of par value	99.994%
Debt instrument, redemption price, percentage		1.20%
2.875% senior notes due 2020
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,500,000,000
Interest rate (as a percent)	2.875%
Debt instrument, issuance price as percentage of par value	99.819%
Debt instrument, redemption price, percentage		1.20%
3.550% senior notes due 2022
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Interest rate (as a percent)	3.55%
Debt instrument, issuance price as percentage of par value	99.729%
Debt instrument, redemption price, percentage		1.25%
3.875% senior notes due 2025
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,500,000,000
Interest rate (as a percent)	3.875%
Debt instrument, issuance price as percentage of par value	99.034%
Debt instrument, redemption price, percentage		1.30%
5.000% senior notes due 2045
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,000,000,000
Interest rate (as a percent)	5.00%
Debt instrument, issuance price as percentage of par value	99.691%
Debt instrument, redemption price, percentage		1.35%
2015 Notes Redemption
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		101.00%
2.450% senior notes due 2015
Debt Instrument [Line Items]
Debt instrument, face amount		$ 500,000,000
Interest rate (as a percent)		2.45%
Senior Notes | 2.125% senior notes due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)		2.125%
Senior Notes | 2.875% senior notes due 2020
Debt Instrument [Line Items]
Interest rate (as a percent)		2.875%
Senior Notes | 3.550% senior notes due 2022
Debt Instrument [Line Items]
Interest rate (as a percent)		3.55%		3.55%
Senior Notes | 3.875% senior notes due 2025
Debt Instrument [Line Items]
Interest rate (as a percent)		3.875%
Senior Notes | 5.000% senior notes due 2045
Debt Instrument [Line Items]
Interest rate (as a percent)		5.00%
Derivative
Debt Instrument [Line Items]
Accumulated OCI, loss position		$ 68,100,000
Gain as a Result of Past Swap Contract Settlements
Debt Instrument [Line Items]
Deferred (gain) loss on discontinuation of fair value hedge		(33,100,000)
Gain Related to Settlement of Swap Contracts During Current Fiscal Year
Debt Instrument [Line Items]
Deferred (gain) loss on discontinuation of fair value hedge		$ (6,000,000)

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015	Jun. 18, 2014
Stockholders' Equity Note [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, shares authorized	1,150,000,000	1,150,000,000			1,150,000,000
Common stock, shares issued	940,100,000	924,800,000
Aggregate value of common shares authorized to be purchased under share repurchase program	$ 17,500,000,000			$ 4,000,000,000
Amount of stock repurchased under share repurchase program	$ 3,251,000,000	$ 2,928,000,000	$ 2,769,000,000
Stock repurchase program, aggregate shares repurchased	146,900,000
Average price of shares repurchased under share repurchase program (in dollars per share)	$ 92.67
Cost of shares repurchased under share repurchase program	$ 13,610,000,000

Stockholders' Equity (Summary o

Stockholders' Equity (Summary of Common and Treasury Stock) (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Changes in common stock issued and treasury stock
Balance at the beginning of the period (in shares)	924,800,000
Exercise of stock options and conversion of restricted stock units (in shares)	11,500,000
Balance at the end of the period (in shares)	940,100,000	924,800,000
Common Stock
Changes in common stock issued and treasury stock
Balance at the beginning of the period (in shares)	924,800,000	906,500,000	880,900,000
Exercise of stock options and conversion of restricted stock units (in shares)	15,300,000	18,300,000	25,000,000
Issuance of common stock for employee benefit plans (in shares)	0	0	600,000
Shares repurchased under share repurchase program (in shares)	0	0	0
Balance at the end of the period (in shares)	940,100,000	924,800,000	906,500,000
Treasury Stock
Changes in common stock issued and treasury stock
Balance at the beginning of the period (in shares)	(124,600,000)	(101,500,000)	(78,700,000)
Exercise of stock options and conversion of restricted stock units (in shares)	(1,200,000)	(1,300,000)	(500,000)
Issuance of common stock for employee benefit plans (in shares)	400,000	200,000	0
Shares repurchased under share repurchase program (in shares)	(28,100,000)	(22,000,000)	(22,300,000)
Balance at the end of the period (in shares)	(153,500,000)	(124,600,000)	(101,500,000)

Accumulated Other Comprehensi77

Accumulated Other Comprehensive Income (Summary of Components) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of accumulated other comprehensive income (loss), net of tax
Balance at the beginning of the period	$ 914.8	$ 94
Other comprehensive income (loss) before reclassifications	188.6	842.1
Amount reclassified from accumulated other comprehensive income	(335.7)	(21.3)
Total other comprehensive income (loss)	(147.1)	820.8	$ 143.7
Balance at the end of the period	767.7	914.8	94
Pension Liability
Summary of accumulated other comprehensive income (loss), net of tax
Balance at the beginning of the period	(15.5)	(6.9)
Other comprehensive income (loss) before reclassifications	1.6	(8.6)
Amount reclassified from accumulated other comprehensive income	0	0
Total other comprehensive income (loss)	1.6	(8.6)
Balance at the end of the period	(13.9)	(15.5)	(6.9)
Net Unrealized Gains (Losses) From Marketable Securities
Summary of accumulated other comprehensive income (loss), net of tax
Balance at the beginning of the period	460.9	137.3
Other comprehensive income (loss) before reclassifications	(204.6)	320.1
Amount reclassified from accumulated other comprehensive income	15.2	3.5
Total other comprehensive income (loss)	(189.4)	323.6
Balance at the end of the period	271.5	460.9	137.3
Net Unrealized Gains (Losses) From Hedges
Summary of accumulated other comprehensive income (loss), net of tax
Balance at the beginning of the period	519.6	(36)
Other comprehensive income (loss) before reclassifications	417.7	580.4
Amount reclassified from accumulated other comprehensive income	(350.9)	(24.8)
Total other comprehensive income (loss)	66.8	555.6
Balance at the end of the period	586.4	519.6	(36)
Foreign Currency Translation Adjustment
Summary of accumulated other comprehensive income (loss), net of tax
Balance at the beginning of the period	(50.2)	(0.4)
Other comprehensive income (loss) before reclassifications	(26.1)	(49.8)
Amount reclassified from accumulated other comprehensive income	0	0
Total other comprehensive income (loss)	(26.1)	(49.8)
Balance at the end of the period	$ (76.3)	$ (50.2)	$ (0.4)

Accumulated Other Comprehensi78

Accumulated Other Comprehensive Income (Reclassification Out AOCI) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)									$ (310.6)	$ (176.1)	$ (91.6)
Income tax benefit	$ (184.5)	$ (14.2)	$ (114.6)	$ (108.2)	$ (96.9)	$ (69)	$ (109)	$ (52.6)	(421.5)	(327.5)	(215.5)
Total reclassification, net of tax	$ 561	$ (34.1)	$ 356.2	$ 718.9	$ 613.9	$ 508.5	$ 597.8	$ 279.7	1,602	1,999.9	1,449.9
Reclassification out of accumulated other comprehensive income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassification, net of tax									335.7	21.3	9.1
Reclassification out of accumulated other comprehensive income | Gains (losses) from cash-flow hedges:
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income tax benefit									2.2	1.7	6.9
Reclassification out of accumulated other comprehensive income | Gains (losses) from cash-flow hedges: | Foreign exchange contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net product sales									354.4	27.5	10.7
Reclassification out of accumulated other comprehensive income | Gains (losses) from cash-flow hedges: | Treasury rate lock agreements
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)									(4.2)	(3.5)	(3.4)
Reclassification out of accumulated other comprehensive income | Gains (losses) from cash-flow hedges: | Interest rate swaps
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)									(1.5)	(0.9)	0
Reclassification out of accumulated other comprehensive income | Gains (losses) from available-for-sale marketable securities:
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income tax benefit									8.2	1.9	2.2
Interest and investment income, net									$ (23.4)	$ (5.4)	$ (7.3)

Share-Based Compensation (Discu

Share-Based Compensation (Discussion of Compensation Plans) (Details) - shares	Jun. 17, 2015	Dec. 31, 2015
Share-Based Compensation
Number of common shares in the share reserve	247,800,000
Additional shares authorized, post-split shares of common stock	19,800,000
Shares of common stock available for future share-based grants under all plans		38,300,000
Options
Share-Based Compensation
Award vesting period, maximum (in years)		4 years
Award expiration period (in years)		10 years
Additional award vesting period, retirement provision, maximum		3 years
PSU
Share-Based Compensation
Performance measurement period for PSUs		3 years
Specified performance and market targets for revenue, weighting		37.50%
Specified performance and market targets for earnings per share, weighting		37.50%
Specified performance and market targets for relative total shareholder return, weighting		25.00%
Restricted trading period upon vesting for PSU's		1 year 1 day
PSU | Minimum
Share-Based Compensation
Performance based percentage target for PSUs granted		0.00%
PSU | Maximum
Share-Based Compensation
Performance based percentage target for PSUs granted		200.00%

Share-Based Compensation (Compo

Share-Based Compensation (Components of Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock-Based Compensation
Total share-based compensation expense	$ 576.6	$ 447.6	$ 325.8
Tax benefit related to share-based compensation expense	161.2	129.3	94.5
Reduction in income	415.4	318.3	231.3
Non-qualified stock options
Stock-Based Compensation
Total share-based compensation expense	346.1	276.3	197.6
Cost of goods sold
Stock-Based Compensation
Total share-based compensation expense	31.7	26.2	18.5
Research and development
Stock-Based Compensation
Total share-based compensation expense	250.7	196.5	144.7
Selling, general and administrative
Stock-Based Compensation
Total share-based compensation expense	$ 294.2	$ 224.9	$ 162.6

Share-Based Compensation (Assum

Share-Based Compensation (Assumptions) (Details) - Options - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-Based Compensation
Unrecognized compensation cost	$ 640.9
Weighted-average period over which unrecognized compensation cost is expected to be recognized	2 years
Weighted-average grant date fair value of the stock options issued (in dollars per share)	$ 38.83	$ 27.92	$ 20.22
Assumptions used in the estimation of fair value of options granted
Weighted average expected volatility	34.00%	33.00%	31.00%
Expected dividend yield	0.00%	0.00%	0.00%
Period of settlement of publicly traded options	6 months
Minimum
Assumptions used in the estimation of fair value of options granted
Risk-free interest rate	1.17%	1.51%	0.68%
Expected volatility	31.00%	28.00%	27.00%
Expected term (years)	5 years 7 days	5 years 7 days	5 years 10 days
Maximum
Assumptions used in the estimation of fair value of options granted
Risk-free interest rate	1.72%	1.90%	1.70%
Expected volatility	38.00%	37.00%	35.00%
Expected term (years)	5 years 15 days	5 years 22 days	5 years 6 months

Share-Based Compensation (Plan

Share-Based Compensation (Plan Activities) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options
Outstanding, beginning balnce (in shares)	77,200
Granted (in shares)	11,800
Exercised (in shares)	(11,500)
Forfeited (in shares)	(1,700)
Expired (in shares)	(100)
Outstanding, ending balance (in shares)	75,700	77,200
Vested or expected to vest in the future (in shares)	75,100
Vested (in shares)	41,200
Weighted Average Exercise Price Per Option
Outstanding, beginning balance (in dollars per share)	$ 49.47
Granted (in dollars per share)	118.65
Exercised (in dollars per share)	34.39
Forfeited (in dollars per share)	74.20
Expired (in dollars per share)	39.48
Outstanding, ending balance (in dollars per share)	61.99	$ 49.47
Vested or expected to vest in the future (in dollars per share)	61.64
Vested (in dollars per share)	$ 41.12
Weighted Average Remaining Contractual Term (Years)
Outstanding, weighted average remaining (in years)	6 years 7 months 6 days	6 years 10 months 24 days
Vested at December 31, 2015 or expected to vest in the future (in years)	6 years 7 months 6 days
Vested at December 31, 2015 (in years)	5 years 3 months 18 days
Aggregate Intrinsic Value (In Millions)
Outstanding	$ 4,411.8	$ 4,823.8
Vested or expected to vest in the future	4,400.1
Vested	$ 3,238.5
Nonvested RSUs
Share Equivalent
Nonvested, beginning balance (in shares)	9,400
Granted (in shares)	2,500
Exercised (in shares)	(3,800)
Forfeited (in shares)	(400)
Nonvested, ending balance (in shares)	7,700	9,400
Weighted Average Grant Date Fair Value
Nonvested, beginning balance (in dollars per share)	$ 59.02
Granted (in dollars per share)	112.98
Vested (in dollars per share)	37.57
Forfeited (in dollars per share)	71.95
Nonvested, ending balance (in dollars per share)	$ 86.28	$ 59.02
Nonvested Performance-Based RSUs
Share Equivalent
Nonvested, beginning balance (in shares)	133
Granted (in shares)	211
Exercised (in shares)	0
Forfeited (in shares)	(10)
Nonvested, ending balance (in shares)	334	133
Weighted Average Grant Date Fair Value
Nonvested, beginning balance (in dollars per share)	$ 69.57
Granted (in dollars per share)	112.14
Vested (in dollars per share)	0
Forfeited (in dollars per share)	82.91
Nonvested, ending balance (in dollars per share)	$ 96.07	$ 69.57

Share-Based Compensation (Addit

Share-Based Compensation (Additional Information) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Stock-based compensation
Net proceeds from share-based compensation arrangements	$ 251.7	$ 297.2	$ 551.6
Excess tax benefit from share-based compensation arrangements	300.5	250.6	169.4
Options
Stock-based compensation
Total fair value of shares vested	266.5	211.3	159.3
Total intrinsic value of stock options exercised during the period	$ 993.5	$ 946.6	$ 814.7
Ratio of stock options to RSU's in calculating the number of RSU's for employees	4
Unrecognized compensation cost	$ 640.9
Expected weighted-average period in years of compensation cost to be recognized	2 years
Nonvested RSUs
Stock-based compensation
Unrecognized compensation cost	$ 325
Expected weighted-average period in years of compensation cost to be recognized	1 year 4 months 24 days
Nonvested Performance-Based RSUs
Stock-based compensation
Unrecognized compensation cost	$ 17.9
Expected weighted-average period in years of compensation cost to be recognized	1 year 7 months 6 days

Employee Benefit Plans (401K Pl

Employee Benefit Plans (401K Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan, employer contribution limit percentage of compensation	6.00%
Defined contribution plan, cost recognized	$ 35.1	$ 40.7	$ 32.6

Employee Benefit Plans (Deferre

Employee Benefit Plans (Deferred Compensation Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred compensation liability, non-current	$ 170.5	$ 150.5
Deferred Compensation, Excluding Share-based Payments and Retirement Benefits
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Percentage of cash bonuses which the eligible participants can elect to defer	100.00%
Plan related expense	$ 0.3	0.3	$ 0.6
Deferred compensation liability, non-current	$ 104.5	$ 91
Deferred Compensation, Excluding Share-based Payments and Retirement Benefits | Minimum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Employer match as a percentage of participant's base salary	10.00%
Deferred Compensation, Excluding Share-based Payments and Retirement Benefits | Maximum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Percentage of base salary which the eligible participants can elect to defer	90.00%
Employer match as a percentage of participant's base salary	20.00%

Employee Benefit Plans (Long-Te

Employee Benefit Plans (Long-Term Incentive Plan) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)performance_cycle	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Long-Term Incentive Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Performance period	3 years
Number of separate three-year performance cycles | performance_cycle	3
Consecutive trading days	30 days
Estimated payout for the plan, current	$ 17.4
Plan related expense	$ 24.9	$ 42.3	$ 40.8
Long-Term Incentive Plan | Minimum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Payouts as percentage of the participant's salary	0.00%
Long-Term Incentive Plan | Maximum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Payouts as percentage of the participant's salary	200.00%
2016 Long-Term Incentive Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Percentage of non-GAAP net income as component of performance measures of the plans	37.50%
Percentage of total non-GAAP revenue as component of performance measures of the plans	37.50%
Percentage of relative shareholder return as component of performance measures of the plans	25.00%
2016 Long-Term Incentive Plan | Maximum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Potential payout, assuming maximum objectives are achieved	$ 25.2
2017 Long-Term Incentive Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Percentage of non-GAAP net income as component of performance measures of the plans	37.50%
Percentage of total non-GAAP revenue as component of performance measures of the plans	37.50%
Percentage of relative shareholder return as component of performance measures of the plans	25.00%
2017 Long-Term Incentive Plan | Maximum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Potential payout, assuming maximum objectives are achieved	$ 16.4
2018 Long-Term Incentive Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Percentage of non-GAAP net income as component of performance measures of the plans	37.50%
Percentage of total non-GAAP revenue as component of performance measures of the plans	37.50%
Percentage of relative shareholder return as component of performance measures of the plans	25.00%
2018 Long-Term Incentive Plan | Maximum
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Potential payout, assuming maximum objectives are achieved	$ 16.3

Income Taxes (Income Before Tax

Income Taxes (Income Before Tax Provision) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income before income taxes:
U.S.	$ 524.8	$ 565	$ 36.8
Non-U.S.	1,498.7	1,762.4	1,628.6
Income before income taxes	$ 2,023.5	$ 2,327.4	$ 1,665.4

Income Taxes (Components of Tax

Income Taxes (Components of Tax Provision (Benefit)) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Taxes currently payable:
Federal									$ 320.7	$ 489.4	$ 352.6
State and local									63.1	56.3	45.4
Deferred income taxes									(28.7)	(273.8)	(245.1)
Total U.S. tax provision									355.1	271.9	152.9
International:
Taxes currently payable									71.1	54.1	64.1
Deferred income taxes									(4.7)	1.5	(1.5)
Total international tax provision									66.4	55.6	62.6
Total provision	$ 184.5	$ 14.2	$ 114.6	$ 108.2	$ 96.9	$ 69	$ 109	$ 52.6	421.5	327.5	$ 215.5
Undistributed earnings of foreign subsidiaries	9,667								9,667
Unremitted earnings of international subsidiaries	900								900
Deferred tax liability on foreign earnings	$ 316.5				$ 316.5				$ 316.5	$ 316.5

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Assets
NOL carryforwards	$ 56.2	$ 4.5
Deferred revenue	1.8	1.7
Capitalized research expenses	3.8	4.8
Tax credit carryforwards	10.7	5
Non-qualified stock options	340.9	250.5
Plant and equipment, primarily differences in depreciation	2	0
Inventory	11.3	14.5
Other assets	43	41.5
Intangible assets	661.3	654.7
Accrued and other expenses	233.2	191.6
Subtotal	1,364.2	1,168.8
Valuation allowance	(90.8)	(39.7)
Total deferred taxes	1,273.4	1,129.1
Liabilities
Plant and equipment, primarily differences in depreciation	0	(7.4)
Other assets	(3.7)	(4)
Intangible assets	(1,135.4)	(1,183.2)
Unremitted earnings	(316.5)	(316.5)
Unrealized (gains) losses on securities	(129.9)	(236.5)
Subtotal	(1,585.5)	(1,747.6)
Total deferred taxes	(312.1)	(618.5)
Deferred tax assets and liabilities classified on the company's balance sheet:
Current assets	0	11.7
Other assets (non-current)	65.6	56.6
Current liabilities	0	(131.2)
Other non-current liabilities	(377.7)	(555.6)
Total deferred taxes	$ (312.1)	$ (618.5)

Income Taxes (Effective Tax Rat

Income Taxes (Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Percentages
U.S. statutory rate	35.00%	35.00%	35.00%
Foreign tax rate differences	(21.00%)	(22.30%)	(28.80%)
Unremitted earnings	0.00%	0.00%	0.00%
State taxes, net of federal benefit	1.20%	1.00%	0.60%
Change in valuation allowance	2.00%	0.20%	1.20%
Acquisition related differences	4.50%	(0.30%)	3.70%
Changes in uncertain tax positions	(0.50%)	(0.40%)	0.80%
Other	(0.40%)	0.90%	0.40%
Effective income tax rate	20.80%	14.10%	12.90%
Swiss Federal Tax Administration FTA
Operating Loss Carryforwards [Line Items]
Maximum statutory Swiss income tax rate (as a percent)	17.00%	18.40%	19.70%
Reduction in effective tax rates due to difference between maximum statutory Swiss income tax rate and the company's Swiss income tax rate under the tax holiday (as a percent)	25.70%	18.00%	25.10%

Income Taxes (NOL and Tax Credi

Income Taxes (NOL and Tax Credit Carryforwards) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Deferred income taxes	$ (28.7)	$ (273.8)	$ (245.1)
State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	114.2
NOL carryforwards for which deferred tax assets have not been recorded	476.4
Research
Operating Loss Carryforwards [Line Items]
Credit carryforwards	16.8
Credit carryforwards for which deferred tax assets have not been recorded	4
State NOL Expiring 2016 through 2035 | State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	$ 883.5

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Unrecognized tax benefits:
Balance at beginning of year	$ 251.8	$ 219.2
Increases related to prior year tax positions	0	2.8
Decreases related to prior year tax positions	0	0
Increases related to current year tax positions	84.8	44.4
Settlements	0	(10)
Lapse of statute	(10.8)	(4.6)
Balance at end of year	325.8	251.8
Unrecognized tax benefits that, if recognized, would have a net impact on the effective tax rate	300.8
Accrued interest related to uncertain tax positions	$ 32.6	$ 28.1

Income Taxes (Stock Option Dedu

Income Taxes (Stock Option Deductions Benefit) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 27, 2015
Business Acquisition [Line Items]
Increase in additional paid-in capital on realization of stock option deduction benefits for income tax purposes	$ 302.1	$ 252.6	$ 170
Deferred income taxes recorded as a component of accumulated other comprehensive income resulting in a deferred income tax asset	129.9	236.5
Deferred tax liability related to acquisition	$ 312.1	$ 618.5
Receptos
Business Acquisition [Line Items]
Deferred tax liability related to acquisition				$ 2,519

Collaboration Agreements (Detai

Collaboration Agreements (Details) shares in Millions	Mar. 21, 2014USD ($)Collaborative_Arrangement	Dec. 02, 2013product_candidate	Feb. 29, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jul. 31, 2015USD ($)	Jun. 30, 2015USD ($)shares	Apr. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)Amino_Acid_Targetresearch_targets	Jan. 31, 2014USD ($)data_packageproduct_candidate	Apr. 30, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2015USD ($)discovery_stage_program	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Selling, general and administrative														$ 2,305,400,000	$ 2,027,900,000	$ 1,684,500,000
Celgene
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Allocation of cost, as a percentage							70.00%
Acceleron Pharma Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														0	0	0	$ 70,000,000
Milestone payments made														$ 0	$ 0	17,000,000	27,500,000
Percentage of equity investment ownership				14.00%					14.00%					14.00%	14.00%
Additional equity investments made														$ 0	$ 52,400,000	10,000,000	30,500,000
Equity investment				$ 224,900,000					$ 179,700,000					224,900,000	179,700,000
Acceleron Pharma Inc | ACE-011 program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														367,000,000
Acceleron Pharma Inc | ACE-011 - discovery stage programs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														$ 348,000,000
Number of programs | discovery_stage_program														3
Acceleron Pharma Inc | ACE-536 program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														$ 217,500,000
Acceleron Pharma Inc | ACE-536 first discovery stage program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														170,800,000
Acceleron Pharma Inc | ACE-536 second discovery stage program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														148,800,000
Acceleron Pharma Inc | ACE-536 each additional discovery stage program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received														125,400,000
Agios Pharmaceuticals, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments									$ 20,000,000					120,000,000
Upfront fees														9,000,000	0	0	121,200,000
Milestone payments made														$ 0	$ 0	0	0
Percentage of equity investment ownership				13.00%					14.00%					13.00%	14.00%
Additional equity investments made														$ 0	$ 38,300,000	12,800,000	37,500,000
Equity investment				$ 340,400,000					$ 587,400,000					340,400,000	587,400,000
Agios Pharmaceuticals, Inc. | AG-881
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees								$ 10,000,000
Contingent milestone payments to be made								70,000,000
Agios Pharmaceuticals, Inc. | AG-881 | Manufacturing rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees								1,000,000
Agios Pharmaceuticals, Inc. | Research and development payments | AG-881
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees								9,000,000
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														0	0	0	65,000,000
Research and development, period						3 years
Collaboration agreement, termination of agreement, period						120 days
Milestone payments made														$ 0	$ 0	25,000,000	0
Percentage of equity investment ownership				9.00%					11.00%					9.00%	11.00%
Additional equity investments made														$ 0	$ 9,900,000	1,000,000	25,000,000
Equity investment				$ 58,900,000					$ 69,300,000					58,900,000	69,300,000
Epizyme | Amended Agreement with Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees						$ 10,000,000
Epizyme | Developmental milestone | Amended Agreement with Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments						75,000,000
Epizyme | Regulatory milestone | Amended Agreement with Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments						365,000,000
Epizyme | Regulatory milestone | DOT1L Program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments						100,000,000
Epizyme | Sales milestone | Amended Agreement with Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments						170,000,000
Epizyme | Clinical development milestone | DOT1L Program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments						$ 35,000,000
Sutro Biopharma, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees										$ 95,000,000			$ 35,000,000	0	72,600,000	0	26,300,000
Research and development, period										3 years
Research and development additional, period										1 year 6 months
Collaboration agreement, termination of agreement, period										120 days
Collaboration agreement, number of projects | research_targets										6
Ownership percentage										15.00%
Collaboration agreement, performance evaluation | Amino_Acid_Target										5
Milestone payments made														$ 0	$ 0	0	0
Percentage of equity investment ownership				16.00%					15.00%					16.00%	15.00%
Additional equity investments made														$ 0	$ 11,900,000	1,700,000	4,000,000
Equity investment				$ 17,600,000					$ 17,600,000					17,600,000	17,600,000
Sutro Biopharma, Inc | Collaborative arrangement, antibody drug conjugate (ADC)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments													204,000,000
Sutro Biopharma, Inc | Collaborative arrangement, bispecific antibody construct (BAC)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments													$ 279,000,000
Sutro Biopharma, Inc | Collaborative agreement, research and manufacturing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments										$ 75,000,000
Sutro Biopharma, Inc | Regulatory approval
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments										$ 275,000,000
Bluebird
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees							$ 25,000,000							0	0	74,700,000
Contingent milestone payments to be made							$ 230,000,000
Collaboration agreement, termination of agreement, period							90 days
Milestone payments made														0	0	0
Additional equity investments made														0	0	0
FORMA Therapeutics Holdings, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														59,000,000	225,000,000	52,800,000
Collaboration agreement, number of additional agreement | Collaborative_Arrangement	2
Collaboration agreement, term of additional agreement	2 years
Collaboration agreement, payment to exercise additional agreement	$ 375,000,000
Milestone payments made														0	0	0
Additional equity investments made														0	0	0
FORMA Therapeutics Holdings, LLC | Regulatory approval
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments												$ 315,000,000
Research and development, period												4 years
FORMA Therapeutics Holdings, LLC | Research and development payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees	$ 225,000,000											$ 200,000,000
FORMA Therapeutics Holdings, LLC | License payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments												$ 430,000,000
Upfront fees								20,000,000						68,000,000
FORMA Therapeutics Holdings, LLC | Option to license rights to current and future drug candidates
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, term of additional agreement	3 years 6 months
Acetylon
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														0	0	50,000,000	0
Milestone payments made														$ 0	$ 0	0	0
Percentage of equity investment ownership				14.00%					10.00%					14.00%	10.00%
Additional equity investments made														$ 15,000,000	$ 0	10,000,000	$ 15,000,000
Equity investment				$ 30,000,000					$ 25,000,000					30,000,000	25,000,000
Acetylon | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments														1,100,000,000
OncoMed
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														2,500,000	2,500,000	155,000,000
Milestone payments made														$ 70,000,000	$ 0	0
Effective notice period required to be served for termination of agreement														120 days
Codevelopment sharing of global development costs														33.33%
Percentage of equity investment ownership				5.00%					5.00%					5.00%	5.00%
Additional equity investments made														$ 0	$ 0	22,200,000
Equity investment				$ 33,100,000					$ 32,000,000					$ 33,100,000	32,000,000
OncoMed | Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments made			$ 70,000,000
OncoMed | Celgene
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Codevelopment sharing of global development costs														66.67%
OncoMed | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of programs | discovery_stage_program														5
Number of anti-cancer stem cell products candidates from pipeline | product_candidate		6
Worldwide licensing rights for Anti-CSC therapeutic candidates, term		60 days
OncoMed | RSPO-LGR CSC pathway or another CSC Pathway | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of programs | discovery_stage_program														4
OncoMed | Demcizumab | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments to be made														$ 790,000,000
OncoMed | Anti-DLL4/VEGF | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments to be made														505,000,000
OncoMed | Other four biological programs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments to be made														440,000,000
OncoMed | Small molecule program | Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments to be made														100,000,000
NantBioScience
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees											$ 50,000,000			0	50,000,000
Milestone payments made														$ 0	$ 0
Effective notice period required to be served for termination of agreement											30 days
Aggregate collaboration agreement payments											$ 75,000,000
Number of product candidates from pipeline | product_candidate											2
Percentage of equity investment ownership				13.00%					14.00%		14.00%			13.00%	14.00%
Potential future investment											$ 50,000,000
Collaboration agreement, agreement termination milestones, number of product candidates | product_candidate											4
Collaboration agreement, agreement termination milestones, number of data packages for product candidates | data_package											10
Collaboration agreement, agreement termination milestones, expiration period											10 years
Selling, general and administrative											$ 25,000,000
Additional equity investments made											$ 90,000,000			$ 0	$ 90,000,000
Equity investment				$ 90,000,000					$ 90,000,000					$ 90,000,000	90,000,000
MedImmune
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees								$ 450,000,000
Collaboration agreement, termination of agreement, period								9 months
Future cost responsibility, as a percentage														75.00%
Forecasted royalty rate														50.00%
Royalty decrease period								4 years
MedImmune | MEDI4736
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Future royalty rate														70.00%
Lycera
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments							$ 190,000,000
Upfront fees							$ 82,500,000							$ 87,000,000
Collaboration agreement, termination of agreement, period							6 months
Milestone payments made														$ 0
Percentage of equity investment ownership				8.00%										8.00%
Additional equity investments made														$ 10,000,000
Equity investment				$ 10,000,000										10,000,000
Initial term of agreement							3 years
Lycera | Research and development payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees							$ 69,500,000
Lycera | Research and development payments | Other non-current assets
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees							13,000,000
Equity investment							10,000,000
Payment made for warrant rights							3,000,000
Lycera | License payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees				$ 17,500,000
Juno Therapeutics
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees							$ 150,000,000							575,100,000
Collaboration agreement, termination of agreement, period							120 days
Ownership percentage							9.00%
Milestone payments made														$ 0
Percentage of equity investment ownership				9.00%										9.00%
Additional equity investments made														$ 424,900,000
Equity investment				$ 401,800,000										401,800,000
Initial term of agreement							10 years
Allocation of cost, as a percentage							30.00%
Payment made to Juno							$ 1,000,000,000
Investment in Juno, shares owned | shares							9.1
Available-for-sale securities in Juno							$ 424,900,000
Juno Therapeutics | Research and development payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees							$ 425,100,000
Nurix
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees					$ 149,800,000									149,800,000
Ownership percentage					11.00%
Milestone payments made														$ 0
Percentage of equity investment ownership				11.00%										11.00%
Additional equity investments made														$ 17,000,000
Equity investment				$ 17,000,000										17,000,000
Investment in Nurix					$ 17,000,000
First option to license future programs					45 days
Second option to license future programs					4 years
Nurix | License payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments					$ 405,000,000
Other Collaboration Arrangements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront fees														69,800,000	103,500,000	243,300,000
Milestone payments made														8,000,000	8,300,000	1,000,000
Additional equity investments made														50,000,000	55,700,000	$ 71,700,000
Equity investment				$ 105,400,000					$ 132,700,000					105,400,000	$ 132,700,000
Other Collaboration Arrangements | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments to be made														$ 120,000,000

Collaboration Agreements (Sched

Collaboration Agreements (Schedule of Collaboration Agreements) (Details) - USD ($) $ in Millions	1 Months Ended					12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Jan. 31, 2014	Dec. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance						$ 10,858.1	$ 4,067.6
Acceleron
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						0	0	$ 0	$ 70
Milestones						0	0	17	27.5
Extension/ Termination of Agreements						0	0	0	0
Amortization of Prepaid Research and Development						0	0	0	0
Equity Investments Made During Period						0	52.4	10	30.5
Intangible Asset Balance						0	0
Equity Investment Balance						$ 224.9	$ 179.7
Percentage of Outstanding Equity						14.00%	14.00%
Acetylon
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 0	$ 0	50	0
Milestones						0	0	0	0
Extension/ Termination of Agreements						0	0	0	0
Amortization of Prepaid Research and Development						20.2	15.3	4.3	0
Equity Investments Made During Period						15	0	10	15
Intangible Asset Balance						0.2	20.4
Equity Investment Balance						$ 30	$ 25
Percentage of Outstanding Equity						14.00%	10.00%
Agios
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 9	$ 0	0	121.2
Milestones						0	0	0	0
Extension/ Termination of Agreements						0	20	20	20
Amortization of Prepaid Research and Development						0	0	0	0
Equity Investments Made During Period						0	38.3	12.8	37.5
Intangible Asset Balance						1	0
Equity Investment Balance						$ 340.4	$ 587.4
Percentage of Outstanding Equity						13.00%	14.00%
AstraZeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 450
Milestones						0
Extension/ Termination of Agreements						0
Amortization of Prepaid Research and Development						0
Equity Investments Made During Period						0
Intangible Asset Balance						0
Bluebird
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		$ 25				0	$ 0	74.7
Milestones						0	0	0
Extension/ Termination of Agreements						0	0	0
Amortization of Prepaid Research and Development						4.9	0.1	0
Equity Investments Made During Period						0	0	0
Intangible Asset Balance						20.2	0.1
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						0	0	0	65
Milestones						0	0	25	0
Extension/ Termination of Agreements						10	0	0	0
Amortization of Prepaid Research and Development						0	0	0	0
Equity Investments Made During Period						0	9.9	1	25
Intangible Asset Balance						0	0
Equity Investment Balance						$ 58.9	$ 69.3
Percentage of Outstanding Equity						9.00%	11.00%
FORMA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 59	$ 225	52.8
Milestones						0	0	0
Extension/ Termination of Agreements						0	0	0
Amortization of Prepaid Research and Development						0	0.1	0
Equity Investments Made During Period						0	0	0
Intangible Asset Balance						0.1	0.1
Juno Therapeutics
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		150				575.1
Milestones						0
Extension/ Termination of Agreements						0
Amortization of Prepaid Research and Development						0
Equity Investments Made During Period						424.9
Intangible Asset Balance						0
Equity Investment Balance						$ 401.8
Percentage of Outstanding Equity						9.00%
Lycera
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		$ 82.5				$ 87
Milestones						0
Extension/ Termination of Agreements						0
Amortization of Prepaid Research and Development						0
Equity Investments Made During Period						10
Intangible Asset Balance						3
Equity Investment Balance						$ 10
Percentage of Outstanding Equity						8.00%
NantBioScience
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				$ 50		$ 0	50
Milestones						0	0
Extension/ Termination of Agreements						0	0
Amortization of Prepaid Research and Development						0	0
Equity Investments Made During Period				$ 90		0	90
Intangible Asset Balance						0	0
Equity Investment Balance						$ 90	$ 90
Percentage of Outstanding Equity				14.00%		13.00%	14.00%
NantBioScience | Selling, general and administrative
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees							$ 25
Nurix
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees	$ 149.8					$ 149.8
Milestones						0
Extension/ Termination of Agreements						0
Amortization of Prepaid Research and Development						0
Equity Investments Made During Period						17
Intangible Asset Balance						0.2
Equity Investment Balance						$ 17
Percentage of Outstanding Equity						11.00%
OncoMed
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 2.5	2.5	155
Milestones						70	0	0
Extension/ Termination of Agreements						0	0	0
Amortization of Prepaid Research and Development						0	0	0
Equity Investments Made During Period						0	0	22.2
Intangible Asset Balance						0	0
Equity Investment Balance						$ 33.1	$ 32
Percentage of Outstanding Equity						5.00%	5.00%
Sutro
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees			$ 95		$ 35	$ 0	$ 72.6	0	26.3
Milestones						0	0	0	0
Extension/ Termination of Agreements						0	0	0	0
Amortization of Prepaid Research and Development						4.8	0.2	2.1	0.2
Equity Investments Made During Period						0	11.9	1.7	$ 4
Intangible Asset Balance						22.9	12.8
Equity Investment Balance						$ 17.6	$ 17.6
Percentage of Outstanding Equity						16.00%	15.00%
Other Collaboration Arrangements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees						$ 69.8	$ 103.5	243.3
Milestones						8	8.3	1
Extension/ Termination of Agreements						8.1	0	0
Amortization of Prepaid Research and Development						0.9	7.5	0.9
Equity Investments Made During Period						50	55.7	$ 71.7
Intangible Asset Balance						25	34.4
Equity Investment Balance						$ 105.4	$ 132.7

Commitments and Contingencies96

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2012
Abraxis Bio Science, Inc.
Product Liability Contingency [Line Items]
Intangible asset				$ 1,172,000,000
ABRAXANE
Product Liability Contingency [Line Items]
Nonfinancial liabilities		$ 51,900,000	$ 136,300,000
CVR milestone payment		$ 250,000,000
Net sales measurement period		1 year
Milestone payment made	$ 300,000,000
ABRAXANE | If Achieved no later than April 1, 2013
Product Liability Contingency [Line Items]
CVR milestone payment		$ 400,000,000
ABRAXANE | If Achieved after April 1, 2013 and before the fifth anniversary of the Merger
Product Liability Contingency [Line Items]
CVR milestone payment		$ 300,000,000
ABRAXANE | Milestone One
Product Liability Contingency [Line Items]
Royalty rate		2.50%
ABRAXANE | Milestone One | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 1,000,000,000
ABRAXANE | Milestone One | Maximum
Product Liability Contingency [Line Items]
Revenue milestones		$ 2,000,000,000
ABRAXANE | Milestone Two
Product Liability Contingency [Line Items]
Royalty rate		5.00%
ABRAXANE | Milestone Two | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 2,000,000,000
ABRAXANE | Milestone Two | Maximum
Product Liability Contingency [Line Items]
Revenue milestones		$ 3,000,000,000
ABRAXANE | Milestone Three
Product Liability Contingency [Line Items]
Royalty rate		10.00%
ABRAXANE | Milestone Three | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 3,000,000,000
ABRAXANE | Termination date of December 31, 2025 if sales less than $1.0 billion | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		1,000,000,000
ABRAXANE | Termination date of December 31, 2030 or earlier if sales less than $1.0 billion | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 1,000,000,000

Commitments and Contingencies97

Commitments and Contingencies (Details 2) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Leases
2,016	$ 56.1
2,017	47.9
2,018	35.1
2,019	24.1
2,020	19.6
Thereafter	49.5
Total minimum lease payments	232.3
Total rental expense under operating leases	66.2	$ 62.2	$ 50.9
Lines of Credit:
Derivative contract notional amount	9,275
Letters of credit and guarantees issued on behalf of subsidiaries	101.7
Other Commitments:
Product supply contract obligation	183.7
Commited investment	$ 20.4

Commitments and Contingencies98

Commitments and Contingencies (Details 3)	Jul. 30, 2015lawsuit	Apr. 11, 2014lawsuit	Oct. 02, 2013lawsuit	Jun. 07, 2013	Dec. 31, 2015USD ($)	Jul. 31, 2014shareholder	Feb. 28, 2014lawsuit	Dec. 31, 2015USD ($)
Manufacturing Facility Repayment Obligation [Line Items]
Number of claims filed | lawsuit	4	4	1
Number of claims dismissed | lawsuit		2
Final decision of patent dispute, in years (no later than)								1 year
Civil qui tam actions | lawsuit							3
Number of shareholders who demanded corporate action | shareholder						2
Limit on equity grants to non-employee directors, period (at least)					4 years
Switzerland
Manufacturing Facility Repayment Obligation [Line Items]
Contractual obligation | $					$ 4,000,000			$ 4,000,000
Revlimid Royalty
Manufacturing Facility Repayment Obligation [Line Items]
Royalty rate (as a percent)				0.01
Pomalyst Royalty
Manufacturing Facility Repayment Obligation [Line Items]
Royalty rate (as a percent)				0.025
Children's Medical Center Corporation
Manufacturing Facility Repayment Obligation [Line Items]
Range of possible loss minimum | $					0			0
Range of possible loss maximum | $					$ 141,300,000			$ 141,300,000

Geographic and Product Inform99

Geographic and Product Information (Revenue and Long-Lived Assets) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operations by Geographic Area
Total revenues	$ 2,563.3	$ 2,334.1	$ 2,277.8	$ 2,080.8	$ 2,085.5	$ 1,982.2	$ 1,872.7	$ 1,730	$ 9,256	$ 7,670.4	$ 6,493.9
Total long lived assets	814.1				642.6				814.1	642.6
United States
Operations by Geographic Area
Total revenues									5,604	4,482.8	3,862.1
Total long lived assets	585.5				406.1				585.5	406.1
Europe
Operations by Geographic Area
Total revenues									2,624.3	2,310.8	1,865.7
Total long lived assets	215.2				222.2				215.2	222.2
All other
Operations by Geographic Area
Total revenues									1,027.7	876.8	$ 766.1
Total long lived assets	$ 13.4				$ 14.3				$ 13.4	$ 14.3

Geographic and Product Infor100

Geographic and Product Information (Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues by Product
Total net product sales									$ 9,161.1	$ 7,563.8	$ 6,362.3
Other revenue									94.9	106.6	131.6
Total revenue	$ 2,563.3	$ 2,334.1	$ 2,277.8	$ 2,080.8	$ 2,085.5	$ 1,982.2	$ 1,872.7	$ 1,730	9,256	7,670.4	6,493.9
REVLIMID
Revenues by Product
Total net product sales									5,801.1	4,980	4,280.3
ABRAXANE
Revenues by Product
Total net product sales									967.5	848.2	648.9
POMALYST/IMNOVID
Revenues by Product
Total net product sales									983.3	679.7	305.4
OTEZLA
Revenues by Product
Total net product sales									471.7	69.8	0
VIDAZA
Revenues by Product
Total net product sales									590.7	611.9	803.3
Azacitidine
Revenues by Product
Total net product sales									83.9	78.2	23.3
THALOMID
Revenues by Product
Total net product sales									185.4	221.2	244.5
ISTODAX
Revenues by Product
Total net product sales									69.1	65.6	54
Other
Revenues by Product
Total net product sales									$ 8.4	$ 9.2	$ 2.6

Geographic and Product Infor101

Geographic and Product Information (Major Customers) (Details) - Customers' concentration risk	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Amerisource Bergen Corp. | Percent of Total Revenue
Major Customers
Percentage of concentration risk	8.10%	9.00%	10.70%
Amerisource Bergen Corp. | Percent of Net Accounts Receivable
Major Customers
Percentage of concentration risk	8.20%	9.70%
CVS | Percent of Total Revenue
Major Customers
Percentage of concentration risk	10.70%	9.80%	9.30%
CVS | Percent of Net Accounts Receivable
Major Customers
Percentage of concentration risk	8.20%	7.60%

Quarterly Results of Operati102

Quarterly Results of Operations (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Data [Abstract]
Total revenue	$ 2,563.3	$ 2,334.1	$ 2,277.8	$ 2,080.8	$ 2,085.5	$ 1,982.2	$ 1,872.7	$ 1,730	$ 9,256	$ 7,670.4	$ 6,493.9
Gross profit	2,433.8	2,202.7	2,153.3	1,951.2	1,951.7	1,859.1	1,745.7	1,621.4	8,741	7,177.9
Income tax provision	184.5	14.2	114.6	108.2	96.9	69	109	52.6	421.5	327.5	215.5
Net income	$ 561	$ (34.1)	$ 356.2	$ 718.9	$ 613.9	$ 508.5	$ 597.8	$ 279.7	$ 1,602	$ 1,999.9	$ 1,449.9
Net income per share attributable to Celgene
Basic (in dollars per share)	$ 0.71	$ (0.04)	$ 0.45	$ 0.90	$ 0.77	$ 0.64	$ 0.75	$ 0.34	$ 2.02	$ 2.49	$ 1.75
Diluted (in dollars per share)	$ 0.69	$ (0.04)	$ 0.43	$ 0.86	$ 0.74	$ 0.61	$ 0.72	$ 0.33	$ 1.94	$ 2.39	$ 1.68
Weighted average shares:
Basic (in shares)	785.8	791.1	793	798.9	800.2	799.6	799.6	811.5	792.2	802.7	827.7
Diluted (in shares)	816.5	791.1	825.3	834.1	834.6	832.8	831	845.1	824.9	836	860.6

Schedule II - Valuation and 103

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 42.3	$ 55.5	$ 46.3
Charged to Expense or Sales	127.9	87.7	90.1
Deductions	122.5	100.9	80.9
Balance at End of Year	47.7	42.3	55.5
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	20.6	27.9	21.8
Charged to Expense or Sales	(0.1)	(2.7)	6.2
Deductions	2.4	4.6	0.1
Balance at End of Year	18.1	20.6	27.9
Allowance for customer discounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	11.5	12.1	11.2
Charged to Expense or Sales	111.7	87.9	74.3
Deductions	111	88.5	73.4
Balance at End of Year	12.2	11.5	12.1
Subtotal
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	32.1	40	33
Charged to Expense or Sales	111.6	85.2	80.5
Deductions	113.4	93.1	73.5
Balance at End of Year	30.3	32.1	40
Allowance for sales returns
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	10.2	15.5	13.3
Charged to Expense or Sales	16.3	2.5	9.6
Deductions	9.1	7.8	7.4
Balance at End of Year	$ 17.4	$ 10.2	$ 15.5